EirGenix

Our Aspiration. Your Well-Being.

Stock Code：6589

2024 Annual Report

Annual Report Search URL: http://mops.twse.com.tw

Website URL: http://www.eirgenix.com

Printed on Apr. 30th, 2025

I. Names, Titles, Contact telephone numbers, and E-mail addresses of the Spokesperson and Deputy Spokesperson:

Spokeperson name:	Deputy Spokeperson name:
Lee-Cheng Liu	Chih-Jung Chang
Title:	Title:
Chairman and President	Senior Vice-President
Tel: +886-2-7708-0123	Tel: +886-2-7708-0123
E-mail: IR@eirgenix.com	E-mail: IR@eirgenix.com

II. Address and Telephone of Headquarters, Branches and Plant:

	Address	Telephone
Headquarters Xizhi	No. 101, Lane 169, Kangning St., Xizhi Dist, New Taipei City 22180	+886-2-7708-0123
Branches Zhubei	No.168, Sec. 1, Shengyi Rd., Zhubei City, Hsinchu County 302	+886-3-620-5088

III. Firm name, Address, Website URL and Telephone number of Stock Transfer Agent:

KGI Securities, Department of Stock Agency

Address: 5F, No. 2, Sec. 1, Chongqing S. Rd., Zhongzheng Dist., Taipei City 100

Tel: +886-2-2389-2999

Website URL: https://www.kgi.com.tw

IV. Firm name, Address, Website URL, Telephone number, and the name of the CPA who attested the most recent year's financial report

Name of the CPA: Shu-Fen Yu, Yu-Fang Yen

Firm name: PricewaterhouseCoopers Taiwan

Address: 27F, No. 333, Sec. 1, Keelung Rd., Xinyi Dist., Taipei City 110

Website URL: http://www.pwc.tw Tel: +886-2-2729-6666

V. The name of any exchanges where the company's securities are traded offshore, and the method by which to access information on said offshore securities: None.

VI. Company Website URL: http://www.eirgenix.com

Table of Contents

I. Letter to Shareholders 1

1. **2024 Business Result** 1
2. **2025 Business Plan Summary** 3
3. **EirGenix's future development strategy** 4
4. **Effects by the external competitive environment, legal environment, and overall business environment** 4

II. Corporate Governance Report 6

1. **Information on the company's directors, supervisors, general manager, assistant general managers, deputy assistant general managers, and the supervisors of all the company's divisions and branch units** 6
2. **Remuneration of Directors, Supervisors, President, and Vice Presidents** 20
3. **Implementation of Corporate Governance** 25
4. **Information Regarding the Company's Audit Fee and Independence** 54
5. **Replacement of CPA** 54
6. **The company's chairperson, general manager, or any managerial officer in charge of finance or accounting matters has in the most recent year held a position at the accounting firm of its certified public accountant or at an affiliated enterprise of such accounting firm** 54
7. **Any transfer of equity interests and/or pledge of or change in equity interests (during the most recent fiscal year or during the current fiscal year up to the date of publication of the annual report) by a director, supervisor, managerial officer, or shareholder with a stake of more than 10 percent during the most recent fiscal year or during the current fiscal year up to the date of publication of the annual report** 55
8. **Relationship information, if among the company's 10 largest shareholders any one is a related party or a relative within the second degree of kinship of another** 56
9. **The total number of shares and total equity stake held in any single enterprise by the company, its directors and supervisors, managerial officers, and any companies controlled either directly or indirectly by the company** 57

III. Capital Overview.....58
1. Source of Capital..... 58
2. List of Major Shareholders..... 58
3. Dividend Policy and Implementation Status..... 59
4. Effect upon business performance and earnings per share of any stock dividend distribution proposed or adopted at the most recent shareholders' meeting..... 59
5. Compensation of employees, directors, and supervisors..... 59
6. Status of a Company Repurchasing its own Shares..... 60
7. Corporate bond..... 60
8. Preferred Shares..... 60
9. Global Depository Receipts..... 60
10. Employee Share Subscription Warrants..... 61
11. Restricted Employee Share..... 71
12. Issuance of new Shares in Connection with Mergers or Acquisitions or With Acquisitions of Shares of Other Companies..... 78
13. The Status of Implementation of Capital Allocation Plans..... 79
IV. Operational Highlights.....82
1. Business Activities..... 82
2. Market and Sales Overview..... 99
3. The number of employees employed for the two most recent fiscal years and during the current fiscal year up to the date of publication of the annual report, their average years of service, average age, and education levels..... 110
4. Disbursements for Environmental Protection..... 110
5. Labor Relations..... 111
6. Cyber security management..... 113
7. Important Contracts..... 116
V. Review of Financial Conditions, Financial Performance, and Risk Management.....118
1. Financial Conditions..... 118
2. Financial Performance..... 120
3. Analysis of Cash Flow..... 121
4. The effect of major capital expenditures during the most recent fiscal year on company's finance and business operations... 121
5. Investment Policy in the Last Year, Main Causes for Profits or Losses, Improvement Plans and Investment Plans for the

Coming Year 121
6. Analysis of Risk Management 122
7. Other important matters 126
VI. Special Disclosure 127
1. Information of Affiliated Companies 127
2. Private Placement Securities in the Most Recent Years 127
3. Other Matters that Require Additional Description 127
4. If any of the situations listed in Article 36, paragraph 3, subparagraph 2 of the Securities and Exchange Act, which might materially affect shareholders' equity or the price of the company's securities, has occurred during the most recent fiscal year or during the current fiscal year up to the date of publication of the annual report 127

I. Letter to Shareholders

Dear Shareholders,

1. 2024 Business Result

(1) Business plan implementing results

EirGenix was established on December 21, 2012 and listed in the market on June 28, 2019. It is a biotechnology and medical company focusing on biosimilars, drug discovery, and biopharmaceutical Contract Development and Manufacturing Organization (CDMO). The revenue was NTD 1,008,960 thousand in 2024 and NTD 1,022,653 thousand in 2023. The difference was mainly due to deferred recognition of the milestone payments as a result of a delay in the overseas medicine certificate, and a slight growth in the CDMO business. EirGenix holds the critical technology of biotechnological drug development and manufacture, and is able to provide differentiated services with high value-added. Once the production line expansion and upgrade have been completed, the growth momentum of revenues will resume. The consistent and stable operating income can cover part of the development expense for biosimilars. Various drug development projects are being implemented successively as planned. EirGenix's financial and business conditions will rise significantly after obtaining the medicine certificate for mass production and selling in Europe and the United States.

(2) Research and development status

A. Establish competitive and complete production line development strategies:

(A) EirGenix is currently developing the product for the treatment of HER2+ breast cancer. The dual-target treatment with Pertuzumab in combination with Trastuzumab for late-stage HER2+ breast cancer is gradually being used for early-stage breast cancer. EG1206A is one of the biosimilar leaders in the Pertuzumab market. This will also boost the market share of EG12014.

(B) Sandoz remains in close contact with the US FDA and EirGenix to reach a resolution in a timely manner. In the US market, 420 mg strength is in high demand, Sandoz and EirGenix are working together to get 150 mg and 420 mg products approved by FDA and launch them into the U.S. market together as planned.

(C) The biosimilar drug EIRGASUN of 420mg lyophilized powder for intravenous administration has been submitted to TFDA.

(D) Phase III clinical trial of EG1206A (Pertuzumab Biosimilar) has been approved by FDA in January 2025 and the application has been submitted to TFDA in February 2025.

(E) The antibody-drug conjugate (ADC) EG12043 (TSY0110), jointly developed by the Company and Formosa Pharmaceuticals, expected to apply for Phase I clinical trial in 2025.

B. Outstanding development and manufacture technology of biotechnological drugs:

(A) The CDMO contracts signed in 2024 reached a total value of NT$1.3 billion (US$39.89 million). The CAGR (compound annual growth rate) was 22.38% in 2017-2024.

(B) In 2024, the mammalian capacity reached 25,500L and the microbial capacity reached 150 L. Building B at the Zhubei plant is expected to be completed in 2026, to increase the microbial capacity to 1,500 L. Meanwhile, a three-stage expansion of the mammalian plant which has 150,000 L capacity, is under planned at Ciaotou Science Park, Kaohsiung.

(C) Granted Accreditation Certificate of Foreign Drug Manufacturer by Japan MHLW, with the accreditation category of "biological products" and effective date from October 24, 2022, to October 30, 2027.

C. Affirmation of business performance:

(A) Top 5% among TPEx-listed companies in the 10th Corporate Governance Evaluation.

(B) Won the Taiwan Biopharma Excellence Awards (TBEA) 2024 Most Promising Monoclonal Antibodies Pipeline Award.

(C) Won the Asia-Pacific Bioprocessing Excellence Awards Best ADC CDMO in Taiwan.

(3) Financial revenue and expenditure and profitability analysis

The annual operating income is NTD 1,008,960 thousand dollars, primarily from CDMO business and cooperative development revenue. The gross profit is NTD 218,985 thousand dollars with 21.70% gross margin rate. The major expenditures were biosimilars development and research expenses. The reason for that is because the products are still in the development stage and require more investments for R&D funds, such as clinical study expenses, R&D material expenses, and R&D staff salaries. CDMO sales and other revenues are still unable to fully cover the R&D expenditure mentioned previously at this point, which is the main reason that caused EirGenix's loss. The investment of R&D expenditure now is to accumulate the energy for future profit growth after the product launches.

Unit: %

Item \ Year		2024	2023
Financial Structure	Debt Ratio	14.88	10.26
	Long Term Funds to property, plant, and equipment	254.19	313.25
Solvency	Current Ratio	628.27	977.92
	Quick Ratio	544.50	868.41
Profitability	Rate of return on assets	(6.29)	(7.88)
	Rate of return on equity	(7.25)	(8.84)
	Net Profit Margin	(69.21)	(89.49)
	Earnings per share (NTD)	($2.28)	($3.00)

(4) Budget implementation status

EirGenix had only set up an internal budget goal for 2024 and did not disclose the financial forecast to the public. The overall budget implementation has met the goal.

2. 2025 Business Plan Summary

(1)Business policy

EirGenix's business policy is to maintain sustainable growth since its establishment. It came up with three major service items after considering the three factors of the sales and developing time of drugs, risk value, and potential returns, three stages of the business focus have been set: 1. Contract Development and Manufacturing Organization (CDMO); 2. Biosimilar Development, and 3. Me too and Novel biologics development to make the best of EirGenix's cGMP production factory, equipment, and high-end technology human resources.

(2)Estimated sales, and its basis, and important production and sales policy.

EirGenix's biosimilars in development are still in the developing stage expect EG12014. The main revenue resource comes from Contract Development and Manufacturing Organization and authorized product collaborations. The senior management team proposes the overall goal and strategy, and the research and development team make various development project plans. The project schedule for plan implementation and sales projection is made by feasibility analysis, market potential and financial evaluation.

3. EirGenix's future development strategy

(1) The short-term development strategy is "Build up the foundation and move forward step by step." The strategy plans for products in development and CDMO sales & marketing development are as follows:

A. EG12014 approved by the FDA and other countries in Aisa.

B. EG12014 (HERWENDA® - Sandoz | EIRGASUN® - EirGenix) market launch

C. EG1206A submits the application for Phase III trials.

D. Application for EG12043 (TSY0110) clinical trials (IND).

E. EG12112 and EG12164 start the pre-clinical testing.

F. Expansion of Building B at Zhubei plant to increase the microbial capacity to 1,500 L in 2026.

(2) The medium- and long-term development strategy is "Products are developing and launching one after another to promote stable revenue growth. The strategy plans for products in development and CDMO sales development are as follows:

A. New dosage forms or new drug delivery systems of biosimilars: development of Trastuzumab high-concentration subcutaneous doses; planning for the development of EG12014+EG1206A dual-targeting high-concentration subcutaneous doses. The successful development of high-concentration subcutaneous doses will strengthen the product market share of these products and enable EirGenix as the primary supplier of biosimilar drugs for the treatment of HER2+ breast cancer.

B. Developing biosimilars for the treatment of blood cancer is currently ongoing. According to the development schedule, one new product will be introduced to the market every 1~2 years starting in 2030. Hence, a three-stage expansion of the mammalian capacity by 150,000L is planned at Ciaotou Science Park, Kaohsiung. The new capacity can be used to manufacture in-house developed drugs and accept customers' orders for commercial and scale production.

4. Effects by the external competitive environment, legal environment, and overall business environment

The mission of EirGenix at the beginning is to provide a high-quality and cost-effective Contract Development and Manufacturing Organization and develop biosimilars with commercial value. The medium to long-term goal to focus on Niche Biologics development to benefit humans and society and improve life quality.

EirGenix insists on making the technology first with excellent quality as the foundation, and being responsible for the customer's success. The goal is to become an international biotechnology and medicine company that begins in Taiwan and focuses on the global market.

We would like to thank all of the shareholders, customers, and collaborating business partners for encouraging and supporting us, as well as our employees for their contributions and hard work. Together, they bring prosperity and constant growth to EirGenix.

EirGenix, Inc.

Chairman & President: Lee-Cheng Liu

Head of Accounting Department: Hsiu-Chuan Yang

II. Corporate Governance Report

1. Information on the company's directors, supervisors, general manager, assistant general managers, deputy assistant general managers, and the supervisors of all the company's divisions and branch units

(1)Directors

A. Information of Directors

As of April 29th 2025

Title	Name	Age/Gender	Nationality/ Place of Incorporation	Date First Elected	Date Elected	Term (Year)	Shareholding when Elected		Current Shareholding		Spouse & Minor Shareholding		Shareholding by Nominee		Experience（Education）	Other Position	Executives, Directors or Supervisors Who are Spouses or within Two Degrees of Kinship		
							Shares	%	Shares	%	Shares	%	Shares	%			Title	Name	Relation
Chairman	Lee-Cheng Liu	M 71~75	R.O.C	2012/12/20	2022/6/10	3	2,286,884	0.75	2,507,330	0.82	169,954	0.06	20,400 (Note)	0.01	- Columbia University Ph D, Chemical Engineering & Applied Chemistry - President and COO of AnGes Inc. - Head of Process Development, Novartis Inc.	- Chairman & President of EirGenix, Inc. - Chairperson, Taiwan Bio Industry Organization - Industry Consultant, Forward BioT Venture Capital.	None	None	None
Director	National Development Fund, Executive Yuan	-	R.O.C	2013/6/14	2022/6/10	3	15,288,860	5.03	15,288,860	4.99	0	0	0	0		- Director, Genovate Biotechnology Co., Ltd. - Director, Taiwan Biotech Co., Ltd. - Director, ScinoPharm Taiwan., Ltd. - Director, Taiwan Flower Biotechnology Co., Ltd. - Director, United Biomedical, Inc., Asia. - Director, Adimmune Corp. - Director, TaiGen Biotechnology Holdings, Ltd. - Director, PharmaEssentia Corp. - Director, PharmaEngine, Inc. - Director, TaiAn Technologies Corp. - Director, Intech Biopharm Corporation. - Director, Point Robotics Holding Ltd. - Director, Locus Cell Corp. - Director, MetaTech (AP) Inc. - Director, Wellell Inc. - Director, TaiMed Biologics, Inc. - Director, Taiwan Bio-Manufacturing Corp.	None	None	None

As of April 29th 2025

Title	Name	Age/Gender	Nationality/ Place of Incorporation	Date First Elected	Date Elected	Term (Year)	Shareholding when Elected		Current Shareholding		Spouse & Minor Shareholding		Shareholding by Nominee		Experience（Education）	Other Position	Executives, Directors or Supervisors Who are Spouses or within Two Degrees of Kinship		
							Shares	%	Shares	%	Shares	%	Shares	%			Title	Name	Relation
	Representative: Hsiu-Hui Chen	F 51~60	R.O.C	2016/9/13	2022/6/10	3	0	0	0	0	0	0	0	0	- Ph.D., Institute of Agricultural Chemistry, National Taiwan University - Vice President, Development Center for Biotechnology - Researcher, Yi-cheng Biotech Inc. - Post-doctoral Researcher, Institute of Plant Biology, Academia Sinica	- Acting President, Development Center for Biotechnology - Director, Genovate Biotechnology Co., Ltd.	None	None	None
Director	Formosa Laboratories, Inc.	-	R.O.C	2013/6/14	2022/6/10	3	18,845,818	6.21	18,552,818	6.06	0	0	0	0	-	- Chairman, Formosa Pharmaceuticals, Inc. - Director, A.R.Z Taiwan Ltd. - Director, Epione Investment Cayman Ltd. - Director & Supervisor, Epione Pharmaceuticals, Inc.	None	None	None
	Representative: Cheng-Yu Cheng	M 71~75	R.O.C	2013/6/14	2022/6/10	3	0	0	0	0	0	0	0	0	- Ph.D., University of California, San Francisco - Postdoctoral Fellow, Massachusetts Institute of Technology - Research, DuPont de Nemours, Inc - Professor, Department of Pharmacy, National Taiwan University - Chairman, L. C. United Chemical Co., Ltd.	- Chairman & President, Formosa Laboratories, Inc. - Chairman, Formosa Pharmaceuticals, Inc. - Authorized Representative of Epione Investment Cayman Ltd., the Corp. Director - Director, Epione Investment HK Ltd. - Chairman, Activus Pharma Co., Ltd. - Chairman& President, Epione Pharmaceuticals, Inc. - Authorized Representative of A. R. Z Taiwan Ltd., the Corp. Director - Director, Rayoung Chemtech Inc. - Consultant, An Rui Management Consulting Co., Ltd.	None	None	None

Director	Yao-Hwa Glass Co., Ltd, Management Commission	-	R.O.C	2019/6/12	2022/6/10	3	13,078,082	4.31	13,078,082	4.27	0	0	0	0	- Director, TaiGen Biotechnology Holdings, Ltd.	- Director, Adimmune Corp. - Director, Locus Cell Corp. - Director, Taiwan Bio-Manufacturing Corp. - Director, Zhi Kang Venture Capital Investment Company, Ltd.	None	None	None
	Representative: Ku-Sung Weng	M 51~60	R.O.C	2022/6/10	2022/6/10	3	0	0	0	0	0	0	0	0	- M.S., Chemical Engineering, National Tsing Hua University - Deputy Director, Consumer Goods and Chemical Industries Division, Industrial Development Administration, Ministry of Economic Affairs - Deputy Director, Consumer Goods and Chemical Industries Division, Industrial Development Bureau, Ministry of Economic Affairs - Director, Stone & Resource Industry R&D Center - Director, Printing Technology Research Institute - Director, SAR Technology Inc.	- Director, Consumer Goods and Chemical Industries Division, Industrial Development Administration, Ministry of Economic Affairs - Adjunct Researcher, Yao-Hwa Glass Co., Ltd, Management Commission - Director, Food Industry Research and Development Institute	None	None	None

Director	Foxconn Technology Co., Ltd.	-	R.O.C	2022/6/10	2022/6/10	3	27,500,000	9.05	27,500,000	8.98	0	0	0	0	-	- Director and Supervisor, Hua-Zhun Investment Co., Ltd.	None	None	None
	Representative: Chun- Fu Lu	M 51~60	R.O.C	2023/1/10	2023/1/10	(Note)	0	0	0	0	0	0	0	0	- Master of EMBA program, Chinese University of HK - Master of EMBA program, National Sun Yat-sen University - Chairman, Foxconn Technology Co., Ltd. - CFO and Spokesman, Foxsemicon Integrated Technology Inc.	- Director, Q-Run Holdings Ltd. - Director, Zap Medical System Ltd. - President, Q-Run Investment Co., Ltd. - President, Ultimate Aluminum Magnesium Technology Co., Ltd. - Director, Foxconn Technology Pte. Ltd. - Director, Atkinson Holdings Limited - Director, Double Wealth Profits Limited - Director, Eastern Star Ltd. - Director, Foxconn Precision Components Holding Company Ltd. - Director, Gold Glory International Ltd. - Director, High Tempo International Ltd. - Director, Kenny International Ltd. - Director, Precious Star International Ltd. - Director, Q-Run Far East Corp. - Director, Topfry Industrial Ltd. - Director, World Trade Trading Ltd. - Chairman, Refront IoMT Corp.	None	None	None
	Representative: Yu-Ting Chen	F 31~40	R.O.C	2022/9/7	2022/9/7	(Note)	0	0	0	0	0	0	0	0	- MBA in Finance, National Taiwan University - Special Assistant to CIO, Hon Hai Precision Industry Co., Ltd. - Director, Retain Biotech Corp.	- Managing Director, GTM Management Co., Ltd. - Senior Investment Manager, Honghan Investment Co., Ltd. - Director, YongLin Healthcare Foundation - Director, YL Capital Ltd.	None	None	None

Independent Director	Ming-Thaur Chang	M 71~75	R.O.C	2016/9/13	2022/6/10	3	0	0	0	0	0	0	0	0	- Rutgers University, NJ, USA MBA - GM, CTBC Bank Tokyo Branch - Chief Rep. (Taipei) United Commercial Bank - EVP, Cosmos/KGI Commercial Bank - Independent Director, Kaison Green Energy Technology Co., Ltd.	- Independent Director, DBS Bank (Taiwan) Ltd.	None	None	None
Independent Director	Po-Chih Chen	M 71~75	R.O.C	2022/6/10	2022/6/10	3	0	0	0	0	0	0	0	0	- Ph.D. in Economics, National Taiwan University - Chairman, Taiwan Thinktank - National Policy Advisor to the President - Economic Advisor to the President - Director, Central Bank of the Republic of China	- Senior Advisors to the President - Honorary Chairman, Taiwan Thinktank - Emeritus Professor, National Taiwan University	None	None	None
Independent Director	Fu-Shiow Yin	F 71~75	R.O.C	2016/9/13	2022/6/10	3	0	0	0	0	0	0	0	0	- Ph.D., Rutgers, the State University of New Jersey, USA - Master, Department of Agricultural Chemistry, National Taiwan University - Independent Director, PharmaEngine, Inc. - Director, TaiGen Biotechnology Holdings, Ltd. - Director, Reber Genetics Co., Ltd. - Independent Director, Pac-Link Bio Ventures - Member of Independent Investment Committee, Boston Life Science Venture Co., IBT Management Corp. - Consultant, Department of Economic Development, Taipei City Government - Science Advisor, Department of Industrial Technology, Ministry of Economic Affairs	- Independent Director, Foresee Pharmaceuticals Co., Ltd.	None	None	None
Independent Director	Ming-Shen Chen	M 61~70	R.O.C	2016/9/13	2022/6/10	3	0	0	0	0	0	0	0	0	- Ph.D., Michigan State University, Finance.	- Professor of Finance at National Taiwan University - Director, Foundation for Autistic Children and Adults in Taiwan	None	None	None

Note:

a. The stock shares delivered to the trust account, and the vested conditions in the restricted stock issuance method will be reversed according to the vested ratio.

b. Director Chun- Fu Lu & Director Yu-Ting Chen, the representatives of Foxconn Technology Co., Ltd., were on board on 2023/01/10 and 2022/09/07.

c. Where the chairman of the Board of Directors and the general manager or person of an equivalent position (the highest level manager) of the company are the same person, spouses, or relatives within the first degree of kinship, an explanation, reasonableness, necessity thereof, and the measures adopted in response thereto (for example, increase the number of independent directors, and there should be more than half of the directors not serving as employees or managers, etc.) shall be given.
The Shareholders Meeting elected the 5th term of the Board members on 2022/6/10. On the same day, the Board of Directors nominated Director Lee-Cheng Liu as the Chairman with the unanimous consent of all of the Directors.
It is necessary to establish four seats for Independent Directors for the Chairman, acting also in the capacity of the President. The Company has complied with applicable law in this regard. The number of Independent Directors and representatives of shareholders from the public sector occupied more than half of the seats of the 5th Board of Director that the monitoring capacity is sound.
On the basis of the current stage of the operation and management of the Company, and in consideration of the development in the future, the 5th Board of Director nominated Director and President Lee-Cheng Liu as the Chairman of the Company for the full-range operation of the Company.
For the proper pursuit of corporate governance and strengthening the independence of the Board of Director, the 5th Board also requested the Company to select the right candidate to act as the President of the Company at the right time.

d. If a director's experience is related to their current position, such as having worked at the accounting firm or its affiliate during the disclosure period, the title and position shall be specified: None.

B. Major shareholders of the institutional shareholder

April 29, 2025

Name of Institutional Shareholders	Major Shareholders	%
National Development Fund, Executive Yuan	Government Agencies	
Formosa Laboratories, Inc.	Cheng-Yu Cheng	6.44
	Taishin Life Insurance Co., Ltd.	4.57
	Li Hsiu-Hui	2.55
	Cathay Life Insurance Company, Ltd.	2.49
	Moraga Inc.	2.22
	Ding Li Development Limited	1.97
	Cathay Dragon Fund	1.93
	Augusta Inc.	1.89
	Labor Pension Fund	1.78
	Tsai, Chang-Jen	1.29
Yao-Hwa Glass Co., Ltd, Management Commission	The Yao-Hwa Co., Ltd. Management Commission is a management commission managed by the Ministry of Economic Affairs.	
Foxconn Technology Co., Ltd.	Hon Hai Precision Industry Co., Ltd.	9.88
	BaoXin International Investment Co., Ltd.	7.93
	Hyield Venture Capital Co., Ltd.	6.01
	HongQi International Investment Co., Ltd.	2.25
	HongYuan International Investment Co. Ltd	2.19
	Standard Chartered Bank as custodian of LGT	2.08
	ChungHwa Post Co., Ltd.	1.18
	Labor Pension Fund	1.14
	Vanguard Total International Stock Index Fund, a series of Vanguard Star Funds	1.10
	VANGUARD EMERGING MARKETS STOCK INDEX FUND, A SERIES OF VANGUARD INTERNATIONAL EQUITY INDEX FUNDS	1.00

C. Major shareholders of the Company's major institutional shareholders

April 29, 2025

Name of Institutional	Major Shareholders	%
Augusta Inc.	Xiu-Hui Li	57.14
	Cheng, Chen-Yu	14.29
	Cheng, Ta-Jung	14.29
	Cheng, Ta-Yueh	14.28
Moraga Inc.	Xiu-Hui Li	64.28
	Wen-Jing Lin	7.14
Taishin Life Insurance Co., Ltd.	Taishin Financial Holding Co., Ltd.	100
Cathay Life Insurance Company, Ltd.	Cathay Financial Holding Co., Ltd.	100
Ding Li Development Ltd	Ding-Wu Hu	100
Hon Hai Precision Industry Co., Ltd.	Gou, Tai-Ming	12.54
	New Labor Pension Fund	1.77
	LGT Bank AG	1.27
	Citibank Hosting Government of Singapore Investment Account	1.25
	Standard Chartered Bank in custody for Vanguard Total International Equity Index	1.22
	Citibank Hosting Norges Bank Investment Account	1.16
	JPMorgan Chase Hosting Vanguard Developing Markets Index Fund	1.10
	CTBC Custody of Yuanta Taiwan Excellence 50	1.00
	Deutsche Commerzbank Managed iShares Emerging Markets ETF Investment Account	0.77
	Chunghwa Post Co., Ltd.	0.69
BaoXin International Investment Co., Ltd.	Hon Hai Precision Industry Co., Ltd.	100
Hyield Venture Capital Co., Ltd.	Hon Hai Precision Industry Co., Ltd.	97.95
	BaoXin International Investment Co., Ltd.	2.05
XinSheng Investment Co., Ltd.	Hopetown Properties Ltd.	100
HongQi International Investment Co., Ltd.	Hon Hai Precision Industry Co., Ltd.	100
HongYuan International Investment Co. Ltd	Hon Hai Precision Industry Co., Ltd.	100
Chunghwa Post Co., Ltd	Ministry of Transportation and Communications	100

D. Disclosure of information as professional qualifications and independent status of directors and independent directors

Name \ Qualification	Professional qualifications and experience	Independent Directors' Independence Status	Number of Other Public Companies in Which the Individual is Concurrently Serving as an Independent Director
Lee-Cheng Liu Chairman	For Directors' professional qualification and experience, please refer to "II.1.(1)A. Information Regarding Board Members" on page 6-12 of this Annual Report. None of the Directors has been in or is under any circumstances stated in Article 30 of the Company Law. (Note 1)	Not Applicable	
National Development Fund, Executive Yuan Representative: Hsiu-Hui Chen Director			
Formosa Laboratories, Inc. Representative: Cheng-Yu Cheng Director			
Yao-Hwa Glass Co., Ltd, Management Commission Representative: Ku-Sung Weng Director			
Foxconn Technology Co., Ltd. Representative: Chun-Fu Lu Director			
Foxconn Technology Co., Ltd. Representative: Yu-Ting Chen Director			
Ming-Thaur Chang Independent Director		1. All Independent Directors meet the requirements outlined in Article 14-2 of "Securities and Exchange Act" and "Regulations Governing Appointment of Independent Directors and Compliance Matters for Public Companies" (Note 2) issued by Taiwan's Financial Supervisory Commission. 2. For information on Independent Directors (or nominee arrangement) as well as his/her spouse and minor children's shareholding of EirGenix common shares, please refer to "II.1.(1)A. Information Regarding Board Members" on page 6-12 of this Annual Report. 3. None of the Independent Directors have received compensation or benefits for providing to the Company or its affiliates: (1) any audit service; or (2) commercial, legal, financial, accounting services or other services within the recent two years.	1
Po-Chih Chen Independent Director			0
Fu-Shiow Yin Independent Director			1
Ming-Shen Chen Independent Director			0

Note 1:

1. Having committed an offence as specified in the Statute for Prevention of Organizational Crimes and subsequently convicted of a crime, and has not started serving the sentence, has not completed serving the sentence, or five years have not elapsed since completion of serving the sentence, expiration of the probation, or pardon;
2. Having committed the offence in terms of fraud, breach of trust or misappropriation and subsequently convicted with imprisonment for a term of more than one year, and has not started serving the sentence, has not completed serving the sentence, or two years have not elapsed since completion of serving the sentence, expiration of the probation, or pardon;
3. Having committed the offense as specified in the Anti-corruption Act and subsequently convicted of a crime, and has not started serving the sentence, has not completed serving the sentence, or two years have not elapsed since completion of serving the sentence, expiration of the probation, or pardon;
4. Having been adjudicated bankrupt or adjudicated of the commencement of liquidation process by a court, and having not been reinstated to his/her rights and privileges;
5. Having been dishonored for unlawful use of credit instruments, and the term of such sanction has not expired yet; or
6. Having no or only limited disposing capacity.
7. Having been adjudicated of the commencement of assistantship and such assistantship having not been revoked yet.

Note 2:

1. Not a governmental, juridical person or its representative as defined in Article 27 of the Company Law.
2. Not serving concurrently as an independent director on more than three other Taiwanese public companies in total.

3. During the two years before being elected and during the term of office, meet any of the following situations:
   (1) Not an employee of the company or any of its affiliates;
   (2) Not a director or supervisor of the company or any of its affiliates;
   (3) Not a natural-person shareholder who holds shares, together with those held by the person's spouse, minor children, or held by the person under others' names, in an aggregate amount of one percent or more of the total number of issued shares of the company or ranks as one of its top ten shareholders;
   (4) Not a spouse, relative within the second degree of kinship, or lineal relative within the third degree of kinship, of any of the officer in the preceding (1) subparagraph, or of any of the above persons in the preceding subparagraphs (2) and (3);
   (5) Not a director, supervisor, or employee of a legal entity that directly holds five percent or more of the total number of issued shares of the company, ranks as of its top five shareholders, or has representative director(s) serving on the company's board based on Article 27 of the Company Law;
   (6) Not a director, supervisor, or employee of a company of which the majority of board seats or voting shares is controlled by a company that also controls the same of the company;
   (7) Not a director, supervisor, or employee of a company of which the chairman or CEO (or equivalent) themselves or their spouse also serve as the company's chairman or CEO (or equivalent);
   (8) Not a director, supervisor, officer, or shareholder holding five percent or more of the shares of a specified company or institution that has a financial or business relationship with the company; and
   (9) Neither a director nor his/her spouse has, in any capacity whatsoever, whether as a professional individual, owner, partner, director, supervisor, or officer of a sole proprietorship or any type of legal entity, provided to EirGenix and its affiliates: (1) any audit service; or (2) commercial, legal, financial, accounting services or other services of which its total compensation exceeding NTD500,000 within the recent two years.

The amounts of the pay received by the independent director for any services such as business, legal, financial, or accounting services provided to the Company or any affiliate thereof within the past 2 years.

Unit: NT$ thousands

Independent Director	Remuneration	2023	2024	Until 2025/04/30
Ming-Thaur Chang	Base Compensation	960	960	240
	Allowances	30	35	20
Po-Chih Chen	Base Compensation	960	960	240
	Allowances	25	30	20
Fu-Shiow Yin	Base Compensation	960	960	240
	Allowances	30	35	20
Ming-Shen Chen	Base Compensation	960	960	240
	Allowances	30	35	20

E. Diversity and independence of the Board of Directors

(A)Diversity of the Board of Directors:

Based on the policy of diversification and strengthening of corporate governance in order to promote the sound development of the Company's board composition and structure, the nomination of candidates for directors of the Company shall be adopted the candidate nomination system in accordance with the provisions of the Company's Articles of Incorporation. Each candidate's academic qualifications, work experience, professional background, integrity or relevant professional qualifications, and others are evaluated and considered. After the Board of Directors passed the resolution, the proposed nominees will be submitted to the Shareholders Meeting for election. With regard to the board composition, it is advisable that the number of directors who concurrently serve as the managers of the Company should not exceed one-third of the board seats. In addition, the Company has, based on its own operations, operational patterns and developmental needs, formulated appropriate diversification policies including but not limited to the following:

The Board of Directors guides the operations strategy, supervises management, and examines the operations of corporate governance, while exercising duties and powers in accordance with laws and regulations and resolutions adopted by the shareholders' meeting and being responsible to the Company, shareholders, and employees, to further improve the Company's operating performance.

The Company has adopted a candidate nomination system for all directors as per the Articles of Incorporation and the Rules of Election of Directors to evaluate candidates based on their education and experience, and the shareholders' meeting elects and appoints candidates from the list of candidates. Relevant regulations are disclosed on the Company's website and Market Observation Post System (MOPS). The Company has formulated a board diversity policy according to the operating model and development needs, including basic qualifications, professional backgrounds, and industry experience, to ensure directors' suitability, independence, and professionalism. There should not be over one-third of directors who serve as managers concurrently on the Board, and directors should be equipped with the qualities in two

aspects below:

a. Basic criteria and values: Gender, age, nationality, and culture.

b. Professional knowledge and skills: Professional backgrounds (such as law, accounting, industry, finances, marketing, or technology) as well as professional skills and industry experience needed for performing duties.

To achieve the corporate governance goals, the Board as a whole should be equipped with the capabilities below:

a. Operational judgment.

b. Accounting and financial analysis skills.

c. Business management capability.

d. Risk control and crisis management capabilities.

More than half of the directors on the Company's Board should have the industry experience and overall planning, leadership, and management capabilities. There are currently 10 directors on the 5th Board of Directors. Among them, four are from the professional biotechnology background. All directors have experience in business, finances, and accounting as well as overall planning, leadership, and management capabilities, while possessing the professional knowledge and skills needed to perform their duties and actively participating in Board meetings and exchanging opinions with management to make business decisions. The following details our overall quantitative data and the composition of the Board based on the board diversity policy:

Title	Name	Gender	Age	Nationality/ Place of Incorporation	Professional biotechnology background	Experience in business, finances, and accounting	Overall planning, leadership, and management capabilities	Possession of college lecturer qualifications or professional and national technical certification
Chairman	Lee-Cheng Liu	M	> 60	R.O.C	✓	✓	✓	
Director	Hsiu-Hui Chen	F	< 60	R.O.C	✓	✓	✓	
Director	Cheng-Yu Cheng	M	> 60	R.O.C	✓	✓	✓	✓
Director	Ku-Sung Weng	M	< 60	R.O.C		✓	✓	
Director	Chun-Fu Lu	M	< 60	R.O.C		✓	✓	
Director	Yu-Ting Chen	F	< 40	R.O.C		✓	✓	
Independent Director	Ming-Thaur Chang	M	> 60	R.O.C		✓	✓	
Independent Director	Po-Chih Chen	M	> 60	R.O.C		✓	✓	✓
Independent Director	Fu-Shiow Yin	F	> 60	R.O.C	✓	✓	✓	
Independent Director	Ming-Shen Chen	M	> 60	R.O.C		✓	✓	✓

- There is only one director who also serves as an employee at the Company, accounting for 10%.
- There are four independent directors, accounting for 40% of the total, and the term of office of independent directors should not exceed nine years.
- There are three female directors, accounting for 30%, and seven male ones, accounting for 70%. To implement the gender equality, the goals is the proportion of female director over 30% in the future.
- There are six directors who are over 60 years old, accounting for 60%, three who are 51–60 years old, accounting for 30%, and one who are 31–40 years old, accounting for 10%.
- There are four directors from the professional biotechnology background, accounting for 40%.
- There are three with professional teaching qualifications and professional certifications, accounting for 30%.
- There are ten with overall planning, management, and leadership capabilities, accounting for 100%.

- All directors are Taiwanese citizens, and many directors possess knowledge of and experience in international business.

(B)Independence of the Board of Directors:

The Board of Directors of the Company consists of ten directors, of which four are independent directors, accounting for 40%. None of the circumstances prescribed in paragraph 3 and paragraph 4, Article 26-3 of the Securities Exchange Act exist among the directors and independent directors. No spousal relationship or familial relationship within the second degree of kinship exists between any directors. The Board of Directors of the Company is independent (Please refer to this Annual Report - Disclosure of information on professional qualifications of directors and independence of independent directors).

(2) Information on the company's directors, supervisors, general manager, assistant general managers, deputy assistant general managers, and the supervisors of all the company's divisions and branch units

April 29, 2025; Unit: Shares; %

Title	Name	Gender	Nationality	Date Effective (Note)	Shareholding		Spouse & Minor Shareholding		Shareholding by Nominee Arrangement		Experience (Education)	Other Position	Managers who are Spouses or Within Two Degrees of Kinship		
					Shares	%	Shares	%	Shares	%			Title	Name	Relation
-President -CEO, BioPharma Business Unit	Lee-Cheng Liu	M	R.O.C	2013/04/01	2,507,330	0.82	169,954	0.06	20,400	0.01	- Ph.D., Chemical Engineering & Applied Chemistry, Columbia University - President and COO of AnGes Inc. - Process Development Department Manager, Novartis Inc.	- Chairman, Taiwan Bio Industry Organization - Industry Consultant, Forward BioT Venture Capital.	None	None	None
-CEO of BioManufacturing Business Unit -Senior Vice President	Chih-Jung Chang	M	R.O.C	2013/04/01	822,546	0.27	280,000	0.09	45,891	0.01	- Ph.D., Chemistry, National Taiwan University. - Ex-Director of PM for Oncology, TTY Biopharm	- Director, TFBS Bioscience Inc.	None	None	None
-CBO -Senior Vice President	Ching-Wen Lin	M	R.O.C	2025/01/01	-	-	2,000	0.00	-	-	- Ph.D., Dept of Applied Biology and Chemical Technology of the Hong Kong Polytechnic University - VP of Marketing & Sales & Chief Strategy Officer, ScinoPharm Taiwan	None	None	None	None
-CFO -Manager of Corporate Governance -Vice President	Hsiu-Chuan Yang	F	R.O.C	2016/05/03	484,283	0.16	-	-	44,798	0.01	- Master of Accounting, University of New Haven - General Manager, JIATE Excelsior Co., Ltd. - V.P., Arich Enterprise Co., Ltd.	None	None	None	None
-CENG -Executive Director	Shang-Chung Ju	M	R.O.C	2013/04/01	478,552	0.16	-	-	17,222	0.01	- Ph.D., Chemical Engineering, National Taiwan University - Ex-Head of Production at DCB BPPF	None	None	None	None
-CMC Strategy Lead -Executive Director	Ae-Ning Lin	F	R.O.C	2013/04/01	515,921	0.17	-	-	14,822	0.00	- Ph.D., Chemistry and Biochemistry, University of Maryland College Park. - Ex-head of Purification and Protein Characterizations at DCB BPPF	None	None	None	None

Title	Name	Gender	Nationality	Date Effective (Note)	Shareholding		Spouse & Minor Shareholding		Shareholding by Nominee Arrangement		Experience (Education)	Other Position	Managers who are Spouses or Within Two Degrees of Kinship		
					Shares	%	Shares	%	Shares	%			Title	Name	Relation
-Executive Director	Ching-Ying Chen	F	R.O.C	2021/06/07	78,989	0.03	-	-	16,922	0.01	- Master of Chemical Engineering, National Taiwan University of Science and Technology - V.P., MYCENAX Biotech Inc. - Manager, R&D Department, Taiwan Advance Bio-Pharmaceutical Inc. - Manager, DCB	None	None	None	None
-Executive Director	Ywan-Feng Li	F	R.O.C	2022/04/18	36,750	0.01	-	-	16,922	0.01	- Ph.D., Biology, University of North Carolina at Chapel Hill, USA - Vice President, Medical, Clinical & Regulatory Center, United Biopharma - Division of pharmaceutical science, Center for drug evaluation-Taiwan	None	None	None	None
-Senior Director	Tsan-Hui Wu	M	R.O.C	2017/05/01	241,098	0.08	-	-	11,375	0.00	- Ph.D., Biochemistry, National Taiwan University - Manager, R&D, PharmaEssentia - Director, R&D, Adimmune Corporation - Director, R&D, TPG biologics	None	None	None	None
-Senior Director	Hwei-Rung Wang (Note e)	F	R.O.C	2022/09/26	20,008	0.01	-	-	0	0.00	- Ph.D., Material Science and Engineering, Univ. of Michigan - Director, Drug Delivery and Device Development, Alexion - Principal Engineer and Senior Engineer, Biogen Idec - Principal Engineer, Amgen	None	None	None	None
-Director	Chung-Huan Lin	M	R.O.C	2019/01/02	96,683	0.03	-	-	14,723	0.00	- MBA, Case Western Reserve University - Sr. BD Manager, ScinoPharm Taiwan - BD Manager, TWi Pharma	None	None	None	None
-Director	Yu-Wen Liu	F	R.O.C	2019/05/20	119,837	0.04	-	-	14,723	0.00	- MBA, Business, St. U. of New York, New Paltz - Manager, China Productivity Center	None	None	None	None
-Director	Tsung-Chih Wang	M	R.O.C	2020/08/03	40,171	0.01	578	0.00	14,723	0.00	- MS, Taipei Medical University - Marketing Manager, Marketing, Novartis Sandoz - Pricing Strategy Manager, Pfizer	None	None	None	None
-Director	Ming-Tao Pai	M	R.O.C	2020/12/01	69,179	0.02	-	-	14,723	0.00	- Ph.D., National Tsing Hua University - Director, Bio Manufacturing, WuXi Biologics - Manager, MD, Taiwan Liposome Company	None	None	None	None

Title	Name	Gender	Nationality	Date Effective (Note)	Shareholding		Spouse & Minor Shareholding		Shareholding by Nominee Arrangement		Experience (Education)	Other Position	Managers who are Spouses or Within Two Degrees of Kinship		
					Shares	%	Shares	%	Shares	%			Title	Name	Relation
-Director	Chih-Yuan Ma	M	R.O.C	2022/12/16	3,498	0.00	-	-	347	0.00	- Ph.D., Institute of Basic Medical Sciences, National Cheng Kung University - Associate Director, PMO - Assistant Director, PM Department, WuXi Biologics - Assistant Supervisor, Pipeline Management, MYCENAX Biotech Inc.	None	None	None	None
-Director	Sz-Wei Wu	M	R.O.C	2023/07/03	13,459	0.00	-	-	531	0.00	- Ph.D., National Taiwan University - Sr. Director, Adagene Inc. - Director, WuXi Biologics - Manager, CHO Pharma - Sr. Application specialist, ThermoFisher Scientific - Postdoctoral Fellow, Academia Sinica	None	None	None	None

Note:

a. Date effective is the date which be appointed as the position, not the actual date of on duty.

b. The stock shares delivered to the trust account, and the vested conditions in the restricted stock issuance method will be reversed according to the vested ratio.

c. If a manager's experience is related to their current position, such as having worked at the accounting firm or its affiliate during the disclosure period, the title and position shall be specified: None.

d. Where the chairperson of the board of directors and the general manager or person of an equivalent post (the highest-level manager) of a company are the same person, spouses, or relatives within the first degree of kinship, an explanation shall be given of the reason for, reasonableness, necessity thereof, and the measures adopted in response thereto: Please refer to the following paragraph.

e. Hwei-Rung Wang resigned on February 14, 2025.

(3) Where the chairperson of the board of directors and the general manager or person of an equivalent post (the highest-level manager) of a company are the same person, spouses, or relatives within the first degree of kinship, an explanation shall be given of the reason for, reasonableness, necessity thereof, and the measures adopted in response thereto:

The Shareholders Meeting elected the 5th term of the Board on 2022/6/10. The Board nominated Director Lee-Cheng Liu as the Chairman of the Board at the unanimous consent of the Directors on the same day.
It is necessary to establish four seats for Independent Directors for the Chairman acting also in the capacity as the President. The Company has complied with applicable law in this regard. The number of Independent Directors and representatives of shareholders from the public sector occupied more than half of the seats of the 5th Board that the monitoring capacity is sound.

On the basis of the current stage of the operation and management of the Company, and in consideration of the development in the future, the 5th Board nominated Director and President Lee-Cheng Liu as the Chairman of the Company for the full-range operation of the Company.
For the proper pursuit of corporate governance and strengthening the independence of the Board, the 5th Board also requested the Company to select the right candidate to act as the President of the Company at the right time.

2. Remuneration of Directors, Supervisors, President, and Vice Presidents

(1) Remuneration of Directors

(A)Remuneration of Directors (including Independent Directors) in 2024

Unit: NT$ thousands; %

Title	Name	Remuneration								Ratio of Total Remuneration (A+B+C+D) to Net Income (%)		Relevant Remuneration Received by Directors Who are Also Employees								Ratio of Total Compensation (A+B+C+D+E+F+G) to Net Income (%)		Remuneration from ventures other than subsidiaries or from the parent company
		Base Compensation (A)		Severance Pay (B)		Directors Compensation(C)		Allowances (D)				Salary, Bonuses, and Allowances (E)		Severance Pay (F)		Employee Compensation (G)						
		The company	All companies in the consolidated financial statements	The company	All companies in the consolidated financial statements	The company	All companies in the consolidated financial statements	The company	All companies in the consolidated financial statements	The company	All companies in the consolidated financial statements	The company	All companies in the consolidated financial statements	The company	All companies in the consolidated financial statements	The company		Companies in the consolidated financial statements		The company	Companies in the consolidated financial statements	
																Cash	Stock	Cash	Stock			
Chairman Lee-Cheng Liu		0	0	0	0	0	0	35	35	35 (0.005)	35 (0.005)	20,131 (Note)	20,131 (Note)	0	0	0	0	0	0	20,166 (2.888)	20,166 (2.888)	0
Director National Development Fund, Executive Yuan		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Director Representative Hsiu-Hui Chen		0	0	0	0	0	0	35	35	35 (0.005)	35 (0.005)	0	0	0	0	0	0	0	0	35 (0.005)	35 (0.005)	0
Director Formosa Laboratories, Inc.		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Director Representative Cheng-Yu Cheng		0	0	0	0	0	0	35	35	35 (0.005)	35 (0.005)	0	0	0	0	0	0	0	0	35 (0.005)	35 (0.005)	0
Director Yao-Hwa Glass Co., Ltd, Management Commission		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Director Representative Ku-Sung Weng		0	0	0	0	0	0	30	30	30 (0.004)	30 (0.004)	0	0	0	0	0	0	0	0	30 (0.004)	30 (0.004)	0
Director Foxconn Technology Co., Ltd.		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Director Representative Yu-Ting Chen		0	0	0	0	0	0	35	35	35 (0.005)	35 (0.005)	0	0	0	0	0	0	0	0	35 (0.005)	35 (0.005)	0
Director Representative Chun-Fu Lu		0	0	0	0	0	0	30	30	30 (0.004)	30 (0.004)	0	0	0	0	0	0	0	0	30 (0.004)	30 (0.004)	0

Unit: NT$ thousands; %

Title	Name	Remuneration								Ratio of Total Remuneration (A+B+C+D) to Net Income (%)		Relevant Remuneration Received by Directors Who are Also Employees								Ratio of Total Compensation (A+B+C+D+E+F+G) to Net Income (%)		Remuneration from ventures other than subsidiaries or from the parent company
		Base Compensation (A)		Severance Pay (B)		Directors Compensation(C)		Allowances (D)				Salary, Bonuses, and Allowances (E)		Severance Pay (F)		Employee Compensation (G)						
		The company	All companies in the consolidated financial statements	The company	All companies in the consolidated financial statements	The company	All companies in the consolidated financial statements	The company	All companies in the consolidated financial statements	The company	All companies in the consolidated financial statements	The company	All companies in the consolidated financial statements	The company	All companies in the consolidated financial statements	The company		Companies in the consolidated financial statements		The company	Companies in the consolidated financial statements	
																Cash	Stock	Cash	Stock			
Independent Director	Ming-Thaur Chang	960	960	0	0	0	0	35	35	995 (0.142)	995 (0.142)	0	0	0	0	0	0	0	0	995 (0.142)	995 (0.142)	0
Independent Director	Po-Chih Chen	960	960	0	0	0	0	30	30	990 (0.142)	990 (0.142)	0	0	0	0	0	0	0	0	990 (0.142)	990 (0.142)	0
Independent Director	Fu-Shiow Yin	960	960	0	0	0	0	35	35	995 (0.142)	995 (0.142)	0	0	0	0	0	0	0	0	995 (0.142)	995 (0.142)	0
Independent Director	Ming-Shen Chen	960	960	0	0	0	0	35	35	995 (0.142)	995 (0.142)	0	0	0	0	0	0	0	0	995 (0.142)	995 (0.142)	0

a. Salary, Bonuses, and Allowances (E) including the share-based payment.

b. Please describe the policy, system, standard, and structure of remuneration to independent directors, and the correlation between duties, risk, and time input with the amount of remuneration:

If the Company has net profit in this fiscal year, the Company shall set aside 3% (inclusive) or less of its profits as a bonus to Directors. The distribution of director remuneration shall be heard by over two-thirds of the Board of Directors, be voted in favor of implementation by over one-half of the directors present and represented and also be reported at the shareholders' meeting.

The Company did not pay any director remuneration during the previous two years. Directors only received traffic allowance for conducting businesses. Independent directors receive fixed emoluments for performing businesses. The aforesaid traffic allowance and emoluments for conducting business have been reviewed by the Remuneration Committee and approved by the Board of Directors.

c. In addition to the above remuneration, director remuneration shall be disclosed as follows when received from companies included in the consolidated financial statements in the most recent year to compensate directors for their services, such as being independent contractors: None.

(B)Range of Remuneration for Directors (including Independent Directors)

Range of Remuneration	Name of Directors			
	Total of (A+B+C+D)		Total of (A+B+C+D+E+F+G)	
	The company	Companies in the consolidated financial statements (H)	The company	Companies in the consolidated financial statements (I)
Less than NT$ 1,000,000	Chairman - Lee-Cheng Liu			
	Directors - National Development Fund, Executive Yuan Representative: Hsiu-Hui Chen - Formosa Laboratories, Inc. Representative: Cheng-Yu Cheng - Yao-Hwa Glass Co., Ltd, Management Commission Representative: Ku-Sung Weng - Foxconn Technology Co., Ltd. Representative: Yu-Ting Chen Representative: Chun-Fu Lu		Directors - National Development Fund, Executive Yuan Representative: Hsiu-Hui Chen - Formosa Laboratories, Inc. Representative: Cheng-Yu Cheng - Yao-Hwa Glass Co., Ltd, Management Commission Representative: Ku-Sung Weng - Foxconn Technology Co., Ltd. Representative: Yu-Ting Chen Representative: Chun-Fu Lu	
	Independent Directors - Ming-Thaur Chang - Po-Chih Chen - Fu-Shiow Yin - Ming-Shen Chen		Independent Directors - Ming-Thaur Chang - Po-Chih Chen - Fu-Shiow Yin - Ming-Shen Chen	
NT$1,000,000 (Included) ~ NT$2,000,000 (Not included)	-	-	-	-
NT$2,000,000 (Included) ~ NT$3,500,000 (Not included)	-	-	-	-
NT$3,500,000 (Included) ~ NT$5,000,000 (Not included)	-	-	-	-
NT$5,000,000 (Included) ~ NT$10,000,000 (Not included)	-	-	-	-
NT$10,000,000 (Included) ~ NT$15,000,000 (Not included)	-	-	-	-
NT$15,000,000 (Included)~ NT$30,000,000 (Not included)	-	-	Chairman - Lee-Cheng Liu	
NT$30,000,000 (Included) ~ NT$50,000,000 (Not included)	-	-	-	-
NT$50,000,000 (Included) ~ NT$100,000,000 (Not included)	-	-	-	-
Greater than or equal to NT$100,000,000	-	-	-	-
Total	10			

(2) Remuneration of Supervisors

EirGenix, Inc. has set up the Audit Committee on June 12th, 2018.

(3) Remuneration of the President and Vice President

A.Remuneration of the President and Vice Presidents in 2024

Unit: NT$ thousands

Title	Name	Salary(A)		Severance Pay (B)		Bonuses and Allowances (C) (Note)		Employee Compensation (D)				Ratio of total compensation (A+B+C+D) to net income (%)		Remuneration from ventures other than subsidiaries or from the parent company
		The company	All companies in the consolidated financial statements	The company	All companies in the consolidated financial statements	The company	All companies in the consolidated financial statements	The company		All companies in the consolidated financial statements		The company	All companies in the consolidated financial statements	
								Cash	Stock	Cash	Stock			
President	Lee-Cheng Liu	17,058	17,058	216	216	13,991	13,991	0	0	0	0	31,265 (4.48)	31,265 (4.48)	0
Senior Vice President	Chih-Jung Chang													
Vice President	Hsiu-Chuan Yang													

Note: Remuneration of the President and Vice Presidents includes the expenses of share-based payment.

B. Range of Remuneration for President and Vice President

Range of Remuneration	Name of President and Vice Presidents	
	The company	Companies in the consolidated
Less than NT$ 1,000,000	-	-
NT$1,000,000 (Included)~ NT$2,000,000(Not included)		
NT$2,000,000 (Included)~ NT$3,500,000(Not included)	-	-
NT$3,500,000 (Included) ~ NT$5,000,000(Not included)		
NT$5,000,000 (Included) ~ NT$10,000,000(Not included)	Chih-Jung Chang, Hsiu-Chuan Yang	
NT$10,000,000 (Included) ~ NT$15,000,000(Not included)		
NT$15,000,000 (Included) ~ NT$30,000,000(Not included)	Lee-Cheng Liu	
NT$30,000,000 (Included) ~ NT$50,000,000(Not included)	-	-
NT$50,000,000 (Included) ~ NT$100,000,000(Not included)	-	-
Greater than or equal to NT$100,000,000	-	-
Total	3	

C. Managerial officers with the top five highest remuneration amounts

Unit: NT$ thousands

Title	Name	Salary(A)		Severance Pay (B)		Bonuses and Allowances (C)		Employee Compensation (D)				Ratio of total compensation (A+B+C+D) to net income (%)		Remuneration from ventures other than subsidiaries or from the parent company
		The company	All companies in the consolidated financial statements	The company	All companies in the consolidated financial statements	The company	All companies in the consolidated financial statements	The company		All companies in the consolidated financial statements		The company	All companies in the consolidated financial statements	
								Cash	Stock	Cash	Stock			
President	Lee-Cheng Liu	9,235	9,235	-	-	10,896	10,896	0	0	0	0	20,131 (2.88)	20,131 (2.88)	0
Senior Vice President	Chih-Jung Chang	4,240	4,240	108	108	1,498	1,498	0	0	0	0	5,846 (0.84)	5,846 (0.84)	0
Vice President	Hsiu-Chuan Yang	3,583	3,583	108	108	1,597	1,597	0	0	0	0	5,288 (0.76)	5,288 (0.76)	0
Executive Director	Ching-Ying Chen	2,851	2,851	108	108	2,042	2,042	0	0	0	0	5,001 (0.72)	5,001 (0.72)	0
Executive Director	Shang-Chung Ju	3,179	3,179	108	108	1,089	1,089	0	0	0	0	4,376 (0.63)	4,376 (0.63)	0

Note: Bonuses and Allowances include the expenses of share-based payment.

(4) Employee Profit Sharing Granted to Management Team: None.

(5) Comparison of Remuneration for Directors, Supervisors, President and Vice Presidents in the Most Recent Two Fiscal Years and Remuneration Policy for Directors, Supervisors, President and Vice President

A. The ratio of total remuneration paid by the Company and by all companies included in the consolidated financial statements for the two most recent fiscal years to directors, supervisors, president, and vice presidents of the Company, to the net income.

Item / Title	Ratio of total remuneration paid to directors, supervisors, president, and vice presidents to net income (%)			
	2024		2023	
	Total remuneration	Companies in the consolidated financial statements	Total remuneration	Companies in the consolidated financial statements
Directors	4,175	(0.60)	4,120	(0.45)
President and Vice President	31,265	(4.48)	50,260	(5.49)

B. The policies, standards, and portfolios for the payment of remuneration, the procedures for determining remuneration, and the correlation with risks and business performance.

(A) Remuneration for Directors

Suppose the Company has net profit in this fiscal year. In that case, the Company shall set aside 3% (inclusive) or less of its profits as a bonus to Directors, and over two-thirds shall hear the distribution of director remuneration of the Board of Directors, be voted in favor of implementation by over one-half of the directors present and represented and be reported at the shareholders' meeting. The Company shall first offset its losses in previous years that have not been previously offset, and then set aside annual profits as a bonus to the Company's employees and set aside annual profits as a bonus to Directors.

EirGenix did not pay any director remuneration during the previous two years. Directors only received traffic allowances for conducting business. Independent directors receive fixed emoluments for performing businesses. The remaining remuneration to directors is the salary of the current Chairman as an employee.

The aforesaid traffic allowances and emoluments for conducting businesses have been reviewed by Remuneration Committee and approved by the Board of Directors.

(B) President and Vice Presidents

Suppose the Company has net profit in this fiscal year. In that case, the Company shall set aside between 1% to 5% of its profits as a bonus to the Company's employees. The distribution of bonus to employees may be made by way of cash or shares by the resolution of the Board of Directors. The employees may include certain employees of the subsidiaries who meet the conditions prescribed by the Company. Over two-thirds shall hear the distribution of employee remuneration and director remuneration of the Board of Directors, be voted in favor of implementation by over one-half of the directors present and represented and be reported at the shareholders' meeting.

The President and Vice Presidents of the Company are remunerated in commensurate with their position, contribution to the Company and with reference to industry standards subject to the review of the Remuneration Committee and reporting to the Board for final approval. No remuneration has been appropriated by the company as remuneration to employees in the last 2 years.

(C) Association with operation performance and risks in the future

The remunerations to the Directors and managers will be determined on the basis of the operation of the Company, the operation risk and development in the future with reference to industry standards and the assigned duties and contribution, and the association with the operating performance at a significant level. The management and the Remuneration Committee of the Company will review the remuneration level at regular intervals for appropriate adjustment for a proper balance between risk control and sustainable development of the Company.

3. Implementation of Corporate Governance

(1) Operations of the Board of Directors:

A. Board Meeting Attendance

A total of 8 (A) meetings of the Board of Directors was held in 2024. The attendance of directors was as follows:

Title	Name	Actual Attendance (B)	By Proxy	Attendance Rate (%) (B/A)	Remarks
Chairman	Lee-Cheng Liu	8	0	100	-
Director	National Development Fund, Executive Yuan Representative: Hsiu-Hui Chen	8	0	100	-
Director	Formosa Laboratories, Inc. Representative: Cheng-Yu Cheng	8	0	100	-
Director	Yao-Hwa Glass Co., Ltd, Management Commission Representative: Ku-Sung Weng	7	1	87.50	-
Director	Foxconn Technology Co., Ltd. Representative: Chun-Fu Lu	7	1	87.50	-
Director	Foxconn Technology Co., Ltd. Representative: Yu-Ting Chen	8	0	100	-
Independent Director	Ming-Thaur Chang	8	0	100	-
Independent Director	Po-Chih Chen	7	1	87.50	-
Independent Director	Fu-Shiow Yin	8	0	100	-
Independent Director	Ming-Shen Chen	8	0	100	-

A total of 3 (A) meetings of the Board of Directors was held by the end of April 2025. The attendance of directors was as follows:

Title	Name	Actual Attendance (B)	By Proxy	Attendance Rate (%) (B/A)	Remarks
Chairman	Lee-Cheng Liu	3	0	100	-
Director	National Development Fund, Executive Yuan Representative: Hsiu-Hui Chen	3	0	100	-
Director	Formosa Laboratories, Inc. Representative: Cheng-Yu Cheng	3	0	100	-
Director	Yao-Hwa Glass Co., Ltd, Management Commission Representative: Ku-Sung Weng	3	0	100	-
Director	Foxconn Technology Co., Ltd. Representative: Chun-Fu Lu	2	1	66.67	
Director	Foxconn Technology Co., Ltd. Representative: Yu-Ting Chen	3	0	100	-
Independent Director	Ming-Thaur Chang	3	0	100	-
Independent Director	Po-Chih Chen	3	0	100	-
Independent Director	Fu-Shiow Yin	3	0	100	-
Independent Director	Ming-Shen Chen	3	0	100	-

Other mentionable items:

B. In any of the following circumstances, the dates of the meetings, sessions, contents of motion, all independent directors' opinions and the company's response to independent directors' opinion should be specified:

(A).The circumstances referred to in Article 14-3 of the Securities and Exchange Act:

Date of Meeting Term of Board of Directors	Contents of Motion	Independent Director's Opinion	The Company's Response to Independent Director's Opinion
2024/03/08 The 13th meeting of the 5th board	a. Approved the CPAs replacement due to PricewaterhouseCoopers Taiwan internal organization adjustment. b. Approved the motion of the ratification of the assessment of the independence and competence of the CPAs retained as external Auditors. c. Approved the motion of the ratification of the appointment of CPAs as external auditors and the remuneration to the CPAs. d. Adoption of the 2024 1st Employee Restricted Stock Awards. e. Approved the Company will raise capital through private placements of common shares. f. Approved to sign the contract with clinical CRO and the relevant companies for Phase III clinical trial of the EG1206A.	None	Not applicable
2024/05/09 The 15th meeting of the 5th board	a. Approved the participation of the cash capital increase of AP Biosciences Inc. based on the potential opportunity of business cooperation and the consideration of financial investment. b. Approved to grant 2022 Employee Stock Options to employees.		
2024/08/08 The 16th meeting of the 5th board	a. Approved the rename and amendment of the "Operational Procedure for Preparation and Validation of the Sustainability Report" b. Approved the amendment of "IA-18 Implementation of authorization" and "deputy systems and Approval Authority Form".		
2024/11/12 The 18th meeting of the 5th board	a. Approved the Company's application for listing on the Taiwan Stock Exchange. b. Approved the engagement of an accounting firm to assist with the Company's listing on the Taiwan Stock Exchange. c. Approved the adoption of the "Sustainability Information Management Guidelines." d. Approved the amendment of the "2024 Employee Restricted Stock Awards." e. Approved to grant 2024 Employee Restricted Stock Awards to employees.		
2024/12/16 The 19th meeting of the 5th board	a. Approved to repurchase own company stock to transfer to employees.		
2024/12/20 The 20th meeting of the 5th board	a. Approved the amendment of Implementation Report for the Sound Business Plan and estimation of Income Statement. b. Approved the amendment of the Company's "Corporate Governance Best Practice Principles." c. Approved the authorization for independent directors to sign audit reports. d. Approved the amendments to the Company's "Internal Control System," "Implementation Rules for Internal Audits – Internal Audit System," "Procedures of the receipt and use of negotiable instruments" "Procedures of Managing the Preparation of Financial Statements," "Procedures of Preventing Insider Trading" and its appendix, "Shareholder Services Management Procedures," and "IA-23 Risk Assessment Procedures for Internal Control Deficiencies." e. Approved the amendment of "IA-18 Implementation of authorization" and "deputy systems and Approval Authority Form". f. Approved the proposal to the shareholders meeting to lift the restrictions on the non-competition of directors and their representatives.		
2025/03/12 The 22nd meeting of the 5th board	a. Approved the motion of the ratification of the assessment of the independence and competence of the CPAs retained as external Auditors. b. Approved the motion of the ratification of the appointment of CPAs as external auditors and the remuneration to the CPAs. c. Adoption of the 2025 1st Employee Restricted Stock Awards. d. Approved the Company will raise capital through private placements of common shares. e. Approved the extension of the land lease agreement in land of Zhubei Phase II for 40 years with the Hsinchu Science Park Bureau, NSTC. f. Approved changes in the Company's accounting estimates.		

Date of Meeting Term of Board of Directors	Contents of Motion	Independent Director's Opinion	The Company's Response to Independent Director's Opinion
	g. Approved the proposal to the shareholders meeting to lift the restrictions on the non-competition of directors and their representatives h. Approved the participation in the investment in GeneFab, LLC based on the potential opportunity of business cooperation and the consideration of strategic investment.		

(B). In addition to said circumstances, any other matter about which an independent director expresses an objection or reservation that has been included in records or stated in writing: None.

C. If there is Directors' avoidance of motions in conflict of interest, the Directors' names, contents of motions, causes for avoidance, and voting should be specified:

Date of Meeting	Name	Meeting Agenda	Causes for avoidance	Result of Voting
2024/01/25	Lee-Cheng Liu	a. Approved the granting of annual performance bonuses to managers based on the 2023 performance bonus, budget and evaluation results.	Excused from the discussion and resolution of this agenda item pursuant to paragraph 3 of Article 206 of the Company Act.	
2024/05/09	Lee-Cheng Liu	a. Approved the 2024 salary adjustment plan for managers and employees in accordance with the Company's compensation policy, system, standards, and structure.		
2024/09/30	Lee-Cheng Liu	a. Approved the cancellation of shares reclaimed due to unmet vesting conditions under the Company's Restricted Stock Awards Issuance Plan, and the designation of the capital reduction record date.		
2024/12/20	Ming-Thaur Chang National Development Fund, Executive Yuan Yao-Hwa Glass Co., Ltd, Management Commission Lee-Cheng Liu	a. Approved the authorization for independent directors to sign audit reports. b. Approved the proposal to the shareholders meeting to lift the restrictions on the non-competition of directors and their representatives. c. Approved the appointment and compensation of senior managers at Grade 13 and above.		

D. Conducting Evaluations of Board Performance

Evaluation cycle	Evaluation period	Evaluation scope	Evaluation method	Evaluation content
Conducting once a year	January 1st— December 31st, 2024	Board of Directors, individual board member, and functional committees (including Remuneration Committee and Audit Committee)	Internal self-evaluation of the board of directors and self-evaluation of directors	a. Performance evaluation of the board of directors: Include the degree of participation in the company's operations, the decision-making quality of the board of directors, the composition and structure of the board of directors, the selection and continuous education of directors, internal control, etc. Finance Dept. has reported to Board in 2025Q1. b. Performance evaluation of individual directors: Include grasping the company's objectives and tasks, recognition of directors' responsibilities, level of participation in the company's operations, internal relationship management and communication, expertise and continuous education of directors, internal control, etc. Finance Dept. has reported to Board in 2025Q1. c. Performance evaluation of functional committees: the degree of participation in the company's operations, the recognition of functional committee's responsibilities, the decision-making quality of functional committees, the composition of functional committees and the selection of members, internal control, etc. Finance Dept. has reported to Board in 2025Q1. d. The Board, Boardmembers, and functional committees (including Remuneration Committee and Audit Committee) receiveda self-assessment score over 90. Finance Dept. has reported to Board in 2025Q1.
Conducting every three years	October 1st,2021— September 30th, 2022	Conducting Evaluations of Board Performance	Appointment of the external professional institutions: Taiwan Investor Relations Institute	a. The organization and professional development of the Board. b. Quality of decision-making of the Board. c. The performance result of the Board. d. Internal control and risk management. e. Level of participation in corporate social responsibility by the Board.

E. An evaluation of targets for strengthening of the functions of the board during the current and immediately preceding fiscal years (e.g., the establishment of the Audit Committee, improvement of information disclosure transparency) and measures taken toward achievement:

(A) Performance of the Board of Directors' Functions:

(a) The Board of Directors is composed of ten directors (including four independent directors) with rich academic and industry experience. The board of directors follows the "Standards of the Board of Directors' Procedures" and the

"Management Measures for the Operation of the Board of Directors' Procedures" and regularly reviews and discusses various business development plans.

(b) Each Board meeting includes the report on the implementation of resolutions from the previous meeting and significant financial and operational updates, enabling the Board of Directors to effectively monitor the progress of corporate plans and ensure sound decision-making.

(c) The PwC accountants attended the Board meeting, provided taxation and legal information and suggestions, and reported the quarterly financial report inspection results to the Directors.

(d) The Company's Directors actively engage in ongoing corporate governance training. For further information, please refer to the Corporate Governance Practices section of this Annual Report.

(B) EirGenix has elected 4 Independent Director and set up a Remuneration Committee, and an Audit Committee. In 2022, set up the Corporate Governance Committee.

(C) EirGenix has set up the spokesman and vice spokesman system and disclosed the financial and business information on the Market Observation Post System and the corporate website according to laws and regulations.

(2) Operation of Audit Committee

A. Audit Committee Attendance:

A total of 6 (A) meetings of the Audit Committee were held in 2024. The attendance of independent directors was as follows:

Title	Name	Attendance in Person(B)	By Proxy	Attendance rate (%) 【B/A】
Independent Director	Ming-Thaur Chang	6	0	100
Independent Director	Po-Chih Chen	5	1	83.33
Independent Director	Fu-Shiow Yin	6	0	100
Independent Director	Ming-Shen Chen	6	0	100

A total of 1 (A) meetings of the Audit Committee was held by the end of April 2025. The attendance of directors was as follows:

Title	Name	Attendance in Person(B)	By Proxy	Attendance rate (%) 【B/A】
Independent Director	Ming-Thaur Chang	1	0	100
Independent Director	Po-Chih Chen	1	0	100
Independent Director	Fu-Shiow Yin	1	0	100
Independent Director	Ming-Shen Chen	1	0	100

B. In any of the following circumstances, the dates of the meetings, sessions, contents of motion, audit committee's resolutions, and the company's response to the audit committee's opinion should be specified:

(A)The circumstances referred to in Article 14-5 of the Securities and Exchange Act:

Date and Term of Meeting	Contents of Motion	Audit Committee's Resolutions	The Company's Response to Audit Committee's Opinion
2024/03/08 The 12th meeting of the 3rd term	a. Accept 2023 Financial Statements and Business Report b. Ratification of the 2023 Deficit Offset Proposal. c. Approved the CPAs replacement due to PricewaterhouseCoopers Taiwan internal organization adjustment. d. Approved the motion of the ratification of the assessment of the independence and competence of the CPAs retained as external Auditors. e. Approved the motion of the ratification of the appointment of CPAs as external auditors and the remuneration to the CPAs. f. Approved the motion of issuance of the 2023 Declaration of Internal Control System of the Company. g. Adoption of the 2024 1st Employee Restricted Stock Awards. h. Approved the Company will raise capital through private placements of common shares.		
2024/05/09 The 13th meeting of the 3rd term	a. Accept 2024 Q1 Financial Statements. b. Approved to grant 2022 Employee Stock Options to employees.	Consent	Approved as proposed
2024/08/08 The 14th meeting of the 3rd term	a. Accept 2024 Q2 Financial Statements. b. Approved the rename and amendment of the "Operational Procedure for Preparation and Validation of the Sustainability Report" c. Approved the amendment of "IA-18 Implementation of authorization" and "deputy systems and Approval Authority Form".		
2024/11/12 The 15th meeting of the 3rd term	a. Accept 2024 Q3 Financial Statements. b. Approved the classification of accounts receivable overdue for more than three months beyond normal credit terms in Q3 2024 as non-lending in nature. c. Approved the Company's "Statement on Internal Control System. d. Approved the proposal to establish the Company's 'Sustainable Information Management Guidelines.' e. Approved to grant 2024 1st Employee Restricted Stock Awards to employees.		
2024/12/16 The 16th ad hoc meeting of the 3rd term	Approved to repurchase own company stock to transfer to employees.		
2024/12/20 The 17th meeting of the 3rd term	a. Approved the operation plan for the fiscal year 2025. b. Approved the amendment of Implementation Report for the Sound Business Plan and estimation of Income Statement c. Approved the preparation of simplified financial forecast information for Q4 2024 to Q1 2025 in accordance with the requirements for the		

Date and Term of Meeting	Contents of Motion	Audit Committee's Resolutions	The Company's Response to Audit Committee's Opinion
	Company's listing application d. Approved the authorization for independent directors to sign audit reports. e. Approved the amendments to the Company's "Internal Control System," "Implementation Rules for Internal Audits – Internal Audit System," "Procedures of the receipt and use of negotiable instruments" "Procedures of Managing the Preparation of Financial Statements," "Procedures of Preventing Insider Trading" and its appendix, "Shareholder Services Management Procedures," and "IA-23 Risk Assessment Procedures for Internal Control Deficiencies." f. Approved the amendment of "IA-18 Implementation of authorization" and "deputy systems and Approval Authority Form". g. Approved the adoption of the 2025 "Annual Audit Plan." h. Approved the proposal to the shareholders meeting to lift the restrictions on the non-competition of directors and their representatives.		
2025/03/12 The 18th meeting of the 3rd term	a. Accept 2024 Financial Statements and Business Report. b. Ratification of the 2024 Deficit Offset Proposal. c. Approved the motion of the ratification of the assessment of the independence and competence of the CPAs retained as external Auditors. d. Approved the motion of the ratification of the appointment of CPAs as external auditors and the remuneration to the CPAs. e. Approved the motion of issuance of the 2024 Declaration of Internal Control System of the Company. f. Adoption of the 2025 1st Employee Restricted Stock Awards. g. Approved the Company will raise capital through private placements of common shares. h. Approved the extension of the land lease agreement in land of Zhubei Phase II for 40 years with the Hsinchu Science Park Bureau, NSTC. i. Approved changes in the Company's accounting estimates. j. Approved the proposal to the shareholders meeting to lift the restrictions on the non-competition of directors and their representatives. k. Approved the participation in the investment in GeneFab, LLC based on the potential opportunity of business cooperation and the consideration of strategic investment.		

(B)Other matters which were not approved by the Audit Committee but were approved by two-thirds or more of all directors: None.

C. If there are independent directors' avoidance of motions in conflict of interest, the directors' names, contents of motion, causes for avoidance, and voting should be specified:

At the 17th meeting of the 3rd Audit Committee, in order to ensure that audit work is conducted with an independent and objective spirit, the company authorized Independent Director Mr. Ming-Thaur Chang to sign off on the audit reports. As Mr. Chang recused himself due to a conflict of interest, the matter was discussed and approved by Acting Chairperson, Independent Director Mr. Ming-Shen Chen, along with all attending directors.

D. Communications between the independent directors, the Company's chief internal auditor, and CPAs (e.g., the material items, methods and results of audits of corporate finance or operations, etc.):

For the implementation of the supervision mechanism, the internal audit reports are submitted to the board of directors and management for review on a regular basis by the audit unit and also delivered and notified to independent directors according to regulations. The Company's execution of the internal control system is compliant with regulations and will be continually followed up. When a board of directors meeting is held, attending directors with opinions may have discussion and communication. If there's any material violation or any likelihood of material damage to the company, related personnel shall promptly prepare and present a report and notify the independent directors.

The Company invites CPA, independent directors, and internal auditors to the communication meeting at least once a year. CPA will report the Company's financial position and auditing process to independent directors and then listen to the voice of independent directors and the chief internal auditor.

The Company has invited the Independent Auditors to sit in the meetings of the Audit Committee and the Board as observers at least 4 times a year (2024/03/08, 2024/05/09, 2024/08/08, 2024/11/12) for engagement in discussion and review the audit or the result of the quarterly reports and annual financial statements, significant accounting standards and interpretation, applicable legal rules governing securities, and tax law. The internal auditor communicated in the meeting with the independent directors and the CPAs on 2024/11/12, and the topic is the explanation of the risk assessment and key audit issues of the Company in terms of the AQI (Audit Quality Indicators). The conclusion suggested closer attention to key audit issues. In addition to the key point of AQI, independent director suggested sharing the information through the CPAs to guide the company to attach importance to shareholder's right and ESG.

E. The powers of the Committee are as follows:

(a) The adoption of or amendments to the internal control system pursuant to Article 14-1 of the Securities and Exchange Act.

(b) Assessment of the effectiveness of the internal control system.

(c) The adoption or amendment, pursuant to Article 36-1 of the Securities and Exchange Act of the procedures for handling financial or business activities of a material nature, such as acquisition or disposal of assets, derivatives trading, loaning of funds to others, and endorsements or guarantees for others.

(d) Matters in which a director is an interested party.

(e) Asset transactions or derivatives trading of a material nature.

(f) Loans of funds, endorsements, or provision of guarantees of a material nature.

(g) The offering, issuance, or private placement of equity-type securities.

(h) The hiring or dismissal of a certified public accountant, or their compensation.

(i) Annual and semi-annual financial reports.

(j) Other material matters as may be required by this Corporation or by competent authority.

F. EirGenix established the Audit Committee to replace supervisors on June 12, 2018

(3) Corporate Governance Implementation Status and Deviations from "the Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies".

Evaluation Item	Implementation Status			Deviations from "Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies" and Reasons
	Y	N	Abstract Illustration	
1. Does the company establish and disclose the Corporate Governance Best-Practice Principles based on "Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies"?	✓		EirGenix has formulated the Corporate Governance Best Practice Principles and Corporate Social Responsibility Best Practice Principles; and EirGenix has operated in accordance with the institutional regulations of internal control and internal audit, and also formulated institutional measures such as Regulations Governing the Acquisition and Disposal of Assets, Procedures for Endorsements and Guarantees, Procedures for Loaning Funds to Others, Rules of Procedure for the Board of Directors Meetings, Management of Procedure for the Board of Directors, Procedure for Election of Directors, Rules of Procedure for Shareholders Meetings and Codes of Ethical Conduct, with the goal of implementing Corporate Governance.	Compliant with "the Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies".
2. Shareholding structure & shareholders' rights (1) Does the company establish an internal operating procedure to deal with shareholders' suggestions, doubts, disputes, and litigations, and implement based on the procedure?	✓		EirGenix has established a spokesman and vice spokesman system and has dedicated personnel responsible for disclosing corporate information and handling shareholders' suggestions and doubts to ensure shareholders' rights.	Compliant with "the Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies"
(2) Does the company possess the list of its major shareholders as well as the ultimate owners of those shares?	✓		EirGenix has regularly collected the list of shareholders according to the list of shareholders obtained by the stock affair agency on the book closure date of EirGenix and maintains good interaction with major shareholders to further collect the list of ultimate controllers.	Compliant with "the Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies"
(3) Does the company establish and execute the risk management and firewall system within its conglomerate structure?	✓		EirGenix has established a German subsidiary and has also established risk control mechanisms such as Management of Related Party Transactions, Measures for Management of Transactions with Related Party, Specific Companies and Group Enterprises, internal control, and internal audit system, which are regularly reviewed and handled in accordance with regulations	Compliant with "the Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies"
(4) Does the company establish internal rules against insiders trading with undisclosed information?	✓		EirGenix has established the administrative measures for preventing insider trading and Codes of Ethical Conduct from forbidding insiders from acquiring private interests or competing with EirGenix with undisclosed information.	Compliant with "the Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies"
3. Composition and Responsibilities of the Board of Director (1) Does the Board develop and implement a diversified policy for the composition of its members?	✓		Please refer to this Annual Report – E. Diversity and independence of the Board of Directors.	Compliant with "the Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies"
(2) Does the company voluntarily establish other functional committees in addition to the Remuneration Committee and the Audit Committee?	✓		EirGenix has set up a Remuneration Committee in 2016, an Audit Committee in 2018, and Corporate Governance Committee in 2022. EirGenix will set up other types of functional committees as required by operational development.	Compliant with "the Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies"
(3) Does the company establish a standard to measure the performance of the Board and implement it annually, and are performance evaluation results submitted to the Board of Directors and referenced when determining the remuneration of individual directors and nominations for reelection?	✓		On November 11, 2020, the Board of Directors formulated the performance evaluation method for the Board of Directors, specifying that external evaluation shall be carried out at least once every three years. EirGenix conducts performance evaluations regularly every year. As recently as March 8, 2025, the Board of Directors submitted a 2024 internal self-assessment of the Board of Directors, assessing 45 items around the degree of participation in the corporate operation, improvement in the decision-making quality of the Board of Directors, the composition, and structure of the Board of Directors, the election of directors and their continuing education, and internal controls with an average score of more than 90 points, good performance and no major matters to be improved. The Company has retained Taiwan Investor Relations Institute to evaluate the Board in performing its function. The evaluation period was 2021/10/1 to 2022/9/30 and the reporting day was 2022/11/11. The summary of the report has been presented to the Boards on 2023/3/10. The overall condition and recommendation are specified as follows:	Compliant with "the Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies"

Evaluation Item	Implementation Status			Deviations from "Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies" and Reasons
	Y	N	Abstract Illustration	
			A. Establishment of the functional committees for the "Sustainable Development Committee": Assist the Board in the ongoing advocacy and intensification of sustainable development and corporate governance pertinent to corporate social responsibility and review the allocation of corporate sources and performance from a higher altitude, and how to systematically connect with and present the ESG Sustainability Report. These will be essential for vitalizing the function of the Board in monitoring and bolstering management mechanisms. B. Early scheduling of the Board meetings and the key issues of the agenda of the year: There are far too many motions proposed in the sessions of the Board and these motions always entail professional content. The early planning of the schedule allows the Directors who do not participate in the routine operation of the Company understand the operation strategy, policy and progress of the Company systematically in full-range and helps to enhance the functional performance of the Board. C. In other words, it should be high time to prepare the 2022 consolidated financial statements and the schedule in compliance with applicable laws (presentation of unaudited financial statements to the Board for resolution within 75 days after the conclusion of the fiscal year).	
(4) Does the company regularly evaluate the independence of CPAs?	✓		The Audit Committee of the Company consult the AQIs annually for the assessment of the independence and competence of the certified public accountants (CPAs) retained as Independent Auditors and present the assessment report to the Board. There are 17 AQIs including the following dimensions: A. The CPAs do not have any direct or indirect financial interest with the Company, and do not share any benefit. B. There is no undue related between the CPAs and the Group in terms of conflict of interest, financing, or acceptance of kickback. C. The CPAs do not hold any stock or other securities issued by the Group. D. The CPAs do not hold any concurrent positions of the Group. E. No CPA has ever been retained by the Company for more than 7 years and the audit fee is justifiable. F. Annual declaration of the independence of CPAs. G. The CPAs have not been subject to disciplinary action or administrative penalty. H. The stability of audit and taxation staff, provide quality service, conforming to time limit requirement and update information on applicable laws. I. The communication between CPAs and the Directors and Management is good. J. The CPAs have presented recommendation to the system and internal control of the Group and assess and monitor the inherent and potential risks. K. The Board and the Audit Committee assessed the independence of Shu-Fen Yu and Yu-Fang Yan, CPAs of PwC Taiwan on 2025/03/12, and confirmed that they are conforming to the aforementioned requirements in independence and competence and are retained as our Independent Auditors for certification.	Compliant with "the Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies"
4. Does the company appoint a suitable number of competent personnel and a supervisor responsible for corporate governance matters (including but not limited to providing information for directors and supervisors to perform their functions, assisting directors and supervisors with compliance, handling work related to meetings of the board of directors and the shareholders' meetings, and producing minutes of board meetings and shareholders' meetings)?	✓		On May 12, 2021, the Board of Directors approved the appointment of Chief Financial Officer Hsiu-Chuan Yang, who has more than three years of experience in the position of head of finance and stock affairs in public issuing companies, as the head of corporate governance to protect the equities of shareholders, strengthen the functions of the Board of Directors, and be responsible for affairs related to corporate governance jointly with the Finance Department. The head of corporate governance main duties includes the following items: A. Handling matters relating to board meetings and shareholders meetings according to laws. B. Assisting in onboarding and continuous development of directors. C. Furnishing information required for business execution by directors.	Compliant with "the Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies"

Evaluation Item	Implementation Status			Deviations from "Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies" and Reasons
	Y	N	Abstract Illustration	
			D. Assisting directors with legal compliance. E. Report to the Board on review result of the Independent Directors at the time of their nomination, election, and eligibility within the term of office. F. Processing the change in Directors. G. Other matters set out in the articles or corporation or contracts.	

Manager of Corporate Governance Directors' training records

Date	Learning institutions	Course Title	Hours
2024/08/16	Accounting Research and Development Foundation	ESG Development Trends and Sustainability Information Disclosure Regulations	3
2024/09/12	Taipei Exchange	Seminar on Insider Shareholding Guidelines for TPEx-Listed Companies	3
2024/10/01	Accounting Research and Development Foundation	Latest Amendments to the "Regulations Governing Establishment of Internal Control Systems" and Practical Compliance with Internal Control and Internal Audit Regulations Related to Financial Reporting	6

5. Does the company establish a communication channel and build a designated section on its website for stakeholders (including but not limited to shareholders, employees, customers, and suppliers), as well as handle all the issues they care for in terms of corporate social responsibilities	✓		EirGenix has set up the spokesman and vice spokesman system and disclosed the financial and business information on the Market Observation Post System and the corporate website according to laws and regulations, designated dedicated personnel responsible for properly responding to important issues regarding corporate social responsibility concerned by stakeholders, and set up a stakeholder's area on the corporate website to maintain a good and smooth communication channel.	Compliant with "the Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies"
6. Does the company appoint a professional shareholder service agency to deal with shareholder affairs	✓		EirGenix has appointed a professional stock affair agency to handle the shareholders' meeting and stock affairs as the Agency Department of KGI Securities (Stock) Company (Address: 5th Floor, No.2, Section 1, Chongqing South Road, Taipei City, 100502, Tel: (02)2389-2999).	Compliant with "the Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies"
7. Information Disclosure (1) Does the company have a corporate website to disclose both financial standings and the status of corporate governance?	✓		The website of the company is www.eirgenix.com, on which the corporate governance, financial and business information are disclosed in Chinese and English versions.	Compliant with "the Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies"
(2) Does the company have other information disclosure channels (e.g., building an English website, appointing designated people to handle information collection and disclosure, creating a spokesman system, webcasting investor conferences)?	✓		The website of the company is equipped with a language switching interface, including Chinese and English versions; there is also the spokesman and acting spokesman system and special personnel responsible for collecting and disclosing the corporate information. In addition, relevant information about the company's participation in the Investor Conference has been published on the Market Observation Post System and the corporate website in accordance with regulations.	Compliant with "the Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies"
(3) Does the company announce and report annual financial statements within two months after the end of each fiscal year and announce and report Q1, Q2, and Q3 financial statements, as well as monthly operation results, before the prescribed time limit?		✓	EirGenix has announced and reported the financial reports for the first, second and third quarters and the operating conditions for each month in advance before the prescribed time limit; and has not announced and reported the annual financial report within two months after the end of the accounting year.	Plan to announce and report annual financial statements within two months after the end of each fiscal year.
8. Is there any other important information to facilitate a better understanding of the company's corporate governance practices (e.g., including but not limited to employee rights, employee wellness, investor relations, supplier relations, rights of stakeholders, directors' and supervisors' training records, the implementation of risk management policies and risk evaluation measures, the implementation of customer relations policies, and purchasing insurance for directors and supervisors)?	✓		(1)Employee rights and employee care: EirGenix has regularly held all-staff communication meetings and Management and Labor Council to exchange opinions with employees, and also learned about the needs of employees in a timely manner through multiple mechanisms such as communication, educational training, and incentive.	Compliant with "the Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies"
	✓		(2)Investor relations and stakeholder rights: In addition to disclosing the financial and business information in accordance with laws and regulations, EirGenix has also established the spokesman and vice spokesman system and special personnel responsible for maintaining good investor relations and stakeholder rights.	Compliant with "the Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies"
	✓		(3)Supplier relationship: EirGenix has set up a supplier management policy whose cooperation with suppliers complies with laws and regulations, and contracts to safeguard the rights of both parties.	Compliant with "the Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies"
(4)Directors' training records in 2024: A. Chairman-Lee-Cheng Liu: Corporate Governance and Corporate Sustainability Workshop; Insider Shareholding Compliance Briefing for TPEx-Listed Companies. B. Director-Hsiu-Hui Chen: Corporate Governance and Corporate Sustainability Workshop; Business Operations and Risk Management Strategies				Compliant with "the Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies"

Evaluation Item	Implementation Status			Deviations from "Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies" and Reasons
	Y	N	Abstract Illustration	
C. Director-Cheng-Yu Cheng: Next-Generation Data Centers: Development Trends in Silicon Photonics and AI Servers; Geoeconomic Risks and Green Transition D. Director-Ku-Sung Weng: Legal Liabilities and Case Studies Related to Corporate Control Disputes; Effective Internal Controls for Sustainability Reporting E. Director-Chun Fu Lu: Asset Succession and Tax Planning Strategies; 2024 Taishin Net Zero Summit F. Director-Yu-Ting Chen: Corporate Governance and Corporate Sustainability Workshop; Corporate Governance: The Role and Accountability of Controlling Shareholders G. Independent Director-Ming-Thaur Chang: TPEx Family: "AI Strategy and Governance"; Analysis of International Climate Change Development Trends and Practical Case Studies H. Independent Director- Po-Chih Chen: Geoeconomic Risks and Green Transition; Trends and Common Issues in Supply Chain Restructuring for Taiwanese Businesses in Mainland China I. Independent Director-Fu-Shiow Yin: How the Board Ensures Corporate Sustainability – Starting with Talent Discovery and Development; Corporate Governance – Trends in the Development of Generative AI Industry J. Independent Director-Ming-Shen Chen: Corporate Governance and Corporate Sustainability Workshop; TPEx Family: "AI Strategy and Governance"				
	✓		(5)Status of implementation of risk management policies and risk measurement standards: EirGenix has set up the risk management policies and procedures and regularly submitted them to the Board of Directors; EirGenix has operated in accordance with laws and regulations, corporate management measures, and various internal control systems, and carried out various risk assessments and controls. Report to the status of risk management at regular intervals of the year: the last report to the Board was presented on 2024/12/20.	Compliant with "the Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies"
	✓		(6)Status of implementation of customer policies: EirGenix has cooperated with the client in accordance with laws and regulations, and contracts to safeguard the equities of both parties and also designated exclusive personnel responsible for client communication and contact matters.	Compliant with "the Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies"
	✓		(7)Status of EirGenix purchasing liability insurance for Directors: In the Articles of Incorporation, it has been stated clearly that, within the term of the Directors, EirGenix shall purchase liability insurance for the compensation liabilities of the Directors in accordance with the law in the scope of their business. EirGenix has underwritten the Directors' Liability Insurance of US$ 5 million to Fubon Insurance Co., Ltd.. In the future, in addition to continuing to underwrite the insurance according to regulations, EirGenix will adjust the insured amount in due course according to operation needs to provide appropriate coverage.	Compliant with "the Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies"
9. Please explain the improvements which have been made in accordance with the results of the Corporate Governance Evaluation System released by the Corporate Governance Center, Taiwan Stock Exchange, and provide the priority enhancement measures. The Company has been repeatedly recognized for outstanding performance in corporate governance assessments in recent years, and will evaluate the feasibility of the strategies in the current year and future through the items that have not passed the evaluation every year in the future, obtain a balance between the policy development of the competent authority and the development of the company, and immediately promote the implementation plan for the items that can be improved at this stage.				

(4) Composition, Responsibilities and Operations of the Remuneration Committee

A.Members of Remuneration Committee

Title	Criteria / Name	Professional Qualification / Work Experience	Independence Criteria	Number of Other Public Companies in Which the Individual is Concurrently Serving as a Remuneration Committee Member
Independent Director	Ming-Thaur Chang	Please refer to Information of Directors.		0
Independent Director	Po-Chih Chen			0
Independent Director	Fu-Shiow Yin			1
Independent Director	Ming-Shen Chen			0

B.Information of Remuneration Committee Operation

(A) Total members of EirGenix's Remuneration Committee are four people.

(B) The remuneration committee shall exercise the care of a good administrator in faithfully performing the official powers listed below and shall submit its recommendations for deliberation by the board of directors.

(a) Prescribe and periodically review the Remuneration Committee Charter.

(b) Prescribe and periodically review the performance review and remuneration policy, system, standards, and structure for directors and managerial officers.

(c) Periodically evaluate and prescribe the remuneration of directors and managerial officers.

(C) The current term of the Remuneration Committee is from August 11, 2022, until June 9, 2025.

A total of 4 (A) Remuneration Committee meetings were held in 2024. The attendance record of the Remuneration Committee members was as follows:

Title	Name	Attendance in Person(B)	By proxy	Attendance Rate (%)【B/A】
Convener	Ming-Thaur Chang	4	0	100
Committee Member	Po-Chih Chen	3	1	75
Committee Member	Fu-Shiow Yin	3	1	75
Committee Member	Ming-Shen Chen	4	0	100

A total of 2 (A) Remuneration Committee meetings was held by the end of April 2025. The attendance of directors was as follows:

Title	Name	Attendance in Person(B)	By Proxy	Attendance rate (%)【B/A】
Independent Director	Ming-Thaur Chang	2	0	100
Independent Director	Po-Chih Chen	2	0	100
Independent Director	Fu-Shiow Yin	2	0	100
Independent Director	Ming-Shen Chen	2	0	100

(D) Other mentionable items:

(a) If the board of directors declines to adopt or modifies a recommendation of the remuneration committee, it should specify the date of the meeting, session, the content of the motion, resolution by the board of directors, and the Company's response to the remuneration committee's opinion (e.g., the remuneration passed by the Board of Directors exceeds the recommendation of the remuneration committee, the circumstances and cause for the difference shall be specified): None.

(b) Resolutions of the remuneration committee objected to by members or expressed reservations and recorded or declared in writing, the date of the meeting, session, the content of the motion, all members' opinions, and the response to members' opinion should be specified: None.

(c) All members of the Company's Remuneration Committee the attended the committee meetings at least twice a year, with a total attendance of 100% and regularly review the policies, systems, standards, and structures for performance evaluation and remuneration to directors and managers as at the 13th meeting convened by the 3rd Remuneration Committee, to comply with the existing system. Its regular review is based on three major aspects: 1. to ensure external competitiveness, it formulates the salary structure for the senior management with reference to the salary levels in the same industry to enhance the Company's competitive advantage; 2. it evaluates the values of their work according to their contribution and

abilities based on their responsibilities and positions to ensure fairness in the organization; 3. it rewards them for their special performance and links senior managers' remuneration with the Company's business performance to ensure individual fairness and the organization's competitiveness. The objectives of this salary policy are reviewed based on fairness, reasonableness, motivation, finance, and market competitiveness.

(d) Performance Evaluation and Compensation Linkage for Directors and Managers

i.Directors:

In accordance with the Company's Articles of Incorporation, if the Company records a profit in a given fiscal year, up to 3% of such profit may be allocated as directors' compensation upon resolution of the Board of Directors. Such resolution must be passed by at least two-thirds of the directors present at a meeting attended by a majority of all directors, and shall be reported to the shareholders' meeting. However, if the Company has accumulated losses, these shall first be covered before any allocation of compensation is made.

In the past two fiscal years, the Company has not distributed any directors' compensation. Directors have only received transportation allowances for the execution of duties, while the former Chairperson and independent directors received fixed compensation for their service. The remaining compensation for directors has been in the form of salary paid to the current Chairperson who also serves as an employee of the Company. The aforementioned transportation allowances and fixed compensation for independent directors were reviewed by the Compensation Committee and approved by the Board of Directors.

ii.Managers:

Managerial compensation primarily consists of employees' remuneration allocated from annual earnings. According to the Company's Articles of Incorporation, if the Company records a profit in a given fiscal year, 1% to 5% of such profit shall be allocated as employees' remuneration, to be distributed in cash or stock upon resolution of the Board of Directors. Eligible recipients may include employees of subsidiaries who meet specified criteria. The distribution must be resolved with the consent of a majority of the directors present at a meeting attended by at least two-thirds of all directors, and shall be reported to the shareholders' meeting. However, if the Company has accumulated losses, these shall first be covered before any allocation is made.

The compensation for the General Manager and Deputy General Managers is determined based on their position, contribution to the Company, and market benchmarks, and is subject to review by the Compensation Committee before submission to the Board of Directors for approval. In the past two fiscal years, no employees' remuneration has been distributed.

iii. The performance evaluation of directors and senior managers is linked to their remuneration and their remuneration is determined with reference to the payment standard in the industry and the salary at each job level, while based on their performance and contribution, responsibilities, continuous learning, realization of the Company's core value, leadership and management abilities, training ability, and business goal achievement rate, financial position (such as revenue or achieving status of after-tax net income target), and the progress of self-developed products (such as launch and sales of EG12014 or international factory inspection and certification). It regularly evaluates performance achievement and reviews the remuneration policy in a timely manner.

C.Nominating Committee: None.

(5) Fulfillment of ESG and Deviations from the "Corporate Social Responsibility Best Practice Principles for TWSE/TPEx Listed Companies" and disclosure of Climate-Related Information of the company.

A. Fulfillment of ESG and Deviations from the "Corporate Social Responsibility Best Practice Principles for TWSE/TPEx Listed Companies"

Evaluation Item		Implementation Status			Deviations from "the Corporate Social Responsibility Best-Practice Principles for TWSE/TPEx Listed Companies" and Reasons
		Y	N	Abstract Explanation	
1. Does the company assess ESG risks associated with its operations based on the principle of materiality and establish related risk management policies or strategies?		✓		The Board of Directors delegates the President to integrate the sustainable development concept into the Company's business strategy and lead the finance, human resources, R&D, production, and other departments to promote the Company's core spirit, namely empathy, integrity, responsibility, and global vision, while implementing corporate governance, employee care, environmental sustainability, and social charity projects, on a long-term and systematic basis. The Department of Finance has been responsible for the integration of relevant sustainable development mechanism since the Company was established and recently reported on the implementation status to the Board of Directors on March 12, 2025. The management team reports on the progress of the financial business and devises and regularly reviews business strategy at each Board meeting. Former Chairman Chung-Hur Lee was appointed the Chief Corporate Sustainable Development Officer and established the Greenhouse Gas Inspection Committee in 2022; planned to complete greenhouse gas inspection and confirmation in 2023, which is ahead of schedule.	None.
2. Does the company assess ESG risks associated with its operations based on the principle of materiality, and establish related risk management policies or strategies?		✓		The Company's and our subsidiaries' main operational sites and sustainable development performance are within the boundaries of risk assessment. Our risk management organization evaluates the concern about and impact of corporate sustainability and risks in the aspects of environment, society, and corporate governance as per the GRI Standards, the Company's business characteristics, and factors of internal and external environments and stakeholders. The management team formulates management policies after discussions to reinforce our business advantages and risk control. Each operating unit completed the planning of implementation of risk countermeasures and reported them to the Board of Directors.	None.
Environment	Environment and Management	(1) EirGenix's Zhubei plant has passed the review by the FDA and obtained an EIR before the drug launch. (2) Granted Accreditation Certificate of Foreign Drug Manufacturer by Japan MHLW, with the accreditation category of "biological products" and effective date from 2022/10/24 to 2027/10/30. (3) Obtains ISO14001 (Certificate No. ARES/TW/I2211076E), the effective date from 2022/11/24 to 2025/11/23. (4) EirGenix has made great efforts in energy conservation and sustainable environmental development and has incorporated the concept of green building into the plant in Zhubei. EirGenix obtained the Green Building Certificate (Green Building Certificate No.: GB-GF-01-00055).			
Social	Safe Working Environment	(1) Obtains ISO45001 Occupational Health and Safety (Certificate No. OHS751791), the effective date from 2024/11/09 to 2027/11/08. (2) Arranges the employee health examination and holds public health and safety training, firefighting drill and the education training relevant GMP regularly.			
	Products and services comply with relevant laws and international standards	EirGenix has designated exclusive personnel responsible for client contacts, and the unit responsible has set up the processing standards to regularly supervise the implementation results, implement product improvement and strengthen service processes.			
Corporate Governance	Legal	We ensure that our personnel duly comply with laws and regulations by establishing a governance organization and implementing the internal control system.			
	Strengthen the functions of directors	(1) Keep updated on the revision of laws and regulations, review various internal norms, and follow laws and regulations to reduce the risk of violations. (2) EirGenix has underwritten the Directors' Liability Insurance of US$ 5 million to Fubon Insurance Co., Ltd. In the future, in addition to continuing to underwrite the insurance according to regulations, EirGenix will adjust the insured amount in due course according to operation needs to provide appropriate coverage.			

<table>
<tr><th colspan="2" rowspan="2">Evaluation Item</th><th colspan="3">Implementation Status</th><th rowspan="2">Deviations from “the Corporate Social Responsibility Best-Practice Principles for TWSE/TPEx Listed Companies” and Reasons</th></tr>
<tr><th>Y</th><th>N</th><th>Abstract Explanation</th></tr>
<tr><td></td><td>Stakeholder rights</td><td colspan="4">(1) We identify the issues various stakeholders are concerned about and include them in the work plan in a timely manner through the positive interaction with them, while providing appropriate responses.
(2) EirGenix has established the stakeholders’ communication mailbox
(3) IR@eirgenix.com, and designed the spokesperson and vice spokesperson to be the external communication channel.</td></tr>
<tr><td colspan="2">3. Environmental issues
(1) Does the company establish proper environmental management systems based on the characteristics of their industries?</td><td>✓</td><td></td><td>As a professional drug R&D and production company, EirGenix has established perfect environmental management systems and implemented them. On February 3, 2020, EirGenix received PMDA's official approval in its issued GMP Compliance Inspection Result Notification, proclaiming EirGenix's compliance with relevant Japanese regulations regarding the quality, effectiveness, and safety of pharmaceutical manufacturing, which represented a remarkable milestone for EirGenix as the GMP biopharmaceutical manufacturing facility to receive the authority's approval. EirGenix’s Zhubei plant has passed the review by the FDA and obtained an EIR before the drug launch. EirGenix passed the review by the TGA in 2023.</td><td>None.</td></tr>
<tr><td colspan="2">(2) Does the company endeavor to utilize all resources more efficiently and use renewable materials which have a low impact on the environment?</td><td>✓</td><td></td><td>EirGenix belongs to the pharmaceutical research and development industry, which basically does not use materials with high impact on environmental load; Moreover, since its establishment, EirGenix has adhered to relevant government environmental protection laws and policies and been committed to improving the efficiency of resource utilization.</td><td>None.</td></tr>
<tr><td colspan="2">(3) Does the company evaluate the potential risks and opportunities in climate change with regard to the present and future of its business and take appropriate action to counter climate change issues?</td><td>✓</td><td></td><td>The President leads all employees to assess climate change and business operations, with a focus on environmental regulations, rising raw material costs, and increased greenhouse gas (GHG) emissions and to devise measures for development green buildings, carbon information disclosure, energy management, and resource reuse, with the aim of minimizing the impact of our operating activities on the environment, and reports regularly to the Board of Directors.</td><td>None.</td></tr>
<tr><td colspan="2">(4) Does the company take inventory of its greenhouse gas emissions, water consumption, and the total weight of waste in the last two years and implement policies on energy efficiency and carbon dioxide reduction, greenhouse gas reduction, water reduction, or waste management?</td><td>✓</td><td></td><td>Unit: tons
<table>
<tr><th>Year</th><th>Water Consumption</th></tr>
<tr><td>2024</td><td>98,800.09</td></tr>
<tr><td>2023</td><td>95,893.97</td></tr>
</table>
Weight of Waste Unit: mt
<table>
<tr><th>Year</th><th>Hazardous waste</th><th>Non-hazardous waste</th><th>Total</th></tr>
<tr><td>2024</td><td>6.1530</td><td>47.2490</td><td>53.4020</td></tr>
<tr><td>2023</td><td>7.3638</td><td>49.0784</td><td>56.4422</td></tr>
</table>
Unit: mt
<table>
<tr><th>Year</th><th>Greenhouse Gas Emissions</th></tr>
<tr><td>2024</td><td>15,101.79(*Note)</td></tr>
<tr><td>2023</td><td>13,837.61(*Note)</td></tr>
</table>
*Note:
Greenhouse gas emissions include Scope 1, Scope 2, and part of Scope 3–6.
The data for 2023 has been assured by a professional third-party.
The 2024 data is calculated by the Company, with actual figures subject to final verification.
To accurately monitor greenhouse gas emissions and implement more effective emission reduction measures, the Company and its German subsidiary have planned to adopt ISO 14064-1 greenhouse gas inventory guidance ahead of regulatory deadlines in 2023, with guidance provided by Leadership (Consulting Firm).
The verification of 2024 data will depend on the schedule of the verification body (anticipated verification body: BSI British Standards Institution). The final greenhouse gas emissions data is expected to be completed by Q2 2025.</td><td>None.</td></tr>
<tr><td colspan="6">Policy on energy conservation and carbon reduction, GHG reduction, water consumption reduction, or other waste management:
(1) The primary source of power consumption for the Company is electricity. The Company will save energy through (1) continued power monitoring and control system, (2) voluntary management of power consumption units, (3) introduction of energy efficient and green equipment, and (4) effective adjustment of production scheduling to enhance the efficient use of power and avoid unnecessary waste.
(2) In responding to global climate change, stabilization of water supply emerged as an issue confronting all countries. The Company seeks to pursue its corporate social responsibility and respond to the issue of global water shortage through (1) the continued water consumption monitoring and control system, (2) recycling and reuse of water emitted from pure water system, (3) effective adjustment of production scheduling to reduce the water productivity intensity (total water consumption volume/production value at US million) with the expectation of tackling the challenge from climate change in joint action with enterprises of the world.
(3) Regularly review climate change-related regulations, establish an internal mechanism for greenhouse gas inventory, and integrate carbon emission information.
(4) EirGenix belongs to the pharmaceutical research and development industry, which basically does not use materials with high impact on</td></tr>
</table>

Evaluation Item	Implementation Status			Deviations from "the Corporate Social Responsibility Best-Practice Principles for TWSE/TPEx Listed Companies" and Reasons
	Y	N	Abstract Explanation	
environmental load; Moreover, since its establishment, EirGenix has adhered to relevant government environmental protection laws and policies and been committed to improving the efficiency of resource utilization. Mitigate the impacts of products on the environment and engage in joint venture with academic units in the development of material for disposable items that could possibly be recycled and reused. (5) Management of toxic substances: duly observe the rules and regulations governing toxic and chemical items of concern and make all functional units staffed with toxic substances management personnel. In addition, the Company keeps track on the volume of toxic substances in the operation with proper marking of the storage zones and operation areas. All these facilities and areas will be controlled by locking.				
4. Social issues (1) Does the company formulate appropriate management policies and procedures according to relevant regulations and the International Bill of Human Rights?	✓		In order to fulfill the corporate social responsibility and implement the protection of human rights, with reference to the principles enshrined in international human rights conventions such as the Universal Declaration of Human Rights and the United Nations Guiding Principles on Business and Human Rights, EirGenix has respected the basic internationally-recognized human rights and formulated human rights policies applicable to EirGenix, to prevent violations of human rights, provide reasonable and safe workplaces and enable the current colleagues to obtain reasonable and dignified treatment.	None.
The Company's human rights policy and specific management program are as follows: (1) Diversity, inclusion, and equal opportunity: In terms of recruitment, remuneration and benefits, training, performance evaluation, promotion, resignation, or retirement, the Company treats all employees and job applicants equally regardless of their socioeconomic status, age, gender, sexual orientation, marriage, family status, disabilities, race, religion, appearance, nationality, language, political affiliation, or pregnancy. We also provide effective and appropriate grievance mechanisms and diverse communication channels to avoid situations that endanger employees' rights and interests, thereby achieving equal employment. (2) Against forced labor and child labor: To ensure compliance with corporate social responsibility and ethical standards, the Company's regulations on normal working hours and extended working hours, leave, paid leave, and other types of leave are in compliance with labor laws. We do not force employees to perform labor services. The Company complies with the local regulations on the minimum working age and does not employ child workers. (3) Physical and psychological health, work balance, and a safe work environment: The Company attaches great importance to safety and health in the workplace for employees to work in a healthy, safe, and humane environment with a healthy body and mind. The Company encourages employees to participate in health promotion activities and set up their own clubs to bond through club activities. In addition to holding the year-end party, cycling, and basketball games to balance their life and help them bond, the Company has installed fitness equipment for them to use after work. (4) The Company has established the policies for the prevention of sexual harassment at workplace and the regulations governing reporting on complaints to protect the employees, dispatched personnel and applicants for jobs from sexual harassment and provide them a workplace free of such harassment. The Company also adopts proper measures to prevent, correct, punish and respond any misconduct of this kind and protect the right and privacy of the complainants. (5) The company values the opinions and thoughts of all circles and devotes itself to providing open and transparent channels. The company has complaint telephone, mailbox, quarterly labor management meetings. Employees may reflect various problems regarding organization, system and working environment through different channels to carry out our diversified voice response and valuation.				
(2) Does the company have reasonable employee benefit measures (including salaries, leave, and other benefits), and do business performance or results reflect on employee salaries?	✓		EirGenix has formulated and implemented reasonable employee welfare measures, which can be detailed in the explanation of V. Labor Relations of this annual report. EirGenix has also appropriately reflected the operating performance and results in the salaries of employees, has set up bonuses associated with the performance target achievement of employees, departments, and company, and has also issued employee stock options associated with in-service seniority, restricted stock awards associated to the corporate objectives at various stages, and cash capital increase to retain employee stock options, so as to share the corporate operation performance with employees.	None.
(3) Does the company provide a healthy and safe working environment and organize training on health and safety for its employees on a regular basis?	✓		EirGenix has attached great importance to providing a healthy and safe working environment, regularly organized public safety and health, GMP-related educational training, arranged physical examination and group insurance for employees to ensure the safety and health of employees, and also provides the COVID-19 rapid test kit for employee to reduce the infection risk. EirGenix obtains ISO45001 Occupational Health and Safety (Certificate No. OHS751791) in 2021 and ISO14001 Environmental Management System (Certificate No. EMS784191) in 2023.	None.

No occupational accident took place in 2024 and 2023. Occupational security education and training over the past two years:

Site	Year	Number of training sessions	Number of attendees for the training
Zhubei	2024	818	2,100
	2023	982	1,905
Xizhi	2024	262	836
	2023	515	1,066

Evaluation Item	Implementation Status			Deviations from "the Corporate Social Responsibility Best-Practice Principles for TWSE/TPEx Listed Companies" and Reasons
	Y	N	Abstract Explanation	
(1)Employee safety and health: A. On the first day when employees enter the Company, they will receive the first-day training; the Company will hold safety education and training for at least 3 hours each time at least twice a year. The training mainly covers fire escape drills, emergency drills for poisoning disasters, basic knowledge of occupational safety, and chemical classification management. B. We provide adequate personal protective equipment according to the needs in the work environment. C. Arrange monthly health check-ins by nurses for colleagues, and also quarterly visits by occupational physicians to the workplace for health consultations. These initiatives provide colleagues with advice on health matters and care for their physical and mental well-being. Additionally, regular health seminars are scheduled, along with weekly distribution of health newsletters via email, fostering a healthy and comfortable work environment for colleagues. D. Each employee undergoes a comprehensive health examination every two years, while employees engaged in special operations undergo a special health examination annually in accordance with the Occupational Safety and Health Act. E. Regular occupational safety and GMP (Good Manufacturing Practices) related educational training sessions are held to enhance the safety and health awareness and capabilities of all staff in the factory. (2)Work environment: A. Every six months, regular workplace environment monitoring is conducted for employees and the work environment. Testing items include illumination, carbon dioxide levels, noise, high temperatures, chemical operations, etc., ensuring that colleagues operate in a safe and harmless environment. B. Daily inspections of the entire factory area are conducted, along with scheduled audits and periodic inquiries to staff about areas needing improvement, eliminating hazards and uncertainties, and providing colleagues with a safe environment. C. Reserved parking spaces for female colleagues who are pregnant or within one year postpartum are provided to create a friendly environment. Additionally, lactation rooms are set up within the factory, with allotted time for breastfeeding, ensuring peace of mind and dedicated space for breastfeeding mothers during work hours. To provide an account of the number of fire incidents, casualties, and the ratio of casualties to the total number of employees for the current year, as well as the corresponding improvement measures in response to fires: No related incidents occurred				
(4) Does the company provide its employees with career development and training sessions?	✓		The employees have been performing to achieve their annual targets based on their personal strength. The supervisors will also provide advice and guidance; EirGenix organized internal education and training regularly and encouraged employees to participate in external educational training or continue their studies to enhance their self-ability. In September 2017, EirGenix established the "EIRGer's Learning Center," planning diversified internal training courses every year. The key learning focus is on professional, technical orientation, supplemented by management and core functions.	None.
(5) Do the company's products and services comply with relevant laws and international standards in relation to customer health and safety, customer privacy, and marketing and labeling of products and services, and are relevant consumer protection and grievance procedure policies implemented?	✓		EirGenix will follow the relevant regulations and international standards on the advertisement, labeling of products and services, customer health and safety, and client privacy When the self-owned products come into the market, EirGenix will formulate the customer protection policies and appealing procedures; In addition, for CDMO of bio-pharmaceuticals, EirGenix has designated exclusive personnel responsible for client contacts, and the responsible unit has set up the processing standards to regularly supervise the implementation results, implement product improvement and strengthen service processes.	None.
(6) Does the company implement supplier management policies, requiring suppliers to observe relevant regulations on environmental protection, occupational health, and safety, or labor and human rights?	✓		The Company is committed to integrating sustainability into its procurement processes and advancing sustainable procurement and supplier management operations (with operational procedures effective as of March 13, 2025). The Company also continues to require suppliers, through contractual terms, to comply with relevant laws and regulations concerning labor, human rights, environmental protection, safety or hygiene, and environmental and social matters, or to provide declarations of compliance, with the shared goal of enhancing corporate sustainability. Furthermore, assessments of environmental and occupational health and safety management, technical capabilities, and supply capacity are incorporated as part of the contractor review and management process.	None.
5. Does the company reference internationally accepted reporting standards or guidelines and prepare reports that disclose non-financial information of the company, such as corporate social responsibility reports? Do the reports above obtain assurance from a third-party verification unit?	✓		EirGenix published the Corporate Social Responsibility Report based on the GRI Standard in 2024 and uploaded to MOPS and company website.	None.

Evaluation Item	Implementation Status			Deviations from "the Corporate Social Responsibility Best-Practice Principles for TWSE/TPEx Listed Companies" and Reasons
	Y	N	Abstract Explanation	

6. Describe the difference, if any, between actual practice and the corporate social responsibility principles if the company has implemented such principles based on the Corporate Social Responsibility Best Practice Principles for TWSE/TPEx Listed Companies:

EirGenix has formulated the corporate social responsibility principles in accordance with the Corporate Social Responsibility Best Practice Principles for TWSE/TPEx Listed Companies, and EirGenix has operated in accordance with relevant laws and regulations without significant difference

7. Other useful information for explaining the status of corporate social responsibility practices:

With the corporate spirit indicators of Empathy, Integrity, Responsibility, and Global Vision, all employees of EirGenix shall follow this indicator spirit to practice corporate social responsibility.

- The specific benefits of investing in energy-efficient or green energy-related environmentally sustainable machinery and equipment, as well as investing in country's green energy peripheral industries, are as follows

Investment equipment	Investment amount	Investment benefits
Chiller Unit	NT$ 12,972 thousands	In 2024, the Company invested in the construction of a new chiller unit, opting for equipment rated at performance level 1, which compared to previous installations using performance level 3 equipment: • Energy Savings: 538,902 kWh per year • Reducing energy consumption by 1,940,047 million joules • Reduction of 266.217 metric tons CO2e
Air Compressor	NT$ 3,974 thousands	In 2024, the Company procured air compressors equipped with high-efficiency permanent magnet synchronous motors rated as Grade 1 in energy performance, representing an upgrade compared to previously used Grade 2 equipment: • Energy Savings: 131,400 kWh per year • Reducing energy consumption by 473,040 million joules • Reduction of 64.90 metric tons CO2e
LED Light	NT$ 2,376 thousands	In 2024, the Company procured energy-saving LED lighting, offering improved efficiency compared to previously used T5 fluorescent fixtures: • Energy Savings: 96,450 kWh per year • Reducing energy consumption by 347,220 million joules • Reduction of 47.6 metric tons CO2e

B. Climate-Related Information of TWSE/TPEx Listed Company

(A) Implementation of Climate-Related Information

<table>
<tr><th>Item</th><th>Implementation status</th></tr>
<tr><td>1. Describe the board of directors' and management's oversight and governance of climate-related risks and opportunities.</td><td>The board of directors has authorized the general manager to integrate sustainable development into the business strategy, guiding each department with corporate core values such as Empathy, Integrity, Responsibility, and Global Vision. This initiative aims to promote corporate governance, employee well-being, environmental sustainability, and social welfare. Company employees are expected to adhere to these values in order to fulfill their corporate social responsibility.
In active cooperation with Taiwan government commitment to achieving net-zero carbon emissions by 2050, EirGenix officially adopted the Task Force on Climate-related Financial Disclosures (TCFD) and established the TCFD Risk Management Task Force starting in 2023. The company follows the four frameworks of TCFD, conducting discussions on climate governance, strategy, risk management, and goal setting. Additionally, climate-related issues are incorporated into the risk management process. The TCFD Risk Management Task Force will hold regular meetings to monitor, assess, and discuss climate risks. It will also provide an annual report to the Board of Directors on the regulation, assessment, and implementation outcomes related to climate risks.</td></tr>
<tr><td>2. Describe how the identified climate risks and opportunities affect the business, strategy, and finances of the business (short, medium, and long term).</td><td>In alignment with the TCFD framework, the Company identifies climate-related risks and opportunities that may impact its business, strategy, and financial planning. The current assessment has identified the following risks and opportunities:
<table>
<tr><th>Category</th><th>Risk/Opportunity</th><th>Time Horizon</th><th>Impact on the Company</th></tr>
<tr><td rowspan="2">Transition Risk</td><td>Carbon pricing</td><td>Short-term</td><td>Increased operating costs</td></tr>
<tr><td>Supply chain disruption due to climate change</td><td>Medium-term</td><td>Increased operating costs</td></tr>
<tr><td rowspan="2">Physical Risk</td><td>Power supply instability</td><td>Short-term</td><td>Losses due to product failure</td></tr>
<tr><td>Operational pressure and impact from water scarcity</td><td>Short-term</td><td>Increased operating costs and project delays</td></tr>
<tr><td rowspan="2">Opportunity</td><td>Enhanced production resilience</td><td>Short-term</td><td>Increased competitiveness and customer attraction</td></tr>
<tr><td>Promotion of low-carbon and green production</td><td>Medium to long-term</td><td>Attracting more business partners and customers</td></tr>
</table></td></tr>
<tr><td>3. Describe the financial impact of extreme weather events and transformative actions.</td><td>Based on observation data from the weather stations of the Central Weather Administration, the average annual temperature in Taiwan has risen by approximately 1.6℃ over the past 110 years (1911-2020). Furthermore, there has been an accelerating trend of warming in the past 50 and 30 years. Based on the scenario which are the temperatures in different regions of Taiwan are expected to continue increasing in the future. Under the worst-case scenario of global warming (SSP5-8.5), the average temperature in the middle and end of the 21st century may rise by more than 1.8℃ and 3.4℃, respectively. Under the ideal mitigation scenario (SSP1-2.6), the temperature may increase by 1.3℃ and 1.4℃ to simulate the potential negative impacts on our company due to extreme weather events in the mid-21st century (2050), and the results are as follows:
<table>
<tr><th>Scenario</th><th>Potential Climate Impacts</th></tr>
<tr><td>RCP 2.6</td><td>• The average annual temperature is projected to increase by over 2.2℃, potentially impacting the temperature within the factory and its surrounding environment, thereby affecting production efficiency. Consequently, it is imperative to invest in improvement equipment.
• A rise in rainfall can potentially cause flooding, particularly with a nearly 10% increase in maximum rainfall. Insufficient drainage facilities near the factory area may result in the flooding of factory buildings or damage to raw materials, finished products, and equipment.</td></tr>
<tr><td>RCP 4.5</td><td>• The average annual temperature is projected to increase by 2.5℃ and 2.8℃, potentially impacting the temperature within the factory and its surrounding environment, thereby affecting production efficiency. Consequently, it is imperative to invest in improvement equipment. Moreover, with the longer duration of high temperatures in recent summers, it may be necessary to enhance ventilation and air conditioning systems to safeguard employees from heatstroke. However, this will lead to increased electricity expenses and equipment maintenance costs.
• The increase in average rainfall may lead to an increase in flooding. Currently, the annual average rainfall in the EirGenix factories' areas has increased by approximately 9 to 11.1%. Poor drainage facilities near the factories may result in flooding of the premises or damage to raw materials, finished products, and machinery.</td></tr>
</table></td></tr>
</table>

<table>
<tr><th>Item</th><th colspan="2">Implementation status</th></tr>
<tr><td></td><td>RCP 8.5</td><td>• There is a possibility that the average annual temperature increase may exceed 3.2℃, which could result in a continuous temperature rise. It is essential to consistently enhance the air conditioning in the factory buildings. Rising annual average temperatures could potentially reduce the frequency of typhoons and increase the likelihood of droughts.
• In the event of extreme weather conditions, the country where EirGenix is situated may be prone to flooding. This could result in transportation disruptions, impacting the commute of personnel and potentially causing injuries.</td></tr>
<tr><td>4. Describe how climate risk identification, assessment, and management processes are integrated into the overall risk management system.</td><td colspan="2">The Board of Directors at EirGenix formulated the “Risk Management Policy and Procedures” in 2020. This policy serves as the highest guiding principle for our risk management and aims to identify potential risks (including market, liquidity, operational, hazards, and legal risks) that may impact our operations and profitability. It provides a reference for formulating operational strategies. Additionally, we take appropriate preventive measures for risk warnings to enhance our ability to respond to risk events and minimize their impact on our business operations. Every year, the responsible units identify the relevant risk factors and analyze various risks to assess their potential impact on operations. Risk control measures are subsequently developed to ensure that the risks remain within manageable and acceptable limits. A report on the implementation of risk management is then submitted to the board of directors.
EirGenix oversees climate-related action plans through the TCFD Risk Management Task Force, which comprises a chairman, convener, multiple departments, and external professional advisory consultants. Under the guidance of the TCFD Risk Management Task Force, department managers and colleagues are evaluating industry characteristics and operational conditions to assess the potential impact of different risks and opportunities on our operations. The board of directors should receive an annual report on the status of risk management operations and execution, which should also include discussions on climate change issues.</td></tr>
<tr><td>5. If scenario analysis is used to assess resilience to climate change risks, the scenarios, parameters, assumptions, analysis factors and major financial impacts used should be described.</td><td colspan="2">The Company conducts climate change risk assessments based on the RCP 2.6, RCP 4.5, and RCP 8.5 climate scenarios developed by the Intergovernmental Panel on Climate Change (IPCC). These scenarios are used to evaluate transition risks, acute physical risks, and long-term physical risks. In addition, the Company references the methodologies outlined in the IPCC’s Sixth Assessment Report (AR6), published in August 2021, for its risk evaluation.</td></tr>
<tr><td>6. If there is a transition plan for managing climate-related risks, describe the content of the plan, and the indicators and targets used to identify and manage physical risks and transition risks.</td><td colspan="2"><table>
<tr><th>Risk Description</th><th>Response Strategy</th><th>Indicators and Targets</th></tr>
<tr><td colspan="3">Transition Risk</td></tr>
<tr><td>Carbon pricing</td><td rowspan="2">- Use of renewable energy
- Establishment of collaborative supply chain partnerships</td><td rowspan="4">- Achieve 1% renewable energy usage by 2025, with a target of 6% by 2030- Improve energy efficiency with annual energy savings of 1%
- Implement low-carbon supply chain management</td></tr>
<tr><td>Supply chain disruptions due to climate change</td></tr>
<tr><td colspan="2">Physical Risk</td></tr>
<tr><td>Power supply instability</td><td>Installation of emergency generators and uninterruptible power systems (UPS)</td></tr>
<tr><td>Operational pressure and impact from water scarcity</td><td>Increased investment in water storage facilities and establishment of emergency water supply agreements with water utility companies</td><td></td></tr>
</table></td></tr>
<tr><td>7. If internal carbon pricing is used as a planning tool, the basis for setting the price should be stated.</td><td colspan="2">The Company does not belong to an industry currently subject to priority carbon taxation. However, in anticipation of future regulatory requirements, it has undertaken carbon pricing assessments based on the following approaches:
(1) External Carbon Pricing: Referencing external carbon market prices as the basis for internal carbon pricing.
(2) Internal Cost Estimation: Evaluating the Company’s own carbon emissions and the costs associated with emission reduction measures.
(3) Risk Management Considerations: Assessing the risks associated with carbon emissions.</td></tr>
</table>

Item	Implementation status
8. If climate-related targets have been set, the activities covered, the scope of greenhouse gas emissions, the planning horizon, and the progress achieved each year should be specified. If carbon credits or renewable energy certificates (RECs) are used to achieve relevant targets, the source and quantity of carbon credits or RECs to be offset should be specified.	In accordance with the timeline set forth in the Financial Supervisory Commission's "Sustainability Roadmap for TWSE/TPEx-Listed Companies," the Company is required to complete a greenhouse gas (GHG) inventory by 2026 and obtain GHG assurance by 2028. The Company proactively initiated its GHG inventory in 2023 and simultaneously completed third-party verification. Moving forward, GHG management results will be reported to the Board of Directors on a quarterly basis for oversight.
9. Greenhouse gas inventory and assurance status and reduction targets, strategy, and concrete action plan	Please refer to the following explanations.

(B) Greenhouse Gas Inventory and Assurance Status for the Most Recent 2 Fiscal Years

i. Greenhouse Gas Inventory Information

Greenhouse Gas Inventory Information for the most recent 2 fiscal years as the following table, and the Scope 1, Scope 2 are the information of EirGenix Inc. and EirGenix Europe GmbH.

Year	Scope 1		Scope 2		Assurance Institutions	Assurance Opinion
	Emission Volume (mt CO2e)	Intensity (mt CO2e/NT$ million)	Emission Volume (mt CO2e)	Intensity (mt CO2e/NT$ million)		
2024	1,235.2595	0.00122	11,209.3419	0.01111	NA	NA
2023	1,090.1268	0.00106	10,348.4132	0.01011	NA	NA

As of 2024, the disclosure of total greenhouse gas emissions by the company is 12,444.6014 metric tons of CO2e (accounting for 82.4% of total emissions) with ISO 14064-3:2019 standards.

ii. Greenhouse Gas Assurance Information

As of 2024, the greenhouse gas emissions inventory for both 2023 and 2024 has been completed. The inventory for the year 2022 was externally assured by BSI in December 2023, in accordance with the ISO 14064-3:2019 assurance standard. The assurance results provide reasonable assurance. According to Financial Supervisory Commission requirements, the assurance is scheduled for completion in 2026 based on the company's capital.

(C) Greenhouse Gas Reduction Targets, Strategy, and Concrete Action Plan

EirGenix is a professional pharmaceutical research and production company that has implemented a comprehensive environmental management system. In order to fulfill its corporate social responsibility and strive for environmental sustainability, EirGenix prioritizes “energy conservation and carbon reduction.” The company is currently in an expansion phase, using 2022 as the base year. Once the expansion is completed, EirGenix will gradually reduce energy intensity and minimize resource and energy waste. To achieve this goal, the company has established three key performance indicators for “Electricity sage,” “Water resources,” and “Waste,” and is actively promoting environmental sustainability initiatives. The company introduced greenhouse gas inventory in 2023 to monitor the Company’s greenhouse gas emissions. The company’s carbon neutrality roadmap as follow.

Carbon Neutrality Roadmap			
Time	Short-term (~2025)	Mid-term (2025~2030)	Long-term (2030~2050)
Reduction Targets	Gradually reduce after the expansion is completed.	Reduce 10% compare with 2022	To achieve carbon neutrality
Strategy, and Concrete Action Plan	1. Obtain ISO 14001:2015 Environmental Management System Certification for Biotechnology Testing and Analysis 2. Implementation of ISO 14064-1 greenhouse gas inventory counseling and planning and verification 3. By 2025, the proportion of renewable energy will reach 1%. 4. Promote low-carbon manufacturing and consistently review the reduction of carbon emission intensity. 5. EirGenix’s Zhubei A plant obtained the Green Building Certificate. 6. Improve energy efficiency to attain an annual energy-saving performance of 1%. 7. Actively engaged in a net-zero green lifestyle.	1. Obtain Certification for ISO 50001 Energy Management System. 2. Gradually increase the utilization of renewable energy to reach 6% by the year 2030. 3. EirGenix’s Zhubei new B plant obtained the Green Building Certificate. 4. Continuously enhance energy management to attain an annual energy-saving efficiency of 1%. 5. Implement low carbon supplier management. 6. Evaluate waste management policies and eco-friendly packaging materials.	1. Gradually increase the utilization of renewable energy to reach 10% by the year 2050. 2. Continued focus on carbon rights, carbon sink, and renewable energy. 3. Implement a green supplier management system and measure sustainability indicators. 4. Participate in climate advocacy organizations or alliances to collectively promote environmental sustainability.

(6) Fulfillment of Ethical Corporate Management and Deviations from the "Ethical Corporate Management Best Practice Principles for TWSE/TPEx Listed Companies"

Evaluation Item	Implementation Status			Deviations from the "Ethical Corporate Management Best Practice Principles for TWSE/TPEx Listed Companies" and Reasons
	Y	N	Abstract Illustration	
1. Establishment of ethical corporate management policies and programs (1) Does the company have a Board-approved ethical corporate management policy and stated in its regulations and external correspondence the ethical corporate management policy and practices, as well as the active commitment of the Board of Directors and management towards enforcement of such policy?	✓		The Board of Directors of EirGenix has passed the establishment of the Ethical Corporate Management Best Practice Principles as well as Procedures and Guidelines of Conduct for Integrity Management to express the policies of integrity operation. The Board of Directors and the management team have also actively implemented integrity management and clearly expressed the policies and practices of integrity management in the corporate regulations and external business contracts.	Compliant with "Ethical Corporate Management Best Practice Principles for TWSE/TPEx Listed Companies."
(2) Does the company have mechanisms in place to assess the risk of unethical conduct and perform regular analysis and assessment of business activities with a higher risk of unethical conduct within the scope of business? Does the company implement programs to prevent unethical conduct based on the above and ensure the programs cover at least the matters described in Paragraph 2, Article 7 of the Ethical Corporate Management Best Practice Principles for TWSE/TPEx Listed Companies?	✓		EirGenix has formulated the Ethical Corporate Management Best Practice Principles, Procedures, and Guidelines of Conduct for Integrity Management, Codes of Ethical Conduct, and Procedures of Administrative Measures for Preventing Insider Trading. The Legal Department and Audit Department have also regularly reported to the Board of Directors on the status of implementation and irregularly checked, analyzed, and evaluated the operating activities within the business scope that have a high risk of dishonest behavior.	Compliant with "Ethical Corporate Management Best Practice Principles for TWSE/TPEx Listed Companies."
A. When engaging in commercial activities, directors, managers, employees, and mandataries of the company or persons having substantial control over such companies shall not directly or indirectly offer, promise to offer, request or accept any improper benefits, nor commit unethical acts including breach of ethics, illegal acts, or breach of fiduciary duty for purposes of acquiring or maintaining benefits. B. The company shall establish a risk assessment mechanism against unethical conduct, analyze and assess on a regular basis business activity within their business scope which are at a higher risk of being involved in unethical conduct, and establish prevention programs accordingly and review their adequacy and effectiveness on a regular basis. The company to refer to prevailing domestic and foreign standards or guidelines in establishing the prevention programs, which shall at least include preventive measures against the following: (A) Offering and acceptance of bribes. (B) Illegal political donations. (C) Improper charitable donations or sponsorship. (D) Offering or accepting unreasonable presents or hospitality, or other improper benefits. (E) Misappropriation of trade secrets and infringement of trademark rights, patent rights, copyrights, and other intellectual property rights. (F) Engaging in unfair competitive practices. (G) Damage directly or indirectly is caused to the rights or interests, health, or safety of consumers or other stakeholders in the course of research and development, procurement, manufacture, provision, or sale of products and services.				

Evaluation Item	Implementation Status			Deviations from the "Ethical Corporate Management Best Practice Principles for TWSE/TPEx Listed Companies" and Reasons
	Y	N	Abstract Illustration	
(3) Does the company provide clearly the operating procedures, code of conduct, disciplinary actions, and appeal procedures in the programs against unethical conduct? Does the company enforce the programs above effectively and perform regular reviews and amendments?	✓		EirGenix has formulated the Ethical Corporate Management Best Practice Principles, Procedures and Guidelines of Conduct for Integrity Management, Employee Working Principles, Codes of Ethical Conduct, and Administrative Measures for Preventing Insider Trading, set up a disciplinary and appealing system for violations, regularly conducted review and correction, and implemented and advocated operating activities to prevent risks of dishonest behavior.	Compliant with "Ethical Corporate Management Best Practice Principles for TWSE/TPEx Listed Companies".
2. Fulfill operations integrity policy. (1) Does the company evaluate business partners' ethical records and include ethics-related clauses in business contracts?	✓		EirGenix has conducted its business activities in a fair and transparent manner. Before business activities, EirGenix has avoided dealings with trading partners who have dishonest behaviors, with the terms of cooperation stated in the contract.	Compliant with "Ethical Corporate Management Best Practice Principles for TWSE/TPEx Listed Companies."
(2) Does the company have a unit responsible for ethical corporate management on a full-time basis under the Board of Directors, which reports the ethical corporate management policy and programs against unethical conduct regularly (at least once a year) to the Board of Directors while overseeing such operations?	✓		EirGenix has set up a dedicated unit under the Board of Directors to promote corporate integrity management as the Legal Department, which is responsible for formulating and supervising the implementation of integrity management policies and prevention plans, handling and reporting the breach of integrity that may be found in the internal control audit in accordance with relevant laws and regulations, and ensuring that the corporate integrity management policies can be implemented and reported to the Board of Directors regularly every year, with the latest reporting date of March 8, 2024.	Compliant with "Ethical Corporate Management Best Practice Principles for TWSE/TPEx Listed Companies."
(3) Does the company establish policies to prevent conflicts of interest and provide appropriate communication channels, and implement it?	✓		EirGenix has formulated the Ethical Corporate Management Best Practice Principles, Procedures and Guidelines of Conduct for Integrity Management, Employee Working Principles, Codes of Ethical Conduct, and Administrative Measures for Preventing Insider Trading, and set up whistle blower policy with a designated email for employees putting a stop on all unethical immoral or illegal work.	Compliant with "Ethical Corporate Management Best Practice Principles for TWSE/TPEx Listed Companies."
(4) Does the company have effective accounting and internal control systems in place to implement ethical corporate management? Does the internal audit unit follow the results of unethical conduct risk assessments and devise audit plans to audit the systems accordingly to prevent unethical conduct, or hire outside accountants to perform the audits?	✓		EirGenix has established effective systems for both accounting and internal control, and the internal audit unit has also conducted audits on a regular basis and reported to the Board of Directors and the audit committee every time; it has also appointed CPAs to carry out the audit.	Compliant with "Ethical Corporate Management Best Practice Principles for TWSE/TPEx Listed Companies."
(5) Does the company regularly hold internal and external educational trainings on operational integrity?	✓		EirGenix has regularly held all-staff communication meetings and internal educational training to make employees understand the corporate spirit indicators and the corporate culture of integrity management and encouraged employees to participate in external educational training.	Compliant with "Ethical Corporate Management Best Practice Principles for TWSE/TPEx Listed Companies."

Evaluation Item	Implementation Status			Deviations from the "Ethical Corporate Management Best Practice Principles for TWSE/TPEx Listed Companies" and Reasons
	Y	N	Abstract Illustration	
3. Operation of the integrity channel (1) Does the company establish both a reward/punishment system and an integrity hotline? Can the accused be reached by an appropriate person for follow-up	✓		EirGenix has formulated the Ethical Corporate Management Best Practice Principles and Guidelines of Conduct for Integrity Management. In case of any breach of integrity, employees can report it to the heads of department, the Legal Department or the Audit Department at any time through the reporting email address or in any form.	Compliant with "Ethical Corporate Management Best Practice Principles for TWSE/TPEx Listed Companies."
(2) Does the company have in place standard operating procedures for investigating accusation cases, as well as follow-up actions and relevant post-investigation confidentiality measures?	✓		EirGenix has formulated the Ethical Corporate Management Best Practice Principles and Guidelines of Conduct for Integrity Management, provided smooth reporting channels, and implemented the principle of confidentiality.	Compliant with "Ethical Corporate Management Best Practice Principles for TWSE/TPEx Listed Companies."
(3) Does the company provide proper whistleblower protection?	✓		EirGenix keeps the contents of reporting on breach of integrity management confidential and protects the whistleblower from improper disposal due to reporting.	Compliant with "Ethical Corporate Management Best Practice Principles for TWSE/TPEx Listed Companies."
4. Strengthening information disclosure Does the company disclose its ethical corporate management policies and the results of its implementation on the company's website and MOPS?	✓		EirGenix has disclosed the Ethical Corporate Management Best Practice Principles and Guidelines of Conduct for Integrity Management, and information related to integrity management on the Market Observation Post System, annual report, and corporate website.	Compliant with "Ethical Corporate Management Best Practice Principles for TWSE/TPEx Listed Companies."
5. If the company has established the ethical corporate management policies based on the Ethical Corporate Management Best-Practice Principles for TWSE/TPEx Listed Companies, please describe any discrepancy between the policies and their implementation: EirGenix has formulated the Ethical Corporate Management Best Practice Principles and Guidelines of Conduct for Integrity Management in accordance with the Integrity Management Principles for TWSE/TPEx Listed Companies, with no difference between the actual operation and the principles.				
6. Other important information to facilitate a better understanding of the company's ethical corporate management policies (e.g., review and amend its policies): (1) EirGenix has formulated the Ethical Corporate Management Best Practice Principles and Guidelines of Conduct for Integrity Management, which will be amended as appropriate according to the operational development. (2) All employees have signed the Declaration of Ethic Code of Conduct and Business Integrity. (3) Education on applicable laws and important notice of insider trade and equity holding of insider for the Directors and the management will be provided every month. The Directors have completed their training of the company operation or related training for 6 hours in 2024. (4) Required training for all employees on laws and prevention of insider trade for one hour on 2024/05/30, respectively. (5) Legal Affairs, Audit Office and Finance Department provide information on applicable laws and case studies to the Directors, managers, and employees from time to time to realize ethical corporate management and the prevention of insider trade. Related rules and regulations have been disclosed at the intranet and external official website of the Company. (6) The Legal Affairs and Audit Office conduct audit on respective functional departments at random, and report to the Board of the status, conduct analysis and control of business activities at high risk of unethical practices within the scope of operation of the Company.				

(7) Other Important Information Regarding Corporate Governance:

All directors, managers, and insider newly assumed office would be released the updated version of the “Regulations Governing the Equity Ownership of Insiders of Companies listed at TPEx and Emerging Stock Market” compiled by Taipei Exchange. Information on the amendment to the regulations will be announced and promoted in the Board meeting and the executive meeting every year for the insiders to abide by.

The Company has established the Corporate Governance Committee organized by the Chairman and four Independent Directors. The purpose is to strengthen corporate governance and upgrade the performance of the Board. This committee shall perform the following functions:

A. Review the institution and amendment to corporate governance systems such as the Corporate Governance Best Practice Principles of the Company.
B. Monitor and supervise the practice of corporate governance of the Company.
C. Monitor and supervise the Company in the participation of corporate governance evaluation.
D. Evaluate the performance of the Board, the committees and the Directors, the independence of the Independent Directors, and present the evaluation result to the Board.
E. Assess the channels for the gathering of information for the Board, and the quality and timing of the information received by the Directors.
F. Monitor the governance relations between the Company and its subsidiaries and other affiliates.
G. Other materiality as required by the Company or the competent authority.

The tenure for the members of the 1st term of the committee started on 2022/12/28 and ends on 2025/06/09. The Committee convened 3 times from 2024 to the end of April 2025 for discussion on the amendment to the Corporate Governance Best Practice Principles.

Title	Name	Main expertise	Attendance in Person	Attendance Rate (%)
Convener	Ming-Shen Chen	Finance、Corporate Governance	3	100
Committee Member	Lee-Cheng Liu	Operation management、Biotechnology、Corporate Governance	3	100
Committee Member	Ming-Thaur Chang	Finance	3	100
Committee Member	Po-Chih Chen	Economist	2	66.67
Committee Member	Fu-Shiow Yin	Biotechnology	3	100

(8) Disclosures Required for the Implementation of the Internal Control System:

A. Statement of Internal Control System: Please refer to https://mopsov.twse.com.tw/nas/cont06/c6589113011140327.pdf

B. If CPA has been hired to carry out a special audit of the Internal Control System, the company shall furnish the CPA audit report: Please refer to https://mopsov.twse.com.tw/nas/cont06/hc6589113011131225.pdf

(9) Material resolutions of a shareholders meeting or a board of directors meeting during the most recent fiscal year (2024) or during the current fiscal year up to the date of publication of the annual report:

Item & Date	Major Resolutions of Shareholders' Meeting/ Board of directors
Board Meeting 2024/01/25	A. Approved the granting of annual performance bonuses to managers based on the 2023 performance bonus, budget and evaluation results.
Board Meeting 2024/03/08	A. Accept 2023 Financial Statements and Business Report. B. Ratification of the 2023 Deficit Offset Proposal. C. Approved the CPAs replacement due to PricewaterhouseCoopers Taiwan internal organization adjustment. D. Approved the motion of the ratification of the assessment of the independence and competence of the CPAs retained as external Auditors. E. Approved the motion of the ratification of the appointment of CPAs as external auditors and the remuneration to the CPAs. F. Approved the motion of issuance of the 2023 Declaration of Internal Control System of the Company. G. Approved the amendment to the "Rules of Procedure for Shareholders Meetings". H. Approved the amendment to the "Regulations Governing Procedure for Board of Directors Meetings". I. Approved the amendment to the "Audit Committee Charter". J. Approved the base date of employee stock option into common stocks capital increase. K. Adoption of the 2024 1st Employee Restricted Stock Awards. L. Approved the discontinue the Private Security Offering Approved by the 2023 Shareholders' Meeting. M. Approved the Company will raise capital through private placements of common shares. N. Approved the extension to The Shanghai Commercial & Savings Bank for the loan. O. Approved the application to Taiwan Business Bank for the 10-year capital expenditure loan and total amount within NT$1.974 billion due to the financial needs of the expansion of Zhubei facility. P. Approved to sign the contract with clinical CRO and the relevant companies for Phase III clinical trial of the EG1206A. Q. Approved the motion of the agenda and related matters of the Shareholders' Meeting of 2024.
Board Meeting 2024/05/09	A. Accept 2024 Q1 Financial Statements. B. Approved the base date of employee stock option into common stocks capital increase. C. Approved the base date of cancellation of the restricted stock award. D. Approved the participation of the cash capital increase of AP Biosciences Inc. based on the potential opportunity of business cooperation and the consideration of financial investment. E. Approved to grant 2022 Employee Stock Options to employees. F. Approved the 2024 salary adjustment plan for managers and employees in accordance with the Company's compensation policy, system, standards, and structure. G. Approved the salary adjustment of a manager at the European subsidiary regarding promotion
Shareholders Meeting 2024/05/30	Proposed Resolutions: A. Accept 2023 Financial Statements and Business Report. Implementation review: Financial Statements have been announced on 2024/03/21and Business Report has been announced on 2024/04/299. B. Ratification of the 2023 Deficit Offset Proposal. Implementation review: It has been announced on 2024/05/30 after the shareholders' meeting. Matters for discussion: A. Amendment to the Rules of Procedure for Shareholders Meeting. Implementation review: The revised version has been uploaded to the Market Observation Post System and the Company's website, and actions have been taken in accordance with the amended regulations. B. Approved the Issuance of Employee Restricted Stock Awards. Implementation review: Implementation completed in accordance with the resolution of the Shareholders Meeting. Approval No. 1130360692 dated Oct. 29, 2024. C. Approved the Company will raise capital through private placements of common shares. Implementation review: Not actually issued. D. Release the Prohibition on Directors or Representatives of Directors from Participation in Competitive Business. Implementation review: Implementation completed in accordance with the resolution of the Shareholders' Meeting.
Board Meeting 2024/08/08	A. Accept 2024 Q2 Financial Statements. B. Approved the base date of employee stock option into common stocks capital increase. C. Approved the base date of cancellation of the restricted stock award. D. Approved the extension to Yuanta Commercial Bank for the loan. E. Approved the extension to Mega Bank for the loan. F. Approved the extension to Far Eastern International Bank for the loan. G. Approved the extension to CTBC Bank for the loan. H. Approved the application to Bank Sinopac for the loan. I. Approved the Company's foreign currency-denominated securities transactions and related authorizations with Citibank, President Securities, and CTBC Bank. J. Approved the rename and amendment of the "Operational Procedure for Preparation and Validation of the Sustainability Report" K. Approved the 2023 ESG Report. L. Approved the amendment of "IA-18 Implementation of authorization" and "deputy systems and Approval Authority Form".
Board Meeting 2024/09/30	A. Approved the base date of cancellation of the restricted stock award.
Board Meeting 2024/11/12	A. Accept 2024 Q3 Financial Statements. B. Approved the classification of accounts receivable overdue for more than three months beyond normal credit terms in Q3 2024 as non-lending in nature.

Item & Date	Major Resolutions of Shareholders' Meeting/ Board of directors
	C. Approved the Company's application for listing on the Taiwan Stock Exchange. D. Approved the appointment of KGI Securities as the lead underwriter to assist with the Company's stock listing. E. Approved the engagement of an accounting firm to assist with the Company's listing on the Taiwan Stock Exchange. F. Approved the Company's "Statement on Internal Control System." G. Approved the base date of employee stock option into common stocks capital increase. H. Approved the base date of cancellation of the restricted stock award. I. Approved the application to Chang Hwa Commercial Bank for the loan. J. Approved the extension to The Shanghai Commercial & Savings Bank for the loan. K. Approved the adoption of the "Sustainability Information Management Guidelines." L. Approved the amendment of the "2024 Employee Restricted Stock Awards." M. Approved to grant 2024 Employee Restricted Stock Awards to employees. N. Approved the appointment and compensation of the Company's managers.
Ad Hoc Board Meeting 2024/12/16	A. Approved to repurchase own company stock to transfer to employees.
Board Meeting 2024/12/20	A. Approved the operation plan for the fiscal year 2024. B. Approved the amendment of Implementation Report for the Sound Business Plan and estimation of Income Statement. C. Approved the preparation of simplified financial forecast information for Q4 2024 to Q1 2025 in accordance with the requirements for the Company's listing application D. Approved the Company's "Corporate Governance Self-Evaluation Report." E. Approved the amendments to the Company's "Corporate Governance Best Practice Principles" F. Approved the authorization for independent directors to sign audit reports. G. Approved the amendments to the Company's "Internal Control System," "Implementation Rules for Internal Audits – Internal Audit System," "Procedures of the receipt and use of negotiable instruments" "Procedures of Managing the Preparation of Financial Statements," "Procedures of Preventing Insider Trading" and its appendix, "Shareholder Services Management Procedures," and "IA-23 Risk Assessment Procedures for Internal Control Deficiencies." H. Approved the amendment of "IA-18 Implementation of authorization" and "deputy systems and Approval Authority Form". I. Approved the adoption of the 2025 "Annual Audit Plan." J. Approved the extension to Cathay United Bank for the loan. K. Approved the proposal to the shareholders meeting to lift the restrictions on the non-competition of directors and their representatives. L. Approved the appointment and delegation of compensation for senior managers at Grade 13 and above M. Approved the amendment of the Company's "Rules for the Repurchase and Transfer of Shares to Employees.
Board Meeting 2025/01/17	A. Approved the granting of annual performance bonuses to managers based on the 2023 performance bonus, budget and evaluation results.
Board Meeting 2025/03/12	A. Accept 2024 Financial Statements and Business Report. B. Ratification of the 2024 Deficit Offset Proposal. C. Approved the motion of the ratification of the assessment of the independence and competence of the CPAs retained as external Auditors. D. Approved the motion of the ratification of the appointment of CPAs as external auditors and the remuneration to the CPAs. E. Approved the motion of issuance of the 2024 Declaration of Internal Control System of the Company. F. Approved the amendment to the "Articles of Incorporation". G. Adoption of the 2025 1st Employee Restricted Stock Awards. H. Approved the discontinue the Private Security Offering Approved by the 2024 Shareholders' Meeting. I. Approved the Company will raise capital through private placements of common shares. J. Approved the extension to Taichung Commercial Bank for the loan. K. Approved the extension of the land lease agreement in land of Zhubei Phase II for 40 years with the Hsinchu Science Park Bureau, NSTC. L. Approved changes in the Company's accounting estimates. M. Approved the nomination and review of the list of candidates for the 6th term of directors, including independent directors. N. Approved the lifting of non-competition restrictions for newly elected directors and their representatives. O. Approved the motion of the agenda and related matters of the Shareholders' Meeting of 2025. P. Approved the amendment of the Company's "Compensation Policy, System, Standards, and Structure." Q. Approved the proposed compensation plan for the General Manager of the German subsidiary. R. Approved the participation in the investment in GeneFab, LLC based on the potential opportunity of business cooperation and the consideration of strategic investment.

(10) Where, during the most recent fiscal year or during the current fiscal year up to the date of publication of the annual report, a director or supervisor has expressed a dissenting opinion with respect to a material resolution passed by the board of directors and said dissenting opinion had been recorded or prepared as a written declaration, disclose the principal content thereof: None.

4.Information Regarding the Company's Audit Fee and Independence

(1) The non-audit fees paid to the certified public accountant, to the accounting firm of the certified public accountant, and/or to any affiliated enterprise of such accounting firm, the amounts of both audit and non-audit fees as well as details of non-audit services:

Unit: NT$ thousands

Accounting Firm	Name of CPAs	Period Covered by CPA's Audit	Audit Fee	Non-audit Fee	Total
PricewaterhouseCoopers Taiwan	Shu-Fen Yu	January 1st,2024 to December 31st,2024	3,050	1,459	4,509
	Yu-Fang Yen				

Details of non-audit services:
- Project Tax Consultation, NT$674,000
- Business Income Tax Audit, NT$350,000
- ESG Report Assurance, NT$250,000
- Others, NT$185,000

(2) When the company changes its accounting firm and the audit fees paid for the fiscal year in which such change took place are lower than those for the previous fiscal year, the amounts of the audit fees before and after the change and the reasons: None.

(3) When the audit fees paid for the current fiscal year are lower than those for the previous fiscal year by 10 percent or more, the reduction in the amount of audit fees, reduction percentage, and reason(s) therefor: None.

5.Replacement of CPA

(1) Regarding the former CPA:

Replacement Date	Date of received the notification for replacement: February 20th, 2024 Date of approval by Board of Directors: March 8th, 2024			
Replacement reasons and explanations	The CPAs replacement due to PricewaterhouseCoopers Taiwan internal organization adjustment.			
Describe whether the Company terminated, or the CPA did not accept the appointment	Status \ Parties		CPA	The Company
	Termination of appointment		-	-
	No longer accepted (continued) appointment		-	-
Other issues (except for unqualified issues) in the audit reports within the last two years	None			
Differences with the company	Y		Accounting principles or practices	
			Disclosure of Financial Statements	
			Audit scope or steps	
			Others	
	N	✓		
	Remarks/specify details: None			
Other Revealed Matters	None			

(2) Regarding the successor CPA:

Accounting Firm	PricewaterhouseCoopers Taiwan
Name of CPA	Shu-Fen Yu and Yu-Fang Yen
Date of appointment	Date of received the notification for replacement: February 20th, 2024 Date of approval by Board of Directors: March 8th, 2024
Consultation results and opinions on accounting treatments or principles with respect to specified transactions and the company's financial reports that the CPA might issue prior to the engagement	None
Succeeding CPA's written opinion of disagreement toward the former CPA	None

(3) The company shall mail to the former certified public accountant a copy of the disclosures it is making pursuant to item A and to (c) of the here preceding item and advise the accountant of the need to respond by mail within 10 days should the accountant disagree. The company shall disclose the content of the reply letter from the former certified public accountant: None.

6.The company's chairperson, general manager, or any managerial officer in charge of finance or accounting matters has in the most recent year held a position at the accounting firm of its certified public accountant or at an affiliated enterprise of such accounting firm: None.

7.Any transfer of equity interests and/or pledge of or change in equity interests (during the most recent fiscal year or during the current fiscal year up to the date of publication of the annual report) by a director, supervisor, managerial officer, or shareholder with a stake of more than 10 percent during the most recent fiscal year or during the current fiscal year up to the date of publication of the annual report:

(1) Net Change in Shareholding by Directors, Management and Shareholders with 10% Shareholdings or More

Unit: Shares

Title	Name	2024		Until April 2025	
		Net Change in Shareholding	Net Change in Shares Pledged	Net Change in Shareholding	Net Change in Shares Pledged
Chairman/President	Lee-Cheng Liu	72,500	0	(33,654)	0
Director	National Development Fund, Executive Yuan	0	0	0	0
	Representative: Hsiu-Hui Chen	0	0	0	0
Director	Formosa Laboratories, Inc.	0	0	0	0
	Representative: Cheng-Yu Cheng	0	0	0	0
Director	Yao-Hwa Glass Co., Ltd, Management Commission	0	0	0	0
	Representative: Ku-Sung Weng	0	0	0	0
Director	Foxconn Technology Co., Ltd.	0	0	0	0
	Representative: Chun- Fu Lu	0	0	0	0
	Representative: Yu-Ting Chen	0	0	0	0
Independent Director	Ming-Thaur Chang	0	0	0	0
Independent Director	Po-Chih Chen	0	0	0	0
Independent Director	Fu-Shiow Yin	0	0	0	0
Independent Director	Ming-Shen Chen	0	0	0	0
Manager	Chih-Jung Chang	(97,588)	0	(109,250)	0
Manager	Hsiu-Chuan Yang	27,989	0	0	0
Manager	Ching-Wen Lin (Note 1)	-			
Manager	Shang-Chung Ju	19,214	0	0	0
Manager	Ae-Ning Lin	19,214	0	0	0
Manager	Ching-Ying Chen	29,714	0	0	0
Manager	Ren-Yo Forng (Note 2)	22,500	0	N/A	
Manager	Ywan-Feng Li	(1,786)	0	4,500	0
Manager	Tsan-Hui Wu	15,652	0	5,000	0
Manager	Hwei-Rung Wang (Note 3)	9,695	0	N/A	
Manager	Chung-Huan Lin	16,485	0	0	0
Manager	Yu-Wen Liu	9,734	0	0	0
Manager	Tsung-Chih Wang	9,723	0	0	0
Manager	Ming-Tao Pai	15,981	0	0	0
Manager	Chih-Yuan Ma	3,474	0	0	0
Manager	Sz-Wei Wu	9,381	0	0	0

Note 1: Ching-Wen Lin was on board on January 1, 2025.
Note 2: Ren-Yo Forng retired on April 3, 2024.
Note 3: Hwei-Rung Wang resigned on February 14, 2025.

(2)Information of Stock Trade: The counterparties of equity transfer are not related parties.

(3)Information of Stock Pledge: The counterparties of share pledges are not related parties.

8.Relationship information, if among the company's 10 largest shareholders any one is a related party or a relative within the second degree of kinship of another：

April 29, 2025; Unit: Shares; %

Name	Current Shareholding		Spouse's/ minor's Shareholding		Shareholding by Nominee Arrangement		Name and Relationship Between the Company's Top Ten Shareholders, or Spouses or Relatives Within Two Degrees	
	Shares	%	Shares	%	Shares	%	Name	Relationship
Foxconn Technology Co., Ltd.	27,500,000	8.98	0	0	0	0	Yonglin Capital Holding Co., Ltd.	Chairman
Representative: Jun-Fu Lu	0	0	0	0	0	0	N/A	N/A
Yonglin Capital Holding Co., Ltd.	26,500,000	8.65	0	0	0	0	Foxconn Technology Co., Ltd.	Chairman
Representative: Kai-Lin Huang	0	0	0	0	0	0	N/A	N/A
Formosa Laboratories, Inc.	18,552,818	6.06	0	0	0	0	N/A	N/A
Representative: Cheng-Yu Cheng	0	0	0	0	0	0	N/A	N/A
National Development Fund, Executive Yuan	15,288,860	4.99	0	0	0	0	N/A	N/A
Convener: Jing-Qing Liu, Minister, National Development Council	0	0	0	0	0	0	N/A	N/A
Yao-Hwa Glass Co., Ltd, Management Commission	13,078,082	4.27	0	0	0	0	N/A	N/A
Representative: Chuan-Neng Lin	0	0	0	0	0	0	N/A	N/A
Wen-Ming Pan	11,001,123	3.59	0	0	0	0	N/A	N/A
Taiwania Capital Buffalo II Bioventures, LP	6,950,286	2.27	0	0	0	0	N/A	N/A
Representative: Taiwania Capital Biotechnology Corporation	0	0	0	0	0	0	N/A	N/A
Development Center for Biotechnology	4,506,484	1.47	0	0	0	0	N/A	N/A
Representative: Shiing-Jer Twu	0	0	0	0	0	0	N/A	N/A
JPMorgan Chase Bank N.A., Taipei Branch in custody for Vanguard Total International Stock Index Fund, a series of Vanguard Star Funds	2,927,277	0.96	0	0	0	0	N/A	N/A
TransGlobe Life Insurance Inc.	2,920,000	0.95	0	0	0	0	N/A	N/A

9. The total number of shares and total equity stake held in any single enterprise by the Company, its directors and supervisors, managerial officers, and any companies controlled either directly or indirectly by the Company:

As of April 29, 2025; Unit: Shares; %

Affiliated Enterprises	Ownership by the Company		Direct or Indirect Ownership by Directors/Supervisors/Managers		Total Ownership	
	Shares	%	Shares	%	Shares	%
EirGenix Europe GmbH	(Note)	100%	-	-	(Note)	100%
EirGenix USA Inc.	10,000,000	100%	-	-	10,000,000	100%

Note: As a limited liability company, there are no shares.

III. Capital Overview

1.Source of Capital

(1)Source of Capital

Month/ Year	Par Value (NT$)	Authorized Capital		Paid-in Capital		Remark		
		Shares	Amount (Unit: NT$)	Shares	Amount (Unit: NT$)	Sources of Capital	Capital Increased by Assets Other than Cash	Other
January 2024	10	400,000,000	4,000,000	306,032,124	3,060,321	Issuing Restricted Stock Awards 25,500 shares Exercising employee stock option 60,500 shares	None	Approval No. 11330003230 dated 2024/01/16
April 2024	10	400,000,000	4,000,000	306,161,149	3,061,611	Exercising employee stock option 129,025 shares	None	Approval No. 11330048560 dated 2024/04/09
May 2024	10	400,000,000	4,000,000	306,109,214	3,061,092	Exercising employee stock option 70,500 shares Deregistering Restricted Stock Awards 122,435 shares	None	Approval No. 11330087470 dated 2024/05/27
August 2024	10	400,000,000	4,000,000	306,213,295	3,062,133	Exercising employee stock option 190,000 shares Deregistering Restricted Stock Awards 85,919 shares	None	Approval No. 11330156600 dated 2024/08/26
October 2024	10	400,000,000	4,000,000	305,711,233	3,057,112	Deregistering Restricted Stock Awards 502,062 shares	None	Approval No. 11330179730 dated 2024/10/08
December 2024	10	400,000,000	4,000,000	306,216,166	3,062,162	Exercising employee stock option 109,725 shares Issuing Restricted Stock Awards 402,388 shares Deregistering Restricted Stock Awards 7,180 shares	None	Approval No. 11330208420 dated 2024/12/06

(2)Type of Stock

April 29, 2025; Unit: Shares

Share Type	Authorized Capital			Remarks
	Issued Shares	Un-issued Shares	Un-issued Shares	
Common Share	306,216,166	93,783,834	400,000,000	TPEx Listed Stock Private Placement 55,000,000 shares Unregister Share: 144,850 shares
Preferred Shares	None			

(3)Information for Shelf Registration: None.

2.List of Major Shareholders

As of April 29, 2025; Unit: Shares; %

Shares / Shareholder's Name	Shares	Percentage
Foxconn Technology Co., Ltd.	27,500,000	8.98
Yonglin Capital Holding Co., Ltd.	26,500,000	8.65
Formosa Laboratories, Inc.	18,552,818	6.06
National Development Fund, Executive Yuan	15,288,860	4.99
Yao-Hwa Glass Co., Ltd, Management Commission	13,078,082	4.27
Wen-Ming Pan	11,001,123	3.59
Taiwania Capital Buffalo II Bioventures, LP	6,950,286	2.27
Development Center for Biotechnology	4,506,484	1.47
JPMorgan Chase Bank N.A., Taipei Branch in custody for Vanguard Total International Stock Index Fund, a series of Vanguard Star Funds	2,927,277	0.96
TransGlobe Life Insurance Inc.	2,920,000	0.95

3. Dividend Policy and Implementation Status

(1) The Dividend Policy Adopted in the Company's Articles of Incorporation

In accordance with Article 25 and Article 25-1 of EirGenix's Articles of Incorporation.

"Article 25: If the Company has net profit in this fiscal year, the Company shall set aside between 1% to 5% of its profits as a bonus to employees of the Company and set aside 3% (inclusive) or less of its profits as a bonus to Directors. The distribution of bonuses to employees may be made by way of cash or shares by the resolution of the Board of Directors. The employees may include certain employees of the subsidiaries who meet the conditions prescribed by the Company. The distribution of employee remuneration and director remuneration shall be heard by over two-thirds of the Board of Directors, be voted in favor for implementation by over one-half of the directors present and represented, and also be reported at the shareholders' meeting. The Company shall first offset its losses in previous years that have not been previously offset, and then set aside annual profits as a bonus to employees of the Company and set aside annual profits as a bonus to Directors. "

"Article 25-1: If the Company has earnings at the end of the fiscal year, the Company shall first pay all relevant taxes, offset its losses in previous years, and set aside a legal capital reserve at 10% of the net profit, until the accumulated paid-in capital reserve has equaled the total capital of the Company; then set aside a special capital reserve in accordance with relevant laws or regulations or as requested by the authorities in charge. The board of directors may propose the distribution for approval in the shareholders' meeting. The company has the surplus profit distributable as dividends and bonuses to shareholders of no less than 50% of its net income and shall be a resolution adopted by a majority of the shareholders present who represent two-thirds or more of the total number of its outstanding shares of the company. As the Company is in the growing stage, the dividend distribution may take the form of a cash dividend and/or stock dividends and shall take into consideration the Company's capital expenditures, R&D plan, future expansion plans, and financial structure and funds requirement for sustainable development needs, etc. The cash dividends may not be less than 10% of the total dividend amount. However, the actual distribution ratio is still subject to the resolution of the shareholders meeting."

(2) The Dividend Distributions Proposed at the Shareholders' Meeting

The proposal for distribution was passed at the Meeting of the Board of Directors. In this proposal, due to net losses of 2024, none of the cash dividend and none of the stock dividend will be discussed at the annual shareholders' meeting.

(3) If a material change in dividend policy is expected, provide an explanation: **None.**

4. Effect upon business performance and earnings per share of any stock dividend distribution proposed or adopted at the most recent shareholders' meeting: None.

5. Compensation of employees, directors, and supervisors

(1) The percentages or ranges with respect to employee, director, and supervisor compensation, as set forth in the company's articles of incorporation.

Please refer to 6. Dividend Policy and Implementation Status.

(2) The basis for estimating the amount of employee, director, and supervisor compensation, for calculating the number of shares to be distributed as employee compensation, and the accounting treatment of the discrepancy, if any, between the actual distributed amount and the estimated figure, for the current period:

The amount of payment in the past will be taken as the foundation for the estimation of the amount.

If there is a significant change in the amount resolved by the Board to pay after the end of the fiscal year, the amount of change will be recognized as the expense of the year.

If there are still further changes at the time of the decision of the Shareholders Meeting, proceed to the accounting principle of change and enter as adjustment of the year under the resolution of the Shareholders Meeting.

(3) Information on any approval by the board of directors of the distribution of compensation: **None.**

A. The amount of any employee compensation distributed in cash or stocks and compensation for directors and supervisors. If there is any discrepancy between that amount and the estimated figure for the fiscal year these expenses are recognized, the discrepancy, its cause, and the status of treatment shall be disclosed: **N ot Applicable.**

B. The amount of any employee compensation distributed in stocks, and the size of that amount as a percentage of the sum of the after-tax net income stated in the parent company only financial reports or individual financial reports for the current period and total employee compensation: N**ot Applicable.**

(4) The actual distribution of employee, director, and supervisor compensation for the previous fiscal year (with an indication of the number of shares, monetary amount, and stock price, of the shares distributed), and, if there is any discrepancy between the actual distribution and the recognized employee, director, or supervisor compensation, additionally the discrepancy, cause, and how it is treated: **Not Applicable.**

6. Status of a Company Repurchasing its own Shares:

Repurchase No.	1st
Repurchase Purpose	Transfer to employees
Repurchase Period	2024/12/18 to 2025/02/11
Repurchase Price Range	NTD 68 to 100
Repurchase Type and Number	Common Share; 4,000,000 shares
Repurchase Amount	NTD 305,465,238
Repurchase quantity as a percentage of planned repurchase quantity (%)	100%
Number of shares cancelled and/or transferred	0 shares
Cumulative number of the Company's treasury shares held	Common Share; 4,000,000 shares
Cumulative number of the company's treasury shares as a percentage of the total number of the Company's issued shares (%)	1.31%

7. Corporate Bond: None.

8. Preferred Shares: None.

9. Global Depository Receipts: None.

10. Employee Share Subscription Warrants

(1)Status of Employee Share Subscription Warrants (as of 2025/04/29)

Type of Stock Option	2014 2nd Employee Share Subscription Warrants		
Regulatory approval date and units issued	2016/07/19 2,100 units		
Issue date	2015/07/01	2015/07/01	2015/07/06
Units issued	1,270	130	80
	Each unit can subscribe 1,000 common shares.		
Number of shares still available for issuance	0		
Option shares to be issued as a percentage of outstanding shares	0.415 %	0.042 %	0.026 %
Exercising Period	2016/07/01 ~ 2025/06/30	2016/07/01 ~ 2025/06/30	2016/07/06 ~ 2025/07/05
Conversion measures	Issue new common shares.		
Conditional conversion periods and percentages	For every expiration of one year, the accumulated maximum exercise subscription proportion will increase 25%. 100% subscription right can be exercised after 4 years.		
Converted shares	1,015,500 shares	92,500 shares	80,000 shares
Exercised amount	NT$ 15,232,500	NT$ 1,950,000	NT$ 1,600,000
Number of shares yet to be converted	15,000 shares	0 shares	0 share
Adjusted exercise price for those who have yet to exercise their rights	NT$ 15	-	-
Unexercised shares as a percentage of total issued shares	0.005%	-	-
Impact on possible dilution of shareholdings	The issuance of employee stock option certificate may create the common interests of the Company and shareholders, which shall be positive effects to the rights of shareholders.		

Type of Stock Option	2014 2nd Employee Share Subscription Warrants			
Regulatory approval date and units issued	2016/07/19 2,100 units			
Issue date	2015/07/15	2015/07/19	2015/07/26	2015/08/17
Units issued	10	30	20	10
	Each unit can subscribe 1,000 common shares.			
Number of shares still available for issuance	0			
Option shares to be issued as a percentage of outstanding shares	0.003%	0.010%	0.007%	0.003%
Exercising Period	2016/07/15 ~2025/07/14	2016/07/19~ 2025/07/18	2016/07/26~ 2025/07/25	2016/08/17~ 2025/08/16
Conversion measures	Issue new common shares.			
Conditional conversion periods and percentages	For every expiration of one year, the accumulated maximum exercise subscription proportion will increase 25%. 100% subscription right can be exercised after 4 years.			
Converted shares	10,000 shares	15,000 shares	20,000 shares	1,875 shares
Exercised amount	NT$ 200,000	NT$ 300,000	NT$ 400,000	NT$ 37,500

Number of shares yet to be converted	0 share	0 share	0 shares	0 share
Adjusted exercise price for those who have yet to exercise their rights	-	-	-	-
Unexercised shares as a percentage of total issued shares	-	-	-	-
Impact on possible dilution of shareholdings	The issuance of employee stock option certificate may create the common interests of the Company and shareholders, which shall be positive effects to the rights of shareholders.			

Type of Stock Option	2014 2nd Employee Share Subscription Warrants			
Regulatory approval date and units issued	2016/07/19 2,100 units			
Issue date	2015/08/20	2015/08/31	2015/09/29	2015/11/10
Units issued	20	60	20	30
	Each unit can subscribe 1,000 common shares.			
Number of shares still available for issuance	0			
Option shares to be issued as a percentage of outstanding shares	0.007%	0.020%	0.007 %	0.010%
Exercising Period	2016/08/20 ~2025/08/19	2016/08/31~ 2025/08/30	2016/09/29~ 2025/09/28	2016/11/10~ 2025/11/09
Conversion measures	Issue new common shares.			
Conditional conversion periods and percentages	For every expiration of one year, the accumulated maximum exercise subscription proportion will increase 25%. 100% subscription right can be exercised after 4 years.			
Converted shares	20,000 shares	40,000 shares	10,000 shares	22,500 shares
Exercised amount	NT$ 400,000	NT$ 800,000	NT$ 200,000	NT$ 450,000
Number of shares yet to be converted	0 share	0 shares	0 share	0 share
Adjusted exercise price for those who have yet to exercise their rights			-	-
Unexercised shares as a percentage of total issued shares	-	-	-	-
Impact on possible dilution of shareholdings	The issuance of employee stock option certificate may create the common interests of the Company and shareholders, which shall be positive effects to the rights of shareholders.			

Type of Stock Option	2014 2nd Employee Share Subscription Warrants		
Regulatory approval date and units issued	2016/7/19 2,100 units		
Issue date	2015/12/01	2015/12/14	2015/12/21
Units issued	5	20	25
	Each unit can subscribe 1,000 common shares.		
Number of shares still available for issuance	0		
Option shares to be issued as a percentage of outstanding shares	0.002%	0.007%	0.008%
Exercising Period	2016/12/01~ 2025/11/30	2016/12/14~ 2025/12/13	2016/12/21~ 2025/12/20
Conversion measures	Issue new common shares.		
Conditional conversion periods and percentages	For every expiration of one year, the accumulated maximum exercise subscription proportion will increase 25%. 100% subscription right can be exercised after 4 years.		

Converted shares	5,000 shares	0 share	25,000 shares
Exercised amount	NT$ 100,000	NT$ 0	NT$ 500,000
Number of shares yet to be converted	0 share	0 share	0 share
Adjusted exercise price for those who have yet to exercise their rights	-	-	-
Unexercised shares as a percentage of total issued shares	-	-	-
Impact on possible dilution of shareholdings	The issuance of employee stock option certificate may create the common interests of the Company and shareholders, which shall be positive effects to the rights of shareholders.		

Type of Stock Option	2014 2nd Employee Share Subscription Warrants			
Regulatory approval date and units issued	2016/07/19 2,100 units			
Issue date	2016/01/01	2016/01/12	2016/01/13	2016/02/14
Units issued	30	10	15	25
	Each unit can subscribe 1,000 common shares.			
Number of shares still available for issuance	0			
Option shares to be issued as a percentage of outstanding shares	0.010 %	0.003 %	0.005 %	0.008 %
Exercising Period	2017/01/01~ 2025/12/31	2017/01/12~ 2026/01/11	2017/01/13~ 2026/01/12	2017/02/14~ 2026/02/13
Conversion measures	Issue new common shares.			
Conditional conversion periods and percentages	For every expiration of one year, the accumulated maximum exercise subscription proportion will increase 25%. 100% subscription right can be exercised after 4 years.			
Converted shares	3,750 shares	5,000 shares	15,000 shares	18,750 shares
Exercised amount	NT$ 75,000	NT$ 100,000	NT$ 300,000	NT$ 375,000
Number of shares yet to be converted	0 share	0 share	0 share	0 share
Adjusted exercise price for those who have yet to exercise their rights	-	-	-	-
Unexercised shares as a percentage of total issued shares	-	-	-	-
Impact on possible dilution of shareholdings	The issuance of employee stock option certificate may create the common interests of the Company and shareholders, which shall be positive effects to the rights of shareholders.			

Type of Stock Option	2014 2nd Employee Share Subscription Warrants		
Regulatory approval date and units issued	2016/07/19 2,100 units		
Issue date	2016/03/1	2016/03/09	2016/03/14
Units issued	150	25	15
	Each unit can subscribe 1,000 common shares.		
Number of shares still available for issuance	0		
Option shares to be issued as a percentage of outstanding shares	0.049%	0.008%	0.005 %
Exercising Period	2017/03/01~2026/02/28	2017/03/09~2026/03/08	2017/03/14~2026/03/13
Conversion measures	Issue new common shares.		
Conditional conversion periods and	For every expiration of one year, the accumulated maximum exercise subscription proportion will increase 25%.		

percentages	100% subscription right can be exercised after 4 years.		
Converted shares	37,500 shares	0 share	15,000 shares
Exercised amount	NT$ 750,000	-	NT$ 300,000
Number of shares yet to be converted	0 share	25,000 shares	0 share
Adjusted exercise price for those who have yet to exercise their rights	-	NT$ 20	-
Unexercised shares as a percentage of total issued shares	-	0.008%	-
Impact on possible dilution of shareholdings	The issuance of employee stock option certificate may create the common interests of the Company and shareholders, which shall be positive effects to the rights of shareholders.		

Type of Stock Option	2016 1st Employee Share Subscription Warrants	
Regulatory approval date and units issued	2016/07/19 2,100 units	
Issue date	2016/05/05	2016/06/01
Units issued	45	55
	Each unit can subscribe 1,000 common shares.	
Number of shares still available for issuance	0	
Option shares to be issued as a percentage of outstanding shares	0.049%	0.008%
Exercising Period	2018/05/05~2026/05/04	2018/06/01~2026/05/31
Conversion measures	Issue new common shares.	
Conditional conversion periods and percentages	50% subscription right can be exercised after 2 years. After 2 years, for every expiration of one year, the accumulated maximum exercise subscription proportion will increase 25%. 100% subscription right can be exercised after 4 years.	
Converted shares	35,000 shares	40,000 shares
Exercised amount	NT$ 1,099,000	NT$ 1,264,000
Number of shares yet to be converted	10,000 shares	0 share
Adjusted exercise price for those who have yet to exercise their rights	NT$ 29.2	-
Unexercised shares as a percentage of total issued shares	0.003%	-
Impact on possible dilution of shareholdings	The issuance of employee stock option certificate may create the common interests of the Company and shareholders, which shall be positive effects to the rights of shareholders.	

Type of Stock Option	2016 2nd Employee Share Subscription Warrants	
Regulatory approval date and units issued	2016/08/30 600 units	
Issue date	2016/10/12	2016/12/29
Units issued	515	85
	Each unit can subscribe 1,000 common shares.	
Number of shares still available for issuance	0	
Option shares to be issued as a percentage of outstanding shares	0.168 %	0.028 %
Exercising Period	2018/10/12~2026/10/11	2018/12/29~2026/12/28

Conversion measures	Issue new common shares.	
Conditional conversion periods and percentages	50% subscription right can be exercised after 2 years. After 2 years, for every expiration of one year, the accumulated maximum exercise subscription proportion will increase 25%. 100% subscription right can be exercised after 4 years.	
Converted shares	241,250 shares	55,000 shares
Exercised amount	NT$ 7,401,750	NT$ 2,141,175
Number of shares yet to be converted	150,000 shares	15,000 shares
Adjusted exercise price for those who have yet to exercise their rights	NT$ 29.2	NT$ 37.5
Unexercised shares as a percentage of total issued shares	0.049 %	0.005 %
Impact on possible dilution of shareholdings	The issuance of employee stock option certificate may create the common interests of the Company and shareholders, which shall be positive effects to the rights of shareholders.	

Type of Stock Option	2017 1st Employee Share Subscription Warrants		
Regulatory approval date and units issued	2017/05/10 1,700 units		
Issue date	2017/08/08	2017/12/27	2018/03/23
Units issued	395	570	175
	Each unit can subscribe 1,000 common shares.		
Number of shares still available for issuance	0		
Option shares to be issued as a percentage of outstanding shares	0.129 %	0.186 %	0.057 %
Exercising Period	2019/08/08~2027/08/07	2019/12/27~2027/12/26	2020/03/23~2028/03/22
Conversion measures	Issue new common shares.		
Conditional conversion periods and percentages	50% subscription right can be exercised after 2 years. After 2 years, for every expiration of one year, the accumulated maximum exercise subscription proportion will increase 25%. 100% subscription right can be exercised after 4 years.		
Converted shares	235,000 shares	351,750 shares	110,000 shares
Exercised amount	NT$ 7,161,000	NT$ 9,157,800	NT$ 2,644,700
Number of shares yet to be converted	0 shares	37,000 shares	0 shares
Adjusted exercise price for those who have yet to exercise their rights	-	NT$ 25	-
Unexercised shares as a percentage of total issued shares	-	0.012 %	-
Impact on possible dilution of shareholdings	The issuance of employee stock option certificate may create the common interests of the Company and shareholders, which shall be positive effects to the rights of shareholders.		

Type of Stock Option	2017 1st Employee Share Subscription Warrants	
Regulatory approval date and units issued	2018/08/09 1,500 units	
Issue date	2019/01/25	2019/05/13
Units issued	520	285
	Each unit can subscribe 1,000 common shares.	
Number of shares still available for issuance	0	

Option shares to be issued as a percentage of outstanding shares	0.170 %	0.093 %
Exercising Period	2021/01/25~2029/01/24	2021/05/13~2029/05/12
Conversion measures	Issue new common shares.	
Conditional conversion periods and percentages	50% subscription right can be exercised after 2 years. After 2 years, for every expiration of one year, the accumulated maximum exercise subscription proportion will increase 25%. 100% subscription right can be exercised after 4 years.	
Converted shares	285,000 shares	119,500 shares
Exercised amount	NT$ 8,399,501	NT$ 4,113,100
Number of shares yet to be converted	18,750 shares	80,000 shares
Adjusted exercise price for those who have yet to exercise their rights	NT$ 28.7	NT$ 34.3
Unexercised shares as a percentage of total issued shares	0.006 %	0.026 %
Impact on possible dilution of shareholdings	The issuance of employee stock option certificate may create the common interests of the Company and shareholders, which shall be positive effects to the rights of shareholders.	

Type of Stock Option	2019 1st Employee Share Subscription Warrants		
Regulatory approval date and units issued	2019/10/29 2,000 units		
Issue date	2019/11/12	2020/04/15	2020/08/12
Units issued	960	775	205
	Each unit can subscribe 1,000 common shares.		
Number of shares still available for issuance	0		
Option shares to be issued as a percentage of outstanding shares	0.314 %	0.253 %	0.067 %
Exercising Period	2021/11/12~2029/11/11	2022/04/15~2030/04/14	2022/08/12~2030/08/11
Conversion measures	Issue new common shares.		
Conditional conversion periods and percentages	50% subscription right can be exercised after 2 years. After 2 years, for every expiration of one year, the accumulated maximum exercise subscription proportion will increase 25%. 100% subscription right can be exercised after 4 years.		
Converted shares	446,100 shares	325,500 shares	137,500 shares
Exercised amount	NT$ 11,241,720	NT$ 9,374,400	NT$ 7,040,000
Number of shares yet to be converted	80,150 shares	25,750 shares	28,750 shares
Adjusted exercise price for those who have yet to exercise their rights	NT$ 25.2	NT$ 28.8	NT$ 51.2
Unexercised shares as a percentage of total issued shares	0.026 %	0.008 %	0.009 %
Impact on possible dilution of shareholdings	The issuance of employee stock option certificate may create the common interests of the Company and shareholders, which shall be positive effects to the rights of shareholders.		

Type of Stock Option	2020 1st Employee Share Subscription Warrants			
Regulatory approval date and units issued	2020/11/06 3,000 units			
Issue date	2020/12/23	2021/05/12	2021/08/12	2021/10/01
Units issued	830	315	505	1,185
	Each unit can subscribe 1,000 common shares.			

Number of shares still available for issuance	0			
Option shares to be issued as a percentage of outstanding shares	0.271 %	0.103 %	0.165 %	0.387 %
Exercising Period	2022/12/23~ 2030/12/22	2023/05/12~ 2031/05/11	2023/08/12~ 2031/08/11	2023/10/01~ 2031/09/30
Conversion measures	Issue new common shares.			
Conditional conversion periods and percentages	50% subscription right can be exercised after 2 years. After 2 years, for every expiration of one year, the accumulated maximum exercise subscription proportion will increase 25%. 100% subscription right can be exercised after 4 years.			
Converted shares	335,250 shares	0 share	0 share	0 share
Exercised amount	NT$ 14,114,025	NT$ 0	NT$ 0	NT$ 0
Number of shares yet to be converted	144,750 shares	200,000 shares	250,000 shares	550,000 shares
Adjusted exercise price for those who have yet to exercise their rights	NT$ 42.1	NT$ 146.4	NT$ 128.4	NT$ 117.5
Unexercised shares as a percentage of total issued shares	0.047 %	0.065 %	0.082 %	0.181 %
Impact on possible dilution of shareholdings	The issuance of employee stock option certificate may create the common interests of the Company and shareholders, which shall be positive effects to the rights of shareholders.			

Type of Stock Option	2021 1st Employee Share Subscription Warrants			
Regulatory approval date and units issued	2021/10/15 3,000 units			
Issue date	2022/03/22	2022/05/12	2022/08/11	2022/09/08
Units issued	160	225	685	510
	Each unit can subscribe 1,000 common shares.			
Number of shares still available for issuance	0			
Option shares to be issued as a percentage of outstanding shares	0.052 %	0.073 %	0.224 %	0.167 %
Exercising Period	2024/03/22~ 2032/03/21	2024/05/12~ 2032/05/11	2024/08/11~ 2032/08/10	2024/09/08~ 2032/09/07
Conversion measures	Issue new common shares.			
Conditional conversion periods and percentages	50% subscription right can be exercised after 2 years. After 2 years, for every expiration of one year, the accumulated maximum exercise subscription proportion will increase 25%. 100% subscription right can be exercised after 4 years.			
Converted shares	0 share	36,000 share	0 share	0 share
Exercised amount	NT$ 0	NT$ 2,577,600	NT$ 0	NT$ 0
Number of shares yet to be converted	55,000 shares	77,500 shares	350,000 shares	295,000 shares
Adjusted exercise price for those who have yet to exercise their rights	NT$ 93.5	NT$ 71.6	NT$ 85.9	NT$ 118.5
Unexercised shares as a percentage of total issued shares	0.018 %	0.025 %	0.114%	0.096 %
Impact on possible dilution of shareholdings	The issuance of employee stock option certificate may create the common interests of the Company and shareholders, which shall be positive effects to the rights of shareholders.			

Type of Stock Option	2022 1st Employee Share Subscription Warrants

Regulatory approval date and units issued	2022/09/06 4,000 units	
Issue date	2022/11/08	2023/03/10
Units issued	615	1,105
	Each unit can subscribe 1,000 common shares.	
Number of shares still available for issuance	2,280	
Option shares to be issued as a percentage of outstanding shares	0.201 %	0.361 %
Exercising Period	2024/11/08~2032/11/07	2025/03/10~2033/03/09
Conversion measures	Issue new common shares.	
Conditional conversion periods and percentages	50% subscription right can be exercised after 2 years. After 2 years, for every expiration of one year, the accumulated maximum exercise subscription proportion will increase 25%. 100% subscription right can be exercised after 4 years.	
Converted shares	0 share	0 share
Exercised amount	NT$ 0	NT$ 0
Number of shares yet to be converted	385,000 shares	645,000 shares
Adjusted exercise price for those who have yet to exercise their rights	NT$ 103.5	NT$ 111.5
Unexercised shares as a percentage of total issued shares	0.126 %	0.211 %
Impact on possible dilution of shareholdings	The issuance of employee stock option certificate may create the common interests of the Company and shareholders, which shall be positive effects to the rights of shareholders.	

Type of Stock Option	2022 1st Employee Share Subscription Warrants	
Regulatory approval date and units issued	2022/09/06 4,000 units	
Issue date	2023/05/10	2023/08/08
Units issued	255	225
	Each unit can subscribe 1,000 common shares.	
Number of shares still available for issuance	1,800	
Option shares to be issued as a percentage of outstanding shares	0.083 %	0.073 %
Exercising Period	2025/05/10~2033/05/09	2025/08/08~2033/08/07
Conversion measures	Issue new common shares.	
Conditional conversion periods and percentages	50% subscription right can be exercised after 2 years. After 2 years, for every expiration of one year, the accumulated maximum exercise subscription proportion will increase 25%. 100% subscription right can be exercised after 4 years.	
Converted shares	0 share	0 share
Exercised amount	NT$ 0	NT$ 0
Number of shares yet to be converted	205,000 shares	190,000 shares
Adjusted exercise price for those who have yet to exercise their rights	NT$ 120	NT$ 101.5
Unexercised shares as a percentage of total issued shares	0.067 %	0.062 %
Impact on possible dilution of shareholdings	The issuance of employee stock option certificate may create the common interests of the Company and shareholders, which shall be positive effects to the rights of shareholders.	

Type of Stock Option	2022 1st Employee Share Subscription Warrants	
Regulatory approval date and units issued	2022/09/06 4,000 units	
Issue date	2023/12/22	2024/05/09
Units issued	270	225
	Each unit can subscribe 1,000 common shares.	
Number of shares still available for issuance	1,800	
Option shares to be issued as a percentage of outstanding shares	0.083 %	0.073 %
Exercising Period	2025/12/22~2033/12/21	2026/05/09~2034/05/08
Conversion measures	Issue new common shares.	
Conditional conversion periods and percentages	50% subscription right can be exercised after 2 years. After 2 years, for every expiration of one year, the accumulated maximum exercise subscription proportion will increase 25%. 100% subscription right can be exercised after 4 years.	
Converted shares	0 share	0 share
Exercised amount	NT$ 0	NT$ 0
Number of shares yet to be converted	215,000 shares	140,000 shares
Adjusted exercise price for those who have yet to exercise their rights	NT$ 100.5	NT$ 80
Unexercised shares as a percentage of total issued shares	0.070 %	0.046 %
Impact on possible dilution of shareholdings	The issuance of employee stock option certificate may create the common interests of the Company and shareholders, which shall be positive effects to the rights of shareholders.	

(2) The annual report shall disclose the names of top-level company executives holding employee share subscription warrants and the cumulative number of such warrants exercised by said executives as of the date of publication of the annual report. The annual report shall also disclose the names of the ten employees holding employee subscription warrants authorizing purchase of the most shares, along with the cumulative number of warrants exercised by these ten employees, as of the date of publication of the annual report.

April 29th, 2025

	Title	Name	No. of Option Shares	Option Shares as a Percentage of Shares Issued	Exercised				Unexercised			
					No. of Shares Converted	Strike Price (NT$)	Amount (NT$)	Converted Shares as a Percentage of Shares issued	No. of Shares Converted	Strike Price (NT$)	Amount (NT$)	Converted Shares as a Percentage of Shares issued
Management	President	Lee-Cheng Liu	2,366,000 shares	0.773%	1,741,000 shares	$10.2 $15.0 $42.1	NT$ 28,878,000	0.569%	625,000 shares	$25.2 $29.2 $34.3 $42.1 $100.5 $111.5 $117.5 $118.5 $128.4 $146.4	NT$ 51,443,000	0.204%
	Senior Vice President	Chih-Jung Chang										
	Vice President	Hsiu-Chuan Yang										
	Executive Director	Ae-Ning Lin										
	Executive Director	Shang-Chung Ju										
	Executive Director	Ching-Ying Chen										
	Executive Director	Ren-Yo Forng (Note 1)										
	Executive Director	Ywan-Feng Li										
	Senior Director	Tsan-Hui Wu										
	Senior Director	Hwei-Rung Wang (Note 2)										
	Director	Chung-Huan Lin										
	Director	Yu-Wen Liu										
	Director	Tsung-Chih Wang										
	Director	Ming-Tao Pai										
	Director	Chih-Yuan Ma										
	Director	Sz-Wei Wu										
Staff	President of EirGenix Europe GmbH	Thomas Schulze	585,000 shares	0.191%	290,000 shares	$15.0 $25.2 $28.8 $42.1	NT$ 7,001,000	0.095%	295,000 shares	$15.0 $23.5 $25.2 $28.8 $42.1 $111.5 $117.5 $120.0 $128.4	NT$ 31,064,000	0.096%
	Executive Director of EirGenix Europe GmbH	Barbara Grohmann-Izay (Note 3)										
	Associate Director	Chien-Hao Chen										
	Associate Director	Wan-Ting Hsieh										
	Associate Director	Chia-Hsin Hsiao (Note 4)										
	Associate Director	Ching-Cheng Hsiao										
	Associate Director	Hsiao-Wen Lin										
	Associate Director	Chia-Wang Chiang										
	Senior Manager	An-Chi Fan										
	Manager	Li-Ting Lin										

Note 1: Ren-Yo Forng retired on April 3, 2024.
Note 2: Hwei-Rung Wang resigned on February 14, 2025.
Note 3: Barbara Grohmann-Izay resigned on December 31, 2024.
Note 4: Chia-Hsin Hsia resigned on April 18, 2025.

11. Restricted Employee Share

(1) Status ofRestricted Employee Share (as of 2025/04/29)

Type of Stock Option	1st Employee Restricted Stock in 2016	
Regulatory approval date and shares issued	2016/10/05 2,000,000 shares	
Issue date	2016/11/18	2016/08/08
Units issued	1,659,500 shares	257,500 shares
Number of shares still available for issuance	0 share	
Strike price	NT$ 0	
Restricted Stock Awards shares to be issued as a percentage of outstanding shares	0.542 %	0.084 %
Conditional conversion periods and percentages	Condition A: Company operation performance and employee personal KPI. Achieve a positive income before tax for three quarters, and employee's average KPI shall be over 2.66 for three consecutive years. 33.3% of total shares will be released. Condition B: Employee job tenure and employee personal KPI. Work in EirGenix for ten years, and employee personal average KPI shall be over 2.66 for three consecutive years. 16.7% of total shares will be released. Condition C: Development of biosimilar EG12014 and employee personal KPI Timing I: Complete EG12014 Phase 3 and the employee's average KPI shall be over 2.66 for three consecutive years. 11.1% of total shares will be released. Timing II: EG12014 Launched to market and employee personal average KPI shall be over 2.66 for three consecutive years. 11.1% of total shares will be released. Condition D: Development of biosimilar EG1206A and employee personal KPI Timing I: Complete EG1206A Phase 1, and employee personal average KPI shall be over 2.66 for three consecutive years. 5.6% of total shares will be released. Timing II: Complete EG1206A out-licensing or Phase 3 and employee personal average KPI shall be over 2.66 for three consecutive years. 11.1% of total shares will be released. Condition E: New plant in Zhubei start running and completes 1,000L or 2*2,000L scale process validation and employee personal KPI. The new plant in Zhubei starts running and completes 1,000L or 2*2,000L scale process validation, and the employee personal average KPI shall be over 2.66 for three consecutive years. 11.1% of total shares will be released. Condition F: Complete IPO in TPEx and employee personal KPI Complete IPO in TPEx and employee personal average KPI shall be over 2.66 for three consecutive years. 10% of total shares will be released	
Restricted Conditions	Please refer to the following table for details.	
Depository methods of new shares	Please refer to the following table for details.	
Handling of an employee's failure to meet the vesting conditions	Please refer to the following table for details.	
Bought-back or canceled new shares of Restricted Stock Awards	744,650 shares	174,750 shares
Shares of Unrestricted Stock Awards	569,000 shares	41,900 shares
New shares of Restricted Stock Awards	345,850 shares	40,850 shares
Percentage of new shares of Restricted Stock Awards to Total Issued Shares (%)	0.113 %	0.013 %
Impacts on Shareholders' Equity	The ratio accounted for by the new shares with restricted rights as above. There is no major impact to the existing shareholders of the Company.	

Type of Stock Option	1st Employee Restricted Stock in 2019	
Regulatory approval date and shares issued	2019/12/30 600,000 shares	
Issue date	2020/05/13	2020/12/10
Units issued	454,500 shares	144,000 shares
Number of shares still available for issuance	0 share	
Strike price	NT$ 0	
Restricted Stock Awards shares to be issued as a percentage of outstanding shares	0.148 %	0.047 %
Conditional conversion periods and percentages	Condition A: Calculated from the working day when relocated to Zhubei branch, after serving for 0.25 years, 0.5 years, 0.75 years and 1 year; 750 shares will be released on each timing. Condition B: Calculated from the working day when relocated to Zhubei branch, after serving for 1.5 years, and 2 years; 2,000 shares will be released on each timing. Condition C Calculated from the working day when relocated to Zhubei branch, after serving for 3 years; 5,000 shares will be released on each timing.	
Restricted Conditions	Please refer to the following table for details.	
Depository methods of new shares	Please refer to the following table for details.	
Handling of an employee's failure to meet the vesting conditions	Please refer to the following table for details.	
Bought-back or canceled new shares of Restricted Stock Awards	35,250 shares	34,500 shares
Shares of Unrestricted Stock Awards	396,000 shares	99,500 shares
New shares of Restricted Stock Awards	23,250 shares	10,000 shares
Percentage of new shares of Restricted Stock Awards to Total Issued Shares (%)	0.008 %	0.003 %
Impacts on Shareholders' Equity	The ratio accounted for by the new shares with restricted rights as above. There is no major impact to the existing shareholders of the Company.	

Type of Stock Option	2nd Employee Restricted Stock in 2019	
Regulatory approval date and shares issued	2019/12/30 1,000,000 shares	
Issue date	2020/08/14	2020/12/10
Units issued	905,700 shares	94,200 shares
Number of shares still available for issuance	0 share	
Strike price	NT$ 0	
Restricted Stock Awards shares to be issued as a percentage of outstanding shares	0.296 %	0.031 %
Conditional conversion periods and percentages	Condition A: Company operation performance and employee personal KPI. Achieve a positive income before tax for three quarters, and employee's average KPI shall be over 2.66 for three consecutive years. 33.3% of total shares will be released. Condition B: Employee job tenure and employee personal KPI. Work in EirGenix for ten years, and employee personal average KPI shall be over 2.66 for three consecutive years. 16.7% of total shares will be released. Condition C: Development of biosimilar EG12014 and employee personal KPI Timing I: Complete EG12014 Phase 3 and the employee's average KPI shall be over 2.66 for three consecutive years. 11.1% of total shares will be released.	

	Timing II: EG12014 Launched to market and employee personal average KPI shall be over 2.66 for three consecutive years. 11.1% of total shares will be released. Condition D: Development of biosimilar EG1206A and employee personal KPI Timing I: Complete EG1206A Phase 1, and employee personal average KPI shall be over 2.66 for three consecutive years. 5.6% of total shares will be released. Timing II: Complete EG1206A out-licensing or Phase 3 and employee personal average KPI shall be over 2.66 for three consecutive years. 11.1% of total shares will be released. Condition E: New plant in Zhubei start running and completes 1,000L or 2*2,000L scale process validation and employee personal KPI. The new plant in Zhubei starts running and completes 1,000L or 2*2,000L scale process validation, and the employee personal average KPI shall be over 2.66 for three consecutive years. 11.1% of total shares will be released. Condition F: Complete IPO in TPEx and employee personal KPI. Complete IPO in TPEx and employee personal average KPI shall be over 2.66 for three consecutive years. 10% of total shares will be released
Restricted Conditions	Please refer to the following table for details.
Depository methods of new shares	Please refer to the following table for details.
Handling of an employee's failure to meet the vesting conditions	Please refer to the following table for details.
Bought-back or canceled new shares of Restricted Stock Awards	331,700 shares / 0 shares
Shares of Unrestricted Stock Awards	273,000 shares / 50,750 shares
New shares of Restricted Stock Awards	301,000 shares / 43,450 shares
Percentage of new shares of Restricted Stock Awards to Total Issued Shares (%)	0.098 % / 0.014 %
Impacts on Shareholders' Equity	The ratio accounted for by the new shares with restricted rights as above. There is no major impact to the existing shareholders of the Company.

Type of Stock Option	1st Employee Restricted Stock in 2021		
Regulatory approval date and shares issued	2021/09/10 1,000,000 shares		
Issue date	2021/10/15	2022/01/15	2022/09/08
Units issued	612,500 shares	184,000 shares	190,000 shares
Number of shares still available for issuance	0 share		
Strike price	NT$ 0		
Restricted Stock Awards shares to be issued as a percentage of outstanding shares	0.200 %	0.060 %	0.062 %
Conditional conversion periods and percentages	Condition A: Company operation performance and employee personal KPI. Achieve a positive income before tax for three quarters, and employee's average KPI shall be over 2.66 for three consecutive years. 33.3% of total shares will be released. Condition B: Employee job tenure and employee personal KPI. Work in EirGenix for ten years, and employee personal average KPI shall be over 2.66 for three consecutive years. 16.7% of total shares will be released. Condition C: Development of biosimilar EG12014 and employee personal KPI Timing I: Complete EG12014 Phase 3 and the employee's average KPI shall be over 2.66 for three consecutive years. 11.1% of total shares will be released. Timing II: EG12014 Launched to market and employee personal average KPI shall be over 2.66 for three consecutive years. 11.1% of total shares will be released.		

	Condition D: Development of biosimilar EG1206A and employee personal KPI Timing I: Complete EG1206A Phase 1, and employee personal average KPI shall be over 2.66 for three consecutive years. 5.6% of total shares will be released. Timing II: Complete EG1206A out-licensing or Phase 3 and employee personal average KPI shall be over 2.66 for three consecutive years. 11.1% of total shares will be released. Condition E: New plant in Zhubei start running and completes 1,000L or 2*2,000L scale process validation and employee personal KPI. The new plant in Zhubei starts running and completes 1,000L or 2*2,000L scale process validation, and the employee personal average KPI shall be over 2.66 for three consecutive years. 11.1% of total shares will be released.
Restricted Conditions	Please refer to the following table for details.
Depository methods of new shares	Please refer to the following table for details.
Handling of an employee's failure to meet the vesting conditions	Please refer to the following table for details.

Bought-back or canceled new shares of Restricted Stock Awards	293,250 shares	91,500 shares	93,750 shares
Shares of Unrestricted Stock Awards	135,000 shares	31,250 shares	22,000 shares
New shares of Restricted Stock Awards	184,250 shares	61,250 shares	74,250 shares
Percentage of new shares of Restricted Stock Awards to Total Issued Shares (%)	0.060 %	0.020 %	0.024 %
Impacts on Shareholders' Equity	The ratio accounted for by the new shares with restricted rights as above. There is no major impact to the existing shareholders of the Company.		

Type of Stock Option	1st Employee Restricted Stock in 2022			
Regulatory approval date and shares issued	2022/09/06 850,000 shares			
Issue date	2022/09/08	2022/11/08	2023/03/10	2023/11/09
Units issued	62,657 shares	195,137 shares	5,929 shares	324,820 shares
Number of shares still available for issuance	261,457 shares			
Strike price	NT$ 0			
Restricted Stock Awards shares to be issued as a percentage of outstanding shares	0.020 %	0.064 %	0.002 %	0.106 %
Conditional conversion periods and percentages	The employee must remain employed by the Company on the last date of each vesting period. During the vesting period, the employee may not breach any agreement with the company or violate the Company's employment agreement, service agreement, trust agreement, company governance best practice principles, ethical corporate management best practice principles, work rules, non-compete and non-disclosure agreement of the Company or any agreement with the Company. Specific employee performance metrics and the Company's business performance metrics are met in the Employee Restricted Stock Awards Rules. Condition A: Employees on board at, or before the third quarter of 2022, 100% of shares will be vested at the end of same year. Condition B: Employees on board in the fourth quarter of 2022, 100% of shares will be vested at the end of following year. Condition C: Employees on board between the first quarter to third quarter of 2023, 100% of shares will be vested at the end of same year. Condition D: Shares granted for employees 2021 personal performance and company performance rating over 2.5, will be vested 100%. Condition E: Shares granted for employees 2022 company performance rating over 2.0, and personal performance rating plus company performance rating total over 5.0 will be vested 100%.			
Restricted Conditions	Please refer to the following table for details.			

Depository methods of new shares	Please refer to the following table for details.			
Handling of an employee's failure to meet the vesting conditions	Please refer to the following table for details.			
Bought-back or canceled new shares of Restricted Stock Awards	0 shares	3,370 shares	0 shares	4,175 shares
Shares of Unrestricted Stock Awards	62,657 shares	191,393 shares	5,929 shares	318,490 shares
New shares of Restricted Stock Awards	0 shares	374 shares	0 shares	2,338 shares
Percentage of new shares of Restricted Stock Awards to Total Issued Shares (%)	-	0.000 %	-	0.001 %
Impacts on Shareholders' Equity	The ratio accounted for by the new shares with restricted rights that have not yet been lifted is a mere 0.012%. There is no major impact to the existing shareholders of the Company.			

Type of Stock Option	1st Employee Restricted Stock in 2023
Regulatory approval date and shares issued	2023/10/27 805,000 shares
Issue date	2023/12/22
Units issued	25,500 shares
Number of shares still available for issuance	779,500 shares
Strike price	NT$ 0
Restricted Stock Awards shares to be issued as a percentage of outstanding shares	0.008 %
Conditional conversion periods and percentages	Condition A: Company operation performance and employee personal KPI. Achieve a positive income before tax for three quarters, and employee's average KPI shall be over 2.66 for three consecutive years. 33.3% of total shares will be released. Condition B: Employee job tenure and employee personal KPI. Work in EirGenix for ten years, and employee personal average KPI shall be over 2.66 for three consecutive years. 16.7% of total shares will be released. Condition C: Development of biosimilar EG12014 and employee personal KPI Timing I: Complete EG12014 Phase 3 and the employee's average KPI shall be over 2.66 for three consecutive years. 11.1% of total shares will be released. Timing II: EG12014 Launched to market and employee personal average KPI shall be over 2.66 for three consecutive years. 11.1% of total shares will be released. Condition D: Development of biosimilar EG1206A and employee personal KPI Timing I: Complete EG1206A Phase 1, and employee personal average KPI shall be over 2.66 for three consecutive years. 5.6% of total shares will be released. Timing II: Complete EG1206A out-licensing or Phase 3 and employee personal average KPI shall be over 2.66 for three consecutive years. 11.1% of total shares will be released. Condition E: New plant in Zhubei start running and completes 1,000L or 2*2,000L scale process validation and employee personal KPI. The new plant in Zhubei starts running and completes 1,000L or 2*2,000L scale process validation, and the employee personal average KPI shall be over 2.66 for three consecutive years. 11.1% of total shares will be released.
Restricted Conditions	Please refer to the following table for details.
Depository methods of new shares	Please refer to the following table for details.
Handling of an employee's failure to meet the vesting conditions	Please refer to the following table for details.

Bought-back or canceled new shares of Restricted Stock Awards	2,750 shares
Shares of Unrestricted Stock Awards	6,250 shares
New shares of Restricted Stock Awards	16,500 shares
Percentage of new shares of Restricted Stock Awards to Total Issued Shares (%)	0.005 %
Impacts on Shareholders' Equity	The ratio accounted for by the new shares with restricted rights as above. There is no major impact to the existing shareholders of the Company.

Type of Stock Option	2nd Employee Restricted Stock in 2023
Regulatory approval date and shares issued	2023/10/27 870,000 shares
Issue date	2023/11/09
Units issued	825,562 shares
Number of shares still available for issuance	44,438 shares
Strike price	NT$ 0
Restricted Stock Awards shares to be issued as a percentage of outstanding shares	0.270 %
Conditional conversion periods and percentages	The employee must remain employed by the Company on the last date of each vesting period. During the vesting period, the employee may not breach any agreement with the company or violate the Company's employment agreement, service agreement, trust agreement, company governance best practice principles, ethical corporate management best practice principles, work rules, non-compete and non-disclosure agreement of the Company or any agreement with the Company. Specific employee performance metrics and the Company's business performance metrics are met in the Employee Restricted Stock Awards Rules. Condition A: When the annual Key-Performance-Indicator (KPI) of the Company is at least 2.5, the employee will be eligible to receive 100% shares of the Company's restricted stock. Condition B: When EirGenix reaches the break-even milestone for a fiscal year based on an audited income statement, the employee will be eligible to receive 100% shares of Company's restricted stock. Condition C: When the Company and employee's annual Key-Performance-Indicator (KPI) is at least 2.5, the employee will be eligible to receive 100% shares of the Company's restricted stock.
Restricted Conditions	Please refer to the following table for details.
Depository methods of new shares	Please refer to the following table for details.
Handling of an employee's failure to meet the vesting conditions	Please refer to the following table for details.
Bought-back or canceled new shares of Restricted Stock Awards	400,000 shares
Shares of Unrestricted Stock Awards	425,562 shares
New shares of Restricted Stock Awards	0 shares
Percentage of new shares of Restricted Stock Awards to Total Issued Shares (%)	-
Impacts on Shareholders' Equity	The ratio accounted for by the new shares with restricted rights as above. There is no major impact to the existing shareholders of the Company.

Type of Stock Option	1st Employee Restricted Stock in 2024
Regulatory approval date and shares issued	2023/10/27 1,400,000 shares
Issue date	2024/11/12
Units issued	402,388 shares
Number of shares still available for issuance	997,612 shares
Strike price	NT$ 0
Restricted Stock Awards shares to be issued as a percentage of outstanding shares	0.131 %
Conditional conversion periods and percentages	The employee must remain employed by the Company on the last date of each vesting period. During the vesting period, the employee may not breach any agreement with the company or violate the Company's employment agreement, service agreement, trust agreement, company governance best practice principles, ethical corporate management best practice principles, work rules, non-compete and non-disclosure agreement of the Company or any agreement with the Company. Specific employee performance metrics and the Company's business performance metrics are met in the Employee Restricted Stock Awards Rules. Condition B: Employees on board at, or before the third quarter of 2024, 100% of shares will be vested at the end of same year.
Restricted Conditions	Please refer to the following table for details.
Depository methods of new shares	Please refer to the following table for details.
Handling of an employee's failure to meet the vesting conditions	Please refer to the following table for details.
Bought-back or canceled new shares of Restricted Stock Awards	4,616 shares
Shares of Unrestricted Stock Awards	361,973 shares
New shares of Restricted Stock Awards	35,799 shares
Percentage of new shares of Restricted Stock Awards to Total Issued Shares (%)	0.012 %
Impacts on Shareholders' Equity	The ratio accounted for by the new shares with restricted rights as above. There is no major impact to the existing shareholders of the Company.

Employee Restricted Stock	
Restricted Conditions	1. During the vesting period, the employee may not sell, pledge, transfer, give to another person, create any encumbrance on, or otherwise dispose of, restricted stock awards 2. Voting right in Shareholders' Meeting: The same as common stock. 3. Dividend: The same as common stock.
Depository methods of new shares	The Employee Restricted Stock issued may be deposited in a security trust account.
Handling of an employee's failure to meet the vesting conditions	1. No matter of the Voluntary departure from employment, Dismissal from employment, Retirement, Death or Job position transfer to an affiliate, EirGenix shall buy back and cancel all Restricted Stock Awards. 2. Sufferers of disability due to an occupational accident: EirGenix shall buy back and cancel Restricted Stock Awards unless the permission by the Board. 3. Employees will not have to return the stock dividend or cash dividend occurred by forfeited restricted stock awards 4. Employees who have not reached the vesting conditions: Employees who has subscribed but fail to meet the grant conditions, EirGenix shall buy back and cancel Restricted Stock Awards in accordance with the laws.

(2) List of Executives and the Top 10 Employees Receiving Restricted Stock Awards

April 29th, 2025

	Title	Name	No. of Receiving Restricted Stock Shares	Receiving Restricted Stock Shares as a Percentage of Shares issued	Unrestricted				Restricted			
					No. of Shares Converted	Strike Price	Amount	Converted Shares as a Percentage of Shares issued	No. of Shares Converted	Strike Price	Amount	Converted Shares as a Percentage of Shares issued
Management	President	Lee-Cheng Liu	2,308,000 shares	0.754%	1,597,000 shares	NT$0	NT$0	0.521%	250,000 shares	NT$0	NT$0	0.082%
	Senior Vice President	Chih-Jung Chang										
	Vice President	Hsiu-Chuan Yang										
	Executive Director	Shang-Chung Ju										
	Executive Director	Ae-Ning Lin										
	Executive Director	Ching-Ying Chen										
	Senior Director	Tsan-Hui Wu										
	Senior Director	Hwei-Rung Wang (Note 1)										
	Director	Chung-Huan Lin										
	Director	Yu-Wen Liu										
	Director	Tsung-Chih Wang										
	Director	Ming-Tao Pai										
	Director	Chih-Yuan Ma										
	Director	Sz-Wei Wu										
Staff	President of EirGenix Europe GmbH	Thomas Schulze	401,000 shares	0.131%	281,000 shares	NT$0	NT$0	0.092%	119,000 shares	NT$0	NT$0	0.039%
	Manager	Wen-Yuan Ting										
	Senior Manager	Ying-Chun Chen										
	Associate Director	Yi-Hsuan Pan										
	Senior Manager	Jui-Chi Lee										
	Associate Director	Chien-Hao Chen										
	Senior Manager	Chia-Feng Liao										
	Associate Director	Chia-Hsin Hsiao (Note 2)										
	Associate Director	Ching-Cheng Hsiao										
	Associate Director	Wan-Ting Hsieh										

Note 1: Hwei-Rung Wang resigned on February 14, 2025.
Note 2: Chia-Hsin Hsia resigned on April 18, 2025.

12. Issuance of new Shares in Connection with Mergers or Acquisitions or With Acquisitions of Shares of Other Companies: None.

13. The Status of Implementation of Capital Allocation Plans

(1)Cash Capital Increase in 2020

A.Description of the Plan: Please refer to https://mopsov.twse.com.tw/mops/web/bfhtm_q2

B.Implementation status: Please refer to https://mopsov.twse.com.tw/mops/web/bfhtm_q2

C.The impact on shareholders' rights and interests

The fundraising will be completed in the second quarter of 2021, which has no major difference from the expected schedule. The raised funds are used to cover research and development expenses and daily operation funds other than EG62054 and EG12021 (non-HER2), as well as the research and development expenses for investing its products and completing the research and development schedule of each stage of the products, to achieve a sound financial structure, enhance solvency, maintain the working capital requirements needed for its operation and further enhance the competitiveness. In the long run, there should be no significant adverse impact on shareholders' rights and interests.

D. Expect the Implementation Benefit

(A) Replenishment of working capital

The total amount of capital increase by EirGenix in this plan is NT$ 3.2025 billion, which will be fully used for replenishment of working capital. Through the long-term and stable capital infusion to ensure the company's daily operation. At the same time, it can implement the drug development smoothly and increase the operation scale and value of the company, also can improve the financial structure, and avoid increasing the financing costs to ensure the company operation normally and decrease the operation risk. Based on the current bank loan interest rate of 1.7970%, it is estimated that EirGenix will save NT$ 38.366 million in 2021 and NT$ 57.549 million in interest expense in the future.

(B)Improve financial structure:

Unit: NT$ thousands; %

Item \ Year		2020 (Before Capital increase)	2021 (After Capital Increase)
Basic Financial Information	Current assets	1,494,307	9,070,266
	Total assets	3,835,215	11,440,873
	Current liabilities	642,163	703,216
	Total liabilities	1,929,598	1,012,122
	Shareholders' equity	1,905,617	10,428,751
	Operation revenue	1,071,838	1,697,359
	Interest expenses	28,500	21,149
	Earnings per share	(5.41)	(0.18)
Financial structure	Debt Ratio	50.31%	8.85%
	Ratio of long-term capital to property, plant and equipment	172.42%	569.09%
Solvency	Current ratio	232.70%	1,289.83%
	Quick ratio	195.19%	1,215.91%

To meet the capital demand for operation, EirGenix conducted this capital increase, with the raised amount of NT$ 3.2025 billion, which was fully used for replenishment of working capital, to enhance EirGenix's capital, make the financial structure sounder, further reduce EirGenix's operating risks, increase long-term capital stability and enhance market competitiveness. The estimated time of completion for this capital increase is 202Q2, and this capital increase will replenish the working capital. The Ratio of long-term capital to property, plant and equipment will increase from 172.42% to 569.09%; the current ratio and quick ratio increased from 232.70% and 195.19% to 1,289.83% and 1,215.91%; Its financial structure will improve compared with that before the capital increase; can maintain the solvency and the stability of the financial structure at the same time when expanding the scale of operation and the flexibility for future capital allocation will be maintained. If EirGenix had failed to raise funds this time, it would have increased its financial burden. Therefore, the capital increase this time to replenish working capital will help fulfill the operation funs, and its benefits will be reasonable.

(2)Private Placement in 2021

A.Description of the Plan:

(A) Date and document reference number for effective registration: Official letter No.11001199560 on November 18th, 2021.

(B) Total Amount of the Plan: NT$ 5,032,500,000.

(C) Source of Funds: Issuance 55,000,000 new common shares for capital increase. Par value is NT$ 10 per shares, issuance price is NT$ 91.5 per share, and the total amount is NT$ 5,032,500,000.

(D) Plan item and Expect implementation progress of fund:

Unit: NT$

Item	The Usage of funds	Budget Amount
Replenishment of working capital	R&D expenses	3,000,000,000
Building factory	Expansion and building factory	500,000,000
Others	Repay bank loans and replenish horizontal and vertical integration, and other operational funding needs	1,532,500,000

(E) Planned benefit:

a. To accelerate the product developing efficiency as well as the process of the same drug series to complete the production line. By the comprehensive effect of expanding the market, it can establish EirGenix's unique status in the international biosimilars and CDMO field.

b. Expand the facility and equipment and increase the production scale to meet the needs of the CDMO business expansion and self-development product commercial operation.

c. Repay bank loan NT$316,322,000 and save annual interest expenses roughly about NT$5,684,000 which calculating under the current EirGenix loan rates of 1.797%. Other unused funds will follow the plan and demonstrate effects continuously.

d. Co-developed the biosimilar drug TSY0110 (EG12043) of ADC for the treatment of breast cancer with Formosa Pharmaceuticals.

(F) Date of entering to MOPS: May 4, 2021; May 12, 2022.

(G) Change the content of the plan, the reason for changing, and the benefit of changing:

a. Approved by the board of directors on May 12, 2022, in response to the company's medium and long-term strategic development plan, the adjustments to the capital utilization plan are as follows:

Unit: NT$

Item	The Usage of funds	Budget Amount
Replenishment of working capital	R&D expenses	1,016,178,000
Building factory	Expansion and building factory	1,700,000,000
Others	Repay bank loans and replenish horizontal and vertical integration, and other operational funding needs.	316,322,000
	Acquisition or purchase the intangible assets, operation- related assets, and right-of-use assets.	2,000,000,000

b. Considering the operation and benefits of the company, and avoiding the impact on the shareholder equity, the capital plan and project expenditure situation will be adjusted and changed appropriately according to the needs. It will benefit the company's business and fund while shareholder equity should not be materially affected.

c. Date of submitting to the shareholders meeting: May 31, 2023.

B.Implementation status

Unit: NT$

The Usage of funds	Budget Amount	Implementation as of 2025 First Quarter
R&D expenses	1,016,178,000	R&D expenses 903,852,997 and deposit other funds in EirGenix bank accounts.
Expansion and building factory	1,700,000,000	Expansion and building factory 1,666,803,340 and deposit other funds in EirGenix bank accounts.
Repay bank loans and replenish horizontal and vertical integration, and other operational funding needs	316,322,000	Repay bank loan 316,322,000
Acquisition or purchase the intangible assets, operation- related assets, and right-of-use assets.	2,000,000,000	Acquisition important assets 60,112,501 and deposit other funds in EirGenix bank accounts.

C.The impact on shareholders' rights and interests

Boost EirGenix's operating scale, horizontal and vertical integration, and product or market development collaboration, assist EirGenix to improve technology, efficiency, expand the operational scale, and elevate the market status. It has positive benefits in creating EirGenix and shareholder value.

D. Expect the Implementation Benefit

(A) EirGenix is currently developing the product for the treatment of HER2+ breast cancer. Received the approval letter from Ministry of Health and Welfare for the biosimilar drug EIRGASUN 150 mg powder for concentrate for infusion. Received the approval letter from EC for EG12014 licensed. Preparing the US BLA resubmission for EG12014. The Phase I clinical trial for EG1206A (Pertuzumab Biosimilar) has been completed.

(B) The second mammalian cell production line for the Zhubei plant phase I facility has been completed. Build microbial cell production line factory for the Zhubei plant phase II facility. The three-stage expansion of the mammalian plant which has 150,000L capacity, is under planning at Ciaotou Science Park, Kaohsiung.

(C) Repay bank loan NT$316,322,000 and save annual interest expenses roughly about NT$5,684,000 which calculating under the current EirGenix loan rates of 1.797%. Other unused funds will follow the plan and demonstrate effects continuously.

(D) Co-developed the biosimilar drug TSY0110 (EG12043) of ADC for the treatment of breast cancer with Formosa Pharmaceuticals.

(E) Improve financial structure:

Unit: NT$ thousands; %

Item \ Year		2021 Q3 (Before Capital increase)	2021 Q4 (After Capital Increase)
Basic Financial Information	Current assets	4,451,420	9,070,266
	Total assets	6,804,041	11,440,873
	Current liabilities	862,482	703,216
	Total liabilities	1,463,501	1,012,122
	Shareholders' equity	5,340,540	10,428,751
	Operation revenue	1,273,814	1,697,359
	Operating cost	401,661	604,305
	Operating profit	872,153	1,093,054
	Interest expenses	17,161	21,149
	Earnings per share	(0.20)	(0.18)
Financial structure	Debt Ratio	21.51%	8.85%
	Ratio of long-term capital to property, plant and equipment	318.70%	569.09%
Solvency	Current ratio	516.12%	1,289.83%
	Quick ratio	461.55%	1,215.91%

To meet the capital demand for operation, EirGenix conducted this capital increase, with the raised amount of NT$ 5.0325 billion, which was fully used for the replenishment of working capital. The private placement can enhance equity capital, make the financial structure sounder, further reduce EirGenix's operating risks, increase long-term capital stability and enhance market competitiveness. The Ratio of long-term capital to property, plant and equipment in 2021 increased from 318.70% to 569.09%; the current ratio and quick ratio increased from 516.12% and 461.55% to 1,289.83% and 1,215.91%; the financial structure improved compared with that before the capital increase; can maintain the solvency and the stability of the financial structure at the same time when expanding the scale of operation and the flexibility for future capital allocation will be maintained. Therefore, the capital increases this time to replenish working capital will help fulfill the operation funds, and its benefits will be reasonable.

IV. Operational Highlights

1. Business Activities

(1)Business Scope

A.Main areas of business operation

①C199990 Other Food Manufacturing Not Elsewhere Classified

②C802041 Drugs and Medicines Manufacturing

③C802060 Animal Use Medicine Manufacturing

④C802990 Other Chemical Products Manufacturing

⑤F107990 Wholesale of Other Chemical Products

⑥F108021 Wholesale of Drugs and Medicines

⑦F108031 Wholesale of Drugs, Medical Goods

⑧F208021 Retail Sale of Drugs and Medicines

⑨F208031 Retail sale of Medical Equipments

⑩F401010 International Trade

⑪I199990 Other Consultancy

⑫IC01010 Pharmaceuticals Examining Services

⑬IG01010 Biotechnology Services

⑭IG02010 Research Development Service

⑮ZZ99999All business items that are not prohibited or restricted by law, except those that are subject to special approval.

EirGenix is a R&D company for biosimilars and new drugs, provides the biopharmaceutical CDMO (Contract Development & Manufacturing Organization) services, including cell line building platform, process development platform, analytical science, protein identification in PIC/S GMP manufacturing plants, and provides production of drugs for clinical trials, etc.

EirGenix employs a dual-track approach encompassing bio-pharmaceutical CDMO and Product Development, effectively leveraging the company's cGMP production equipment and high-caliber technical expertise. Our company's core competitive advantage lies in simultaneously possessing expertise in two major expression systems: Mammalian cell development and Microbial strain fermentation development. Additionally, we have specialized capabilities in research, manufacturing, and analysis. Through a vertically integrated operating model, we achieve quality control and cost management. In light of the exorbitant prices of biopharmaceuticals from original development companies, which many patients cannot afford, coupled with the escalating burden of healthcare costs on governments worldwide, the mission of our company is: in the short term, to provide customers with high-quality and cost-effective services, while also developing biosimilar products with commercial viability; in the middle to long term, to focus on developing niche biologics that enhance human and societal well-being and improve quality of life. Our ultimate goal is to become an international biopharmaceutical company rooted in Taiwan with a global outlook, dedicated to advancing human health and welfare.

B.Revenue distribution

Unit: NT$ thousands

Year / Item	2022		2023		2025Q1	
	Revenue	%	Revenue	%	Revenue	%
Service Revenue	605,990	59.26	592,158	58.69	77,218	42.45
Sales Revenue	275,191	26.91	375,479	37.21	104,611	57.50
Licensing Revenue	141,472	13.83	41,323	4.10	94	0.05
Total	1,022,653	100.00	1,008,960	100.00	181,923	100.00

C.Main products (Service)

Our company has independently developed the following core technologies, and six major platforms related to CDMO and the capacity and scale of the CDMO platform:

(A)Cell line development

To accelerate the development, clinical trials, and market entry of next-generation biopharmaceutical products, our company focuses particularly on the first critical technology in the biopharmaceutical development stage- the development of cell lines and strains. This development includes the establishment and optimization of high-yield cell lines and strains, as well as the optimization of culture media and cultivation methods. It also involves the establishment of MCB (Master Cell Bank) and WCB (Working Cell Bank). The key focus at this stage is on selecting the optimal host cells (such as CHO, Sp2/0, NS0, Hybridoma, HEK 293, PER.C6 cells, etc., for animal cells; and E. coli, S. cerevisiae, Pichia, etc., for microbial cells) and optimizing culture media, process development to achieve the highest production (for recombinant protein or monoclonal antibody drugs) and quality of cell lines/strains. The implementation involves inserting the gene into a vector to express the protein, constructing an expression system, and then transfecting it into host cells (adapted to serum-free and suspension culture). Stable and high-yield cell lines are then selected, comparing the stability and quality of production, and establishing MCB and WCB. Simultaneously, suitable or developed cell culture media for production are selected or developed.

(B)Process development and Scale-up

The upstream process development and scale-up primarily focus on the process development and optimization of fed-batch culture, especially on scalability, and manufacturing suitability leading to high density of cell lines/strains during production.

On the other hand, downstream process development emphasizes the recovery and purification processes, viral clearance assay studies, scale-up (currently mainly at 100 liters), formulation development, and providing products/materials to support animal testing studies, reference standards, and quality control (QC) requirements.

(C)Analytical Method development and validation

The development and validation of analytical methods are crucial for product quality confirmation, including:

(i) Identification: SDS-PAGE, Western blot, IEF, peptide mapping, IEC-HPLC

(ii)Quantitative determination: BCA/Bradford, A280

(iii)Purity: SEC-HPLC, RP-HPLC, SDS-PAGE

(iv)Activity: ELISA, cell-based assay

(v)Impurity: Host cell DNA, host cell protein, ProA residue, endotoxin, bioburden

These analysis methods will be validated through linearity & range, accuracy, and precision.

(D)Product identification

Protein identification has been increasingly emphasized by regulatory authorities year by year. Our company has established a set of HPLC and LC/MS/MS systems capable of conducting peptide mapping, complete sequence analysis, N-/O-linked carbohydrates analysis, disulfide linkages analysis, oxidation analysis, deamidation analysis, and other post-modifications analysis, as well as analysis of N-/C-terminal variants, secondary and higher-order structures, and other related analytical tasks.

(E)cGMP production for clinical trials and stability testing

The pilot run will be able to provide drugs needed for animal toxicity tests, preliminary stability test data, and reference standard samples, and provide sufficient operating parameters as the basis for GMP production preparation. The GMP production section includes GMP trial production (Engineering Run), GMP production, End of production cell banking and

testing, viral clearance assay studies (limited to mammalian cell culture), stability testing, clean validation, and other tasks.

(F)CMC documents

Our company provides comprehensive CMC (Chemistry, Manufacturing, and Control) document services to customers for subsequent product application in clinical trials. At each stage of new drug research, sufficient CMC data should be submitted to ensure appropriate assurance of the new drug's identification, quality, purity, potency, and stability. The required CMC data vary depending on different stages of research, planned testing periods, dosage forms, and other available data. For instance, stability data are necessary throughout all stages of new drug testing to demonstrate that the active pharmaceutical ingredient and drug product remain within acceptable limits during the designated study period. CMC documents can be likened to the manufacturing process's record, serving as a crucial basis for regulatory safety assessments.

(G)The capacity and scale of the CDMO platform

Our company is one of the few in Asia equipped with both upstream mammalian cell and microbial strain fermentation production facilities, along with a comprehensive downstream protein purification system, enabling the production of investigational medicinal products for clinical trials. Within our biopharmaceutical cGMP facilities, we exclusively utilize single-use bioreactors (SUBs) ranging from 50 to 2000 liters. The total production capacity for mammalian cell has reached 25,500 liters and microbial strain 150 liters (will reach 1,500 liters in 2026).

The facilities that have been invested in are outlined below:

Facility	Usage	Highlights
Xizhi Factory	For mammalian cell culture	The production facilities are located on the first floor of the Taiwan Xizhi Plant, including 200L and 1,000L single-use bioreactors (SUBs), purification rooms, final purification rooms, media preparation rooms, buffer preparation rooms, washing rooms, and high-pressure sterilization rooms.
	For microbial cell culture	There is one 30L and one 150L stainless steel bioreactor (SSB) for fermentation.
Zhubei A Factory (in Hsinchu Biomedical Science Park)	For mammalian cell culture	・Officially operational since 2019, including 2 units of 1,000L and 4 units of 2,000L single-use bioreactors (SUB). ・Subsequently, there will be an expansion with an additional 2 units of 2,000L and another production line consisting of 6 units of 2,000L SUBs, totaling 12 units of 2,000L SUBs. It is estimated that the annual production capacity for monoclonal antibodies could reach 1,000 kilograms. ・The services provided are applicable from late-stage clinical trials to commercial-scale production after market approval.
Zhubei B Factory (next to A)	Under construction	・Primarily focused on microbial cell production lines, with the establishment of 1500L, 500L, and 75L fermentation tanks, along with 2-3 purification lines. ・Scheduled for completion and commissioning by December 2025.

In 2017, EirGenix was nominated for Best Process Technology by the Biology Manufacturing Asia (BMA), received the Grand Winner of Best Bioprocess Excellence in Taiwan, received the excellence award for Antibody Drug Conjugate platform at the same time, and won international recognition in bioprocess technology. Received the "Asia's Best CMO (Contract Manufacturing Organization) Award" in Asia-Pacific Bioprocessing Excellence Awards 2018. Won the Grand Winner of Best Bioprocess Excellence in Taiwan Award in Singapore again in 2019. Received 2020 Bioprocessing Excellence Award in Greater China Region. Won the Globalizing Award of "2021 Taipei Biotech Awards". Won the Best Bioprocessing Awards in Taiwan and the Greater China issued by Biologics Manufacturing Asia (BMA) and National Innovation and Advancement Award (EG12014 and CRM197) in 2022. EIRGASUN vial 150 mg won the Golden award of National Pharmaceutical Technology Research Development Award in 2023. In 2024, we received the TBEA award for Most Promising Monoclonal Antibody Development, and in 2025, we were named Best ADC CDMO in Taiwan at the Asia-Pacific Bioprocessing Excellence Awards.

In addition, our company has also obtained the Accreditation Certificate of Foreign Drug Manufacturer issued by the Japanese Ministry of Health, Labor and Welfare, with the recognized category being "Biological Products." The certificate is valid from October 24, 2022, to October 30, 2027. During the validity period, biological products manufactured at our Taiwan facility can be sold and marketed in Japan. In 2017, a Japanese client transferred their product, which was already on the market in Japan, from a Japanese CMO to our company for production. After completing technology transfer and process validation, the Pharmaceuticals and Medical Devices Agency (PMDA), an independent administrative agency of the Japanese government, conducted an inspection at our facility in September 2019. The inspection process went smoothly without significant deficiencies, and on February 3, 2020, we received approval from the PMDA. Subsequently, the Japanese client began placing orders for commercial production at our facility and initiated negotiations for long-term supply. Finally, on March 2, 2021, our

company signed a long-term supply contract with this Japanese pharmaceutical company, becoming the first Taiwanese manufacturer to supply biopharmaceuticals for a product marketed in Japan. This product is essential for cancer treatment, with a market share in Japan exceeding 30% in its category. Our company is not only the first in the Greater China region but also one of the few in Asia to be audited and approved by the PMDA for biopharmaceutical manufacturing. This certification will enhance the willingness and confidence of Japanese and international biotech companies to entrust us with biopharmaceutical production, aiding in business promotion. In recent years, the demand for biopharmaceutical CDMO services in Japan has been growing. Through our successful track record of selling products in Japan, we are expanding our competitive advantage in the Japanese market, significantly increasing the willingness and confidence of Japanese and international biotech companies to entrust us with biopharmaceutical production. This significant milestone will accelerate the expansion of our CDMO business.

In December 2024, our company entered a collaboration with a renowned Japanese chemical company and a domestic R&D firm to jointly advance the development and commercialization of a Denosumab biosimilar (SPD8). Our company is responsible for process development and GMP manufacturing during the clinical and commercial stages. The product is currently in Phase III clinical trials in Japan, with unblinding expected in Q2 2026. Targeting a global market exceeding USD 6 billion in annual sales, this collaboration not only demonstrates the Company’s capabilities in handling advanced processes and international projects but is also expected to bring stable, long-term orders upon commercialization, further strengthening our presence and growth momentum in the global CDMO market.

In addition, on February 10, 2025, our company signed a supply agreement with a leading Australian biopharmaceutical company for EG12014 (a Trastuzumab biosimilar) to support the clinical development and future commercialization of an innovative radiotherapy-immunotherapy (Cu-64/67 SAR-trastuzumab) for breast cancer. The collaboration aims to jointly explore both the Australian and international markets. Under the agreement, our company will supply EG12014 drug substance through to commercialization and will receive milestone payments tied to key development achievements, along with royalties on product sales. This innovative therapy targets a high-potential niche market. Beyond biosimilar development, our company is also expanding into diverse market segments. In addition to the collaboration with the Australian partner, our company is actively engaging in partnerships involving innovative drug development, thereby extending the product life cycle of both pipeline and marketed biosimilars. This strategy also enhances drug substance supply capacity and scalability. A flexible business approach continues to drive our diversification and create new market opportunities.

D.The new products (services) are planning to development:

(A) Biosimilar drugs

(i) EG12014

EG12014 is EirGenix's first self-developed and successfully marketed Trastuzumab biosimilar (EMA approved trade name HERWENDA, TFDA approved trade name EIRGASUN). Its R&D target HERCEPTIN was acquired by Genentech (merged by Roche in March 2009). obtained marketing approval from the US FDA in September 1998. It is a genetically recombinant monoclonal antibody and is a drug against high-phenotype breast cancer caused by the oncogene (HER2/neu). It is mainly used for the treatment of patients with early breast cancer (EBC), metastatic breast cancer (MBC) and metastatic gastric cancer (mGC) with HER2 overexpression or HER2 gene amplification. In terms of early breast cancer (EBC), it includes: (1) adjuvant therapy through surgery and chemotherapy (preoperative or postoperative). (2) Treat with Doxorubicin and Cyclophosphamide, combined with adjuvant therapy of Paclitaxel or Docetaxel. (3) Adjuvant therapy with Docetaxel and Carboplatin. (4) Preoperative combined with chemotherapy and postoperative adjuvant therapy for the treatment of locally advanced (including inflammation) breast cancer or tumors (>2 cm in diameter); in metastatic breast cancer (MBC): (1) Used alone to treat previously treated breast cancer Metastatic breast cancer that has received more than one chemotherapy; unless the patient is not suitable for Anthracycline or Taxane, the previous chemotherapy should at least include Anthracycline or Taxane. For use in hormone receptor-positive patients who have failed hormonal therapy, unless the patient is not suitable for hormonal therapy. (2) Used in combination with Paclitaxel or Docetaxel for metastatic breast cancer that has not received chemotherapy. (3) Combined with aromatic cyclase inhibitors for hormone receptor-positive metastatic breast cancer; in metastatic gastric cancer (mGC): combined with Capecitabine (or 5-fluorouracil) and Cisplatin for HER2 overexpression that has not received chemotherapy Treatment of metastatic gastric adenocarcinoma (or gastroesophageal junction adenocarcinoma).

(ii) EG1206A

EG1206A is a biosimilar of Pertuzumab. Its research and development target PERJETA has obtained indications for early breast cancer (EBC) and metastatic breast cancer (MBC). In the treatment of metastatic breast cancer (MBC): used in combination with trastuzumab and docetaxel to treat patients with HER2-positive metastatic breast cancer who have not been treated with anti-HER2 or chemotherapy after metastasis. In early breast cancer (EBC): When Pertuzumab is used in combination with chemotherapy drugs for preoperative adjuvant therapy, it is suitable for patients with HER2-positive, locally advanced, inflammatory, or early breast cancer (tumor diameter greater than 2 cm or positive lymph nodes) as a part of a complete treatment prescription for early-stage breast cancer. When used as postoperative adjuvant therapy, it is suitable for patients with early-stage breast cancer who are HER2-positive and have a high risk of recurrence. (According to the results of the APHINITY trial, during postoperative adjuvant therapy, HER2-positive early breast cancer patients with a high risk of recurrence are defined as having lymph node-positive breast cancer.) Pertuzumab has different binding mechanisms for HER2 receptors and can produce double blockade (Dual Blockade) effect. EG1206A is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (subregion II) of human epidermal growth factor receptor type 2 (HER2). Therefore, it can block the ligand-dependent heterodimerization of HER2 and other human epidermal growth factor receptor (HER) family members (including EGFR, HER3 and HER4). Inhibits ligand-initiated intracellular signaling through two major signaling pathways: mitogen-activated protein (MAP) kinase and phosphoinositide 3-kinase (PI3K). Inhibition of these signaling pathways will lead to cell growth cessation and apoptosis respectively.

(iii) TSY0110 (EG12043)

EG12043 (TSY0110) is a biosimilar of Trastuzumab Emtansine. It is an ADC (Anti-Drug Conjugate). Its mechanism is an antibody-drug complex that targets HER2. The antibody is human anti-HER2 IgG1 (trastuzumab). The small molecule cytotoxin DM1 is a microtubule inhibitor. After binding to the IV domain of the HER2 receptor, Trastuzumab Emtansine begins to be internalized through the receptor, and the subsequent lysosomal degradation process releases cytotoxic metabolites containing DM1 into the cell. The process of DM1 binding to tubulin will destroy the intracellular microtubule network, leading to cell cycle arrest and apoptosis. In addition, in vitro experiments also show that Trastuzumab Emtansine, similar to Trastuzumab, also inhibits the function of HER2 receptor signaling, causes antibody-dependent cell-mediated cytotoxicity, and inhibits HER2 extracellular domain shedding in HER2-overexpressing human breast cancer cells. Trastuzumab Emtansine can be used alone to treat HER2-positive metastatic breast cancer in patients who have previously received Trastuzumab and a Taxane drug, or their combination, if they meet the following conditions: have previously received treatment for metastatic cancer or are receiving adjuvant therapy Patients whose cancer relapses during or within 6 months after completing treatment. Early Breast Cancer: Used alone, it is suitable for adjuvant therapy for patients with HER2-positive early breast cancer who still have residual disease after receiving Taxane and Trastuzumab-based lead treatment (neoadjuvant therapy).

(iv) EG12112

EG12112 is a biosimilar of Atezolizumab. Its R&D target TECENTRIQ is an Fc-engineered, humanized monoclonal antibody that binds to PD-L1 and blocks its interaction with PD-1 and B7.1 receptors. Atezolizumab is an unglycosylated IgG1 kappa immunoglobulin with a calculated molecular weight of 145 kDa. Its pharmacological effect is that PD-L1 can be expressed on tumor cells and/or tumor-infiltrating immune cells and can inhibit the anti-tumor immune response in the tumor microenvironment. PD-L1 binds to PD-1 and B7.1 receptors on T cells and antigen-presenting cells to inhibit the activity of cytotoxic T cells, T cell proliferation and cytokine production. Atezolizumab is a monoclonal antibody that binds to PD-L1 and blocks its interaction with PD-1 and B7.1 receptors. This releases PD-L1/PD-1-mediated suppression of immune responses, including activation of anti-tumor immune responses without inducing antibody-dependent cellular cytotoxicity. In syngeneic mouse tumor models, blocking PD-L1 activity resulted in reduced tumor growth. Indications span a variety of cancer types: 1. Locally advanced or metastatic urothelial cancer is suitable for the treatment of patients with locally advanced or metastatic urothelial cancer whose disease has worsened after receiving platinum-containing chemotherapy or who are not suitable for cisplatin-containing therapy. 2. Used alone for locally advanced or metastatic non-small cell lung cancer. It is suitable for the treatment of patients with locally advanced or metastatic non-small cell lung cancer whose disease has worsened after receiving platinum-containing chemotherapy. If patients have EGFR or ALK tumor gene abnormalities, they must first be treated with EGFR or ALK inhibitors. If the disease worsens after treatment, TECENTRIQ can be used. Used in combination with Avastin (bevacizumab), paclitaxel and carboplatin, as a first-line

treatment for metastatic non-squamous non-small cell lung cancer without EGFR or ALK tumor gene abnormalities. 3. The combination of TECENTRIQ and nab-paclitaxel for triple-negative breast cancer is suitable for the treatment of unresectable locally advanced or metastatic triple-negative breast cancer, and the tumor has PD-L1 manifestations (tumor-infiltrating immune cells (IC) ≥ 1%) and has not received Chemotherapy is used for patients with metastatic breast cancer. 4. Small cell lung cancer, combined with carboplatin and etoposide, is suitable for the first-line treatment of adults with extensive stage small cell lung cancer. 5. The combined use of hepatocellular carcinoma and bevacizumab is suitable for the treatment of patients with hepatocellular carcinoma who have not received systemic therapy and are unresectable or metastatic, and their liver function is Child-Pugh A.

(v) EG12164

EG12164 is a biosimilar of Daratumumab. The target of its R&D, DARZALEX, is a humanized IgG1κ monoclonal antibody that can bind to the CD38 antigen. This strain is produced in a mammalian cell line (Chinese Hamster Ovary [CHO]) through recombinant DNA technology. Its pharmacology Mechanism is an IgG1κ human monoclonal antibody (mAb) that binds to the CD38 protein that is highly expressed on the surface of multiple myeloma cells and to varying degrees on other cell types and tissues. CD38 protein has multiple functions, such as receptor-mediated adhesion, signaling and enzyme activity. DARZALEX is suitable for: 1. Patients who have received at least three previous therapies (including a protease inhibitor and an immunomodulator) as a single drug, or whose disease has worsened under treatment with both a protease inhibitor and an immunomodulator (double-refractory to a protease inhibitor and an immunomodulatory agent) in adults with multiple myeloma. 2. Use in combination with lenalidomide plus dexamethasone or with bortezomib plus dexamethasone to treat adult patients with multiple myeloma who have previously received at least one therapy.

(B) New dosage forms and new drug delivery systems of biosimilars

(i) EG13084

EG13084 is a new subcutaneous injection drug that combines Trastuzumab and Pertuzumab. Its R&D target is PHESGO-approved indications for early breast cancer (EBC) and metastatic breast cancer (MBC). In terms of early breast cancer (EBC), when EG13084 is used in combination with chemotherapy drugs for preoperative adjuvant therapy, it is suitable for patients with HER2-positive, locally advanced, inflammatory or early breast cancer (tumor diameter greater than 2cm or positive lymph nodes). Part of a complete treatment prescription. When used as adjuvant treatment after surgery, it is suitable for patients with early-stage breast cancer (EBC) who are HER2-positive and have a high risk of recurrence. (According to the results of the APHINITY clinical trial, in postoperative adjuvant therapy, patients with HER2-positive early breast cancer who have a high risk of recurrence are defined as having lymph node-positive breast cancer.) In terms of metastatic breast cancer (MBC), it is used together with docetaxel to treat metastasis patients with HER2-positive metastatic breast cancer who have not been treated with anti-HER2 or chemotherapy. In addition to the significant clinical benefits of this product, once successfully launched on the market, it will also greatly increase the convenience of breast cancer patients receiving treatment.

(ii) EG7412X

The R&D target of EG7412X is "recombinant human hyaluronidase PH20 (rHuPH20)", which is equivalent to the soluble fragment of human HYAL5. It is genetically engineered in hamster culture cells (CHO) culture containing a DNA plasmid encoding the enzyme. Produced as a type of hyaluronidase (hyaluronidase), its main function is to catalyze the degradation of hyaluronic acid (HA). According to the enzyme reaction products, they are divided into three different types: two eukaryotic endoglycosidase hydrolases and one prokaryotic lyase-type glycosidase. Hyaluronidase catalyzes the hydrolysis of HA, causing the viscosity of HA to decrease, thereby increasing tissue permeability. Therefore, it is often used in medicine together with other drugs, which can accelerate the dispersion and delivery of drugs through subcutaneous absorption.

(C) Special biological drugs

(i) EG74032

EG74032 is CRM197 modified from Diphtheria toxin. It is no longer toxic after modification of amino acids. Therefore, it can be used as a carrier to make a mixed vaccine (Conjugate vaccine) to promote immune effect. CRM197 is a carrier protein that assists vaccine immunity without patent protection. This protein has been widely used in commercial products and clinical development products. In addition to traditional infectious disease vaccines, the field of cancer vaccine research and development has also attracted much attention in recent years. Both R&D units and biotech companies at home and abroad are actively investing in the development of cancer vaccines, hoping to bring a glimmer of hope to various types of cancers for which effective treatments currently do not exist. Early production processes used Corynebacterium diphtheria (Corynebacterium diphtheria) for production, and then carried out downstream recovery, purification and other steps. The yield and recovery rate were usually relatively low. In addition, the acquisition of this strain requires signing an authorization agreement with a specific unit, and the production unit must have a biological protection level that meets the specifications before it can produce.

(2)Industry Overview

A. The Current Status and Development of the Industry

Our company focuses on the research, development, and manufacturing of biopharmaceuticals, with CDMO services as the main focus. We accept commissions from biotechnology and pharmaceutical companies, providing services related to the development and manufacturing of biotech products and biopharmaceuticals. These services include product evaluation and design, overall development and market entry processes, cell lines and strains, processes, culture media required for CMC development to production, clinical trial drugs, raw material production, and developing process of scale-up.

(A) Biopharmaceutical industry

The biopharmaceutical industry can be divided into two categories of drugs based on molecular size: large molecules (Macromolecular) and small molecules. Small molecule drugs have a long history of development and are mostly manufactured through chemical synthesis. Common examples include antibiotics, analgesics, and sedatives. Macromolecular drugs, also known as biologics, have a molecular weight much higher than small molecule drugs. They are primarily produced

by genetically modified microorganisms, plants, or animal cells for therapeutic purposes. Common examples include insulin, rheumatoid arthritis (RA) monoclonal antibody therapy drugs, and targeted cancer therapies. Biosimilars are also a category of macromolecular drugs. According to the FDA, biosimilars are defined as follows: A biosimilar is a biologic that is highly similar to another biologic that is already FDA-approved (known as the original biologic). It is both normal and expected for both biosimilars and original biologics to have minor differences between batches of the same medication in terms of the safety, purity, and potency.

Unlike traditional small molecule drugs, biologics have stable chemical structures, larger molecular weights, and complex structures. After approval, biologics, due to their specificity in disease treatment, high safety, and significant efficacy, often become blockbuster drugs shortly after market introduction. With the increasing severity of safety and drug resistance issues caused by chemical drugs, biologics can fill the gaps in the treatment field left by chemical drugs. Their growth rate continues to rise, overwhelming the overall pharmaceutical market trend.

(B) CDMO market

Compared to small molecule drugs, the development and manufacturing of biopharmaceuticals have relatively higher entry barriers. In addition to requiring significant investment in infrastructure, the production process is also more complex, with greater difficulty in scaling up processes. The capacity utilization rate of small to medium-sized biopharmaceutical CDMO companies is higher than that of large-scale biopharmaceutical CDMO companies. This is mainly due to the higher flexibility of small to medium-sized CDMO companies in adjusting production capacity, allowing them to meet the diverse production needs of clients.

According to 2024 Market Data Forecast, the biologics CDMO market started from US$ 160.3 billion in 2024 and estimated grow with 11.52% compound annual growth rate (CAGR) to reach US$ 383.7 billion in 2033. In order to seize the opportunity of this global trend, EirGenix has been actively expanding its plants and preparing for the market demand in the next 10 years. In addition to the sales of self-developed products, the company has also been actively seizing the contract manufacturing market where biologics manufacturing and demand have significant growth, of which biosimilars are the focus of the fastest growth.

According to the 2021 market research report by BioPlan Associates, Inc., nearly 70% of global biopharmaceutical manufacturing capacity is concentrated in Europe and the United States. The main reason for this is the expiration of patents for major biopharmaceuticals worldwide. Additionally, healthcare systems in European and American countries, which serve as benchmarks, are actively seeking high-quality and cost-effective biosimilar drugs to alleviate fiscal pressures on healthcare systems. Our company is currently actively developing biosimilar drugs. Upon completion of the expansion, we will not only be able to meet the market demand for our own products but also offer the remaining capacity to domestic and international clients for contract manufacturing. This strategy will enable us to establish a strong existence in Taiwan and offer the service to clients around the world as well as seize the profit base of competition in the global market.

Figure: 2021 Regional distribution of Global Biomanufacturing Capacity

Region	Regional Capacity, L	Global Capacity %, by Region
US/North America	5,496,290 L	31.7%
Europe	5,982,977 L	34.7%
Asia/Rest of World	5,826,070 L	33.6%
Total Worldwide	~17,300,000 L	100%

Source: BioPlan Associates, *18th Annual Report and Survey of Biopharmaceutical Manufacturing*, April 2021

The use of cell types in the manufacturing of biopharmaceuticals also indicates a gradual decrease in microbial cell fermentation, while the use of mammalian cells shows a relative growth trend. This phenomenon is due to the fact that biotech products produced by mammalian cells, such as monoclonal antibodies (mAb), require much higher therapeutic doses compared to protein drugs produced by microbial cells, leading to higher production volumes. Currently, our company's development of biosimilar drugs primarily focuses on mAb. Therefore, we have proactively expanded and established mammalian cell facilities while retaining space for microbial production facilities. We continue to monitor market changes and trends, and will evaluate the timing for establishing microbial cell fermentation facilities.

(C) Biosimilars

Macromolecule drugs, due to their complex structure, cannot be replicated 100% identical from the original developers. Therefore, for macromolecule drugs developed with reference to marketed biopharmaceuticals, they must be highly similar to the reference product in terms of molecular structure, physical, chemical, and biological properties, with no clinically meaningful differences in safety, quality, and efficacy, as verified by regulatory authorities before being marketed, in order to be termed biosimilar drugs.

The development costs and timelines for biosimilar drugs are much higher than for small molecule generic drugs. The main difference from developing new drugs lies in the reverse engineering of cell lines and processes in the front end, ensuring that the product achieves a high degree of similarity to the reference product in molecular structure, physical, chemical, and biological properties. The selection of cell lines and reverse engineering techniques are a highly challenging barrier in the development of biosimilar drugs. Even after process development, biosimilar drugs still need to undergo two stages of human clinical trials. The first stage is a Phase I clinical trial comparing the pharmacokinetics of the drug in the body (bioequivalence), and the second stage compares the efficacy of the biosimilar drug with the reference biopharmaceutical (equivalence). If reliable biomarkers are available, they can also be used as primary clinical endpoints. The development of biosimilar drugs differs from innovative drug development; innovative drug development entails considerable time and cost, especially in late-stage clinical trials, where the failure rate is quite high. Conversely, if a biosimilar product achieves a high degree of similarity and demonstrates bioequivalence in clinical pharmacokinetic studies, the failure rate in Phase III clinical trials is almost negligible.

Affected by the slowing global economic growth and the rapid increase in the elderly population, healthcare systems in various countries are facing increasingly heavy burdens. The prices of biologic drugs, which have significant effects and relatively low side effects but incur high development costs, remain high. Against this backdrop, the adoption of biosimilar drugs, which offer no differences in safety, quality, and efficacy compared to patented biologic drugs but are relatively lower in price, has become one of the effective methods for healthcare systems worldwide to address the current challenges. The momentum generated by the expiration of patents for biologic drugs will also accelerate the replacement of market share held by original biologic drugs with biosimilar drugs.

According to Global Market Insights' 2023 forecast, the global market size of biosimilar drugs reached approximately $35 billion in 2022 and is expected to continue exponential growth. It is estimated to surpass $122.9 billion by 2032, with a high CAGR of 13%. This represents a rare surge in the history of pharmaceutical development. The primary market growth opportunities are focused on regions such as the US, which has relatively late-stage biosimilar markets, as well as the Asia-Pacific and Latin America regions, which offer cost-effective growth potential. The increasing prevalence of diabetes worldwide, along with government support, has increased the demand for insulin biosimilars, further driving the adoption of biosimilar drugs.

The regulatory framework for biosimilar drugs in Europe was established in 2001. Since the approval of the world's first biosimilar drug, Omnitrope®, in April 2006, Europe has approved a total of 126 biosimilar drugs as of January 2025. Among them, the most approved biosimilar drugs are granulocyte colony-stimulating factors (G-CSF), followed by biosimilar drugs referencing Roche's MabThera® (Rituxan®). Other biosimilar drugs referencing Humira®, Herceptin®, Avastin®, Forsteo®, Humalog®, and others are also either approved or pending approval. In addition to the rapid growth of biosimilar drugs in the European and American markets, Japan has also seen an increasing number of biosimilar drugs obtaining marketing approval, with the overall market continuing to grow at an extremely fast pace.

Since the enactment of The Patient Protection and Affordable Care Act in 2010, the United States (US) has established legislative authority for reviewing biosimilar drugs through the Biologics Price Competition and Innovation (BPCI) Act. As of March 2025, the FDA has approved a total of 69 biosimilar product applications covering 20 different active ingredients. Regulatory authorities in US are actively accelerating the review of biosimilar drugs. Additionally, a landmark decision by the US Supreme Court in June 2017 clarified two key aspects of biosimilar regulation. First, it ruled that the BPCI Act provision requiring biosimilar drug manufacturers to submit their CMC applications to the original biologic manufacturer for review of potential process patent infringement is discretionary rather than mandatory. Second, it provided a definitive ruling on the timing of notification to the original biologic manufacturer by biosimilar manufacturers seeking to launch their products within 180 days, allowing them to notify the original manufacturer before FDA approval. This decision is expected to remove barriers to biosimilar market entry and accelerate their approval process in the US.

According to the 2024 IQVIA report, the global oncology drug market is expected to continue its robust growth driven by the emergence of new drugs, primarily immunotherapy drugs, from 2020 to 2026. It is projected to reach $409 billion by 2028,

accounting for 20% of total global drug expenditures. In response to the high cost but remarkable efficacy of newly launched



drugs, various countries in Europe and America have actively promoted the extensive use of biosimilar drugs to replace off-patent biologics. This initiative not only helps alleviate the increasingly challenging financial pressures on global healthcare systems, but also accelerates the adoption of next-generation therapeutic drugs. Consequently, advanced countries including those in Europe, America, and Japan have achieved a certain proportion of biosimilar drug utilization in a short period, indirectly bringing certain benefits to the developers of biosimilar drugs.

Figure: Estimated Global Top 20 Therapeutic Area Drug Spending and Their Projected Five-Year Compound Annual Growth Rate

After biosimilar are launched, their prices do not decrease as significantly as generic drugs. It is estimated that there will only be a reduction of about 20-35% in the early stages of product launch. However, due to the high cost of treatment, even a slight decrease in price contributes to the overall reduction in healthcare expenditure. Countries are increasing the use of biosimilar drugs to lower medical costs, thereby bringing promising business opportunities, and expected profits to biosimilar drug developers. Based on the experience of using biosimilar drugs in Europe, it can be observed that their price reduction rate is much slower than that of generic drugs. Despite the decrease in unit price, total sales revenue increases. This can be attributed to two main factors: (1) doctors start treating patients proactively before their condition worsens, and (2) patients who could not afford the original biologic drug (reference drug) now have the opportunity to use biosimilar drugs with no clinical differences in safety, quality, and efficacy compared to the reference drug.

(D) Antibody drug conjugate (ADC) drugs

ADC, which involve highly cytotoxic small molecules linked to mAb, represent a novel class of drugs with both high specificity and antibody properties. These drugs precisely target malignant tumors with cytotoxic agents in a "targeted" manner, minimizing impact on other normal tissues. The highly cytotoxic small molecules exhibit potent activity in inhibiting cell growth when reaching picomolar concentrations (pM). To align with the trend of developing novel drugs, international CDMO are integrating High Potency Active Pharmaceutical Ingredient (HPAPIs) technology with enhanced capabilities in the production and development of ADCs. Undoubtedly, ADC technology and products have become a trend in the development of novel antibody drugs. Collaborating with CDMOs to become partners for small to medium-sized biotech companies can establish a new market positioning and continue to seize opportunities in the development of biosimilar drugs and antibody-based therapeutics.

The next-generation antibody therapeutics market encompasses ADCs, bispecific antibodies, Fc-fusion antibodies, antibody fragments, and antibody proteins. According to a report by Market Data Forecast in 2024, the ADC market is projected to reach $ 23 billion in 2024 and is expected to surpass $168.2 billion by 2033, with a CAGR of 24.74% from 2024 to 2033. As of October 2023, the FDA has approved and successfully launched 15 ADC drugs: Elahere (2022), Tivdak (2021), Zylonta (2021), Aidixi (2021), Blenrep (2020), Trodelvy (2020), Akalux (2020), Enhertu (2019), Padcev (2019), Polivy (2019), Lumoxiti (2018), Besponsa (2017), Mylotarg (2017), Kadcyla (2013), and Adcetris (2011).

Currently, the manufacturing of ADC requires expensive upstream mammalian cell bioreactors and downstream protein purification equipment, along with specialized antibody and chemical drug conjugation technologies, and high-efficiency cytotoxic small molecule chemical drug manufacturing facilities. These factors have led to most ADC drug manufacturers relying on a few specific CDMOs that can provide various technical services, including monoclonal antibodies, chemical linkers, and cytotoxins. However, only a few companies can offer integrated development services for ADC drugs. It is anticipated that over 10 new commercial ADC products will drive the growth of the entire market in the next decade. Our company is currently collaborating with Formosa Laboratories, Inc., with small molecule technology capabilities to jointly provide this platform service. The collaboration aims to seize the next wave of biotech advancements, potentially setting new milestones for Taiwan

in the international market.

B. Upstream and downstream relevance in the industry

The process of developing new drugs generally consists of five stages: drug discovery, preclinical trials, clinical trials, inspection registration, and post-market surveillance. Typically, the entire development process requires decades of effort and significant investment of high-risk funds. Our company and its subsidiaries' CDMO business possess both development and manufacturing capabilities, mastering key technologies in the development and manufacturing of biopharmaceuticals, and possessing international regulatory expertise, enabling us to provide high-value-added differentiated services. The development of biosimilar drugs eliminates the need for drug discovery and preclinical trials but increases the number of product comparative structural analysis testing items, focusing on the CMC part.

Our company's service offerings include cell line development, biopharmaceutical process development and optimization, related analytical method development and validation, compliance with regulatory requirements for quality control, and GMP pilot production. The establishment of expertise in biopharmaceutical CMC and a customer-centric project management mechanism enables us to provide efficient and internationally standardized quality-stable biopharmaceuticals that are safe, effective, and economically viable. Our CDMO business combines development and manufacturing capabilities, mastering key technologies in the development and manufacturing of biopharmaceuticals, and possessing international regulatory expertise, enabling us to provide high-value-added differentiated services.

C. Development Trends

(A) Biosimilar drugs

(i) EG12014

EG12014 is a biosimilar of Trastuzumab, and its R&D target HERCEPTIN has global annual sales of 1.38 billion CHF according to Roche's 2024 financial report, of which the European and US markets account for 41.1%. According to data from the Taiwan Health Insurance Administration, breast cancer ranked second among the top ten cancer health insurance medical expenses in Taiwan in 2023, with drug expenditures of 9.107 billion NTD (the average growth rate from 2019 to 2023 was 6.72%).. In 2025, the latest health insurance drug price of HERCEPTIN frozen crystal injection form (440 mg) was NT$29,895 per tube. Currently, the National Health Insurance reimbursed Trastuzumab for patients with early breast cancer (EBC), metastatic breast cancer (MBC) and metastatic gastric cancer (mGC). The number of breast cancer and gastric cancer patients in Taiwan increases every year, and medical expenses also increase accordingly. The latest health insurance price of EirGenix's EIRGASUN 150 mg in 2025 is NT$11,323/tube, which brings more benefits to more people with a more affordable price and wider treatment benefits. Patients who need to undergo breast cancer treatment can achieve expected clinical efficacy while reducing their medical expenses by using EG12014 (EIRGASUN 150 mg), which has no clinically significant difference in safety, quality and efficacy from HERCEPTIN, to achieve the purpose of truly benefiting the people.

EG12014 authorized to be marketed in the European and American regions is under the brand name HERWENDA® by the partner Sandoz. According to the current historical experience of biosimilars launched, if HERWENDA® enters the market in the seventh to sixth position, it has the potential to capture a market share of 10% to 20% of Trastuzumab. Sandoz, seeing the future potential of the biosimilars market, officially launched the 'Act4Biosimilars Action Plan' in June 2023 to accelerate the growth of Sandoz's global biosimilar business. “Act4Biosimilars Action Plan” clearly set the goal of promoting biosimilars globally to achieve over 30% market share in more than thirty countries by the year 2030. Since the main collaborator, Sandoz, actively plays a key role to accelerate the direction of biosimilars access. The performance boost from sales of HERWENDA® in Sandoz's European and American markets can be anticipated.

In terms of the Taiwan market, the National Health Insurance Administration implemented a pilot program for the biosimilar drug incentive scheme starting in July 2024, aiming to achieve a target of over 30% usage of biosimilars drug within three years. Currently, including EirGenix’s EIRGASUN®, there are only four companies that have the widest range of National Health Insurance coverage indications for Trastuzumab Biosimilars. EirGenix aims to achieve a market share of over 20% for Trastuzumab IV biosimilars by the year 2026, and to reach over 30% of the entire Trastuzumab IV market (including Reference Drug) by the year 2028. Following the launch of EG1206A, EirGenix will provide a more comprehensive treatment for patients with HER2-positive breast cancer.

(ii) EG1206A

EG1206A is a biosimilar of Pertuzumab. Since its R&D target PERJETA was launched in the United States in 2013,

sales have grown rapidly every year. According to the results of the APHINITY trial of Pertuzumab combined with Trastuzumab and chemotherapy in the treatment of early breast cancer published by Roche in 2022, this combination therapy can reduce the risk of recurrence or death by 23% compared with the control group. From this excellent test results, it is foreseeable that the subsequent product development and therapeutic application of EG1206A will be more extensive. Roche is currently actively promoting the expansion of indications and is expected to continue to expand the treatment scope and market. According to Roche's 2024 annual financial report: the global annual sales of this product still reached 3.62 billion CHF, with an annual growth rate of 1%, and the European and US markets accounted for 55% of revenue contribution.

(iii) TSY0110 (EG12043)

EG12043 (TSY0110) is a biosimilar of Trastuzumab Emtansine. According to Roche's 2024 annual financial report, its R&D target KADCYLA: the global annual sales of this product reached 1.99. billion CHF, with an annual growth rate of 7%, and the European and US markets accounted for 67% of the revenue contribution. According to the2024 Precedence Research, the global ADC (Anti-Drug Conjugate) market will be approximately US$11.43 billion in 2024 and is expected to reach US$31.96 billion by 2034 with a compound annual growth rate of 10.83%.

(iv) EG12112

EG12112 is a biosimilar of Atezolizumab. Its R&D target TECENTRIQ is an immune checkpoint inhibitor (Immune Checkpoint Inhibitor). According to Roche's 2024annual financial report, global annual sales reached 3.64billion CHFwith the flat growth rate of which the European and US markets accounted for 72%. As the world's first approved PD-L1 immune checkpoint inhibitor, Roche has invested considerable resources in clinical trials for multiple cancer types, and has successively obtained results for locally advanced or metastatic urothelial cancer, locally advanced or metastatic non-Small cell lung cancer, triple negative breast cancer, small cell lung cancer, hepatocellular carcinoma and other cancer indications. According to a report by IMARC Group, the global immune checkpoint inhibitor market size will reach US$43.1 billion in 2023, and the market size is expected to reach US$157.2 billion by 2032. Immune checkpoint inhibitors are drugs that treat cancer by inhibiting specific proteins produced by immune system cells, such as T cells and cancer cells. It can be used alone or in combination with other cancer treatments, including chemotherapy and radiation therapy, to further enhance the effectiveness of the treatment.

(v) EG12164

Multiple myeloma is a disease caused by the malignant proliferation of plasma cells in the bone marrow. The normal function of plasma cells in the human body is to produce antibodies to resist invasion by foreign germs. Usually the number is not large. When specific germs enter the human body, the production of antibodies will be started. However, the plasma cells of multiple myeloma patients can only produce one type of antibody and cannot resist foreign germs. In addition, excessive production of plasma cells invades the bone marrow cavity, resulting in multiple myeloma patients with low immune function and very vulnerable to infection. Bacterial infection. Diagnosis is often delayed due to atypical symptoms. As the global population continues to age, the incidence rate of myeloma is also increasing year by year. According to 2022 The Lancet Haematology, there are approximately 176,000 newly diagnosed patients worldwide every year, accounting for 14% of blood tumors. Currently, there are more than 700 newly diagnosed cases of myeloma in Taiwan every year. DARZALEX has also driven a substantial growth in its revenue due to the excellent results of its clinical trials. According to J&J's 2024 annual financial report, global sales reached US$11.67 billion, an increase of 20% from 2023.

(B) New dosage forms and new drug delivery systems of biosimilars

(i) EG13084

EG13084 is a new subcutaneous injection drug that combines Trastuzumab and Pertuzumab. Its R&D target is PHESGO-approved indications for early breast cancer (EBC) and metastatic breast cancer (MBC). Since Roche obtained the marketing approval of PHESGO from the EMA and FDA in 2020, it has begun to strategically and actively convert PHESGO in Europe and the US for patients who use Trastuzumab and Pertuzumab in combination. According to Roche's 2024 annual financial report: the global annual sales of this product have to 1.74 billion CHF, with an annual growth rate of 62%. Among them, the European and US markets account for 75%. According to the excellent results of the APHINITY trial (Roche published in 2022, Pertuzumab combined with Trastuzumab and chemotherapy in the treatment of early breast cancer: this combination therapy can reduce the risk of recurrence or death by 23% compared with the control group and), it is foreseeable that EG13084 and EG1206A will jointly expand the treatment scope of patients and continue to expand

the market of dual-target therapy in the treatment of HER2 breast cancer

(ii) EG7412X

According to the Hyaluronidase Market Size, Share & Trends Analysis Report 2023-2030 report, the global market value of hyaluronidase (hyaluronidase) in 2023 will be US$910 million, of which "recombinant human hyaluronidase PH20 (rHuPH20) "Accounting for 23%. Due to its stable purity, the market share is expected to grow more rapidly. It is estimated to grow at a compound growth rate of 9.40% by 2030 and is widely used in new dosage forms of pharmaceuticals.

(C) Special biological drugs

(i) EG74032

EG74032 can be widely used in vaccine products and used as a carrier to make mixed vaccines. A number of vaccines with products such as CRM197 have been launched, and a number of vaccines are also in clinical development. Take Prevnar13 produced by Pfizer as an example. This vaccine combines the capsular antigens of Streptococcus Pneumonia serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F. The sugar suspension is chemically linked to the carrier protein to form a mixed vaccine. It is also used in the clinical development products of many large international pharmaceutical companies (such as Novartis and Mitsubishi Tanabe Pharmaceuticals) to produce multiple types of mixed vaccines, such as Haemophilus type B vaccine, typhoid vaccine or meningitis vaccine, demonstrating its wide application sex.

D. Competition for the Company's Products

Global biotech and pharmaceutical companies are optimistic about the subsequent development potential of the biosimilar drugs and ADC market. International major manufacturers have invested in this market, including biotech giants Amgen and Biogen. Well-known multinational pharmaceutical companies include Sandoz, Pfizer, Merck, and Eli. Lilly et al. In addition to the major international pharmaceutical companies actively exploring the field of biosimilar drugs through joint cooperation or mergers and acquisitions, there are also many small and medium-sized biopharmaceutical companies joining this battle. However, due to the company's size or its own capabilities, they can only strategically Cutting into part of the biosimilar drug value chain, EirGenix is different from other small and medium-sized biopharmaceutical companies. EirGenix's structure strengthens the company's international competitive advantage on the basis of CDMO. Its niche points are: 1. Through the R&D energy of the Taiwan team, master the cell line development capabilities and keep exclusive technology and manufacturing capabilities in Taiwan; 2. Implement process research and development, as well as product analysis and manufacturing technology through a team with international experience; 3. At the same time Possess Mammalian (mammalian cell line development) and Microbial (microbial cell fermentation) technology platforms; 4. Complete the commercial production base at the Zhubei factory to systematically retain production technology capabilities and provide competitive production costs and profits; 5. Have regulatory experience in international clinical applications and drug approvals. EirGenix is a professional biopharmaceutical company with high concentration of technology and experience. Its business strategy mainly focuses on two major directions: 1. Provide domestic and foreign biopharmaceutical development companies with high-quality and market-competitive entrusted process development and production services. EirGenix has cGMP-related facilities that comply with international regulatory standards for clinical/marketed production of biopharmaceuticals. It has two cGMP plants for mammalian cell and microbial fermentation and related technical manpower, which has greatly improved the integrity and quality of the production system for clinical trials and marketed biopharmaceuticals. complementarity. 2. Simultaneously develop high-quality and market-competitive biopharmaceuticals/biosimilar drugs. Through the above two business axes, EirGenix can provide customers with high-quality and cost-effective biotech drug manufacturing services, and jointly develop high-quality and cost-effective biotech drugs with partners to benefit the global medical system and their needs. All patients treated will be the biggest beneficiaries.

(A) Biosimilar drugs

(i) Market Competition Analysis of EG12014

In recent years, although the global sales of Roche, the original developer of HERCEPTIN, have declined year by year due to the entry of biosimilars into the market competition, the global sales of related products developed with its main ingredient Trastuzumab have increased due to the increase in breast cancer patients worldwide and the launch of biosimilars (As of the date of publication, the US FDA has approved 6 items and the EU EMA has approved 7 items), which has improved treatment opportunities for patients and maintained growth. According to the Trastuzumab Biosimilars Global Market Report 2025, global sales of trastuzumab biosimilars have reached 4.27 billion USD in 2024. With the extensive

experience and marketing advantages of Sandoz, a strategic partner of EirGenix, in leading global biosimilars, EG12014 is expected to quickly gain market share after being launched in the European and American markets. In the Taiwan market, where EirGenix is responsible for its own marketing, although 5 Trastuzumab biosimilars have been approved for marketing, only 4 of them (including EIRGASUN 150 mg) have obtained a wider range of National health insurance payment conditions and are substantially competitive. EIRGASUN 150 mg is the only trastuzumab developed and manufactured in Taiwan, and under the premise of the government's policy to promote the stability of the biotechnology industry and supply chain, it is successively entering the procurement list of hospitals at all levels according to the plan and gradually expanded the revenue.

In addition, in April 2019, EirGenix Inc. signed a licensing and co-development agreement with Sandoz AG, a global leader in generics and biosimilars. The agreement includes the up-front payment, milestone by the stage and the royalty payment in the authorized markets after product launch. Sandoz holds a leading position in the field of generic drugs and biosimilars with a long history and rich experience in the development and sales of biosimilar drugs and cancer medications. This strategic cooperation is expected to improve the global competitiveness of EirGenix's production line, thus expanding EirGenix's overall operating scale and increasing profits, which is of great positive help to financial and business development.

(ii) Market Competition Analysis of EG1206A

Although Roche is currently marketing another subcutaneous injection drug PHESGO that combines Trastuzumab and Pertuzumab globally, which has affected the growth of PERJETA, according to Roche's 2024annual financial report: the global annual sales of this product still reached 3.62billion CHF, with an annual growth rate of 1%, and the European and US markets accounted for 55% of revenue contribution. At present, EirGenix’s EG1206A R&D progress ranks among the top three in the global pertuzumab biosimilars, which will be more conducive to seizing the biosimilar market after the expiration of Pertuzumab's patent. The current progress is preparing to enter phase 3 clinical trials, which are expected to be launched in the second half of 2028. Once EG1206A passes Phase III clinical trials and is successfully launched, it will be paired with EG12014 and EG13084 to further strengthen the integrity of the HER2 product portfolio and provide more treatment options for breast cancer patients around the world.

(iii) Market Competition Analysis of TSY0110 (EG12043)

In response to the increasing demand for research and production of anti-drug conjugates and highly cytotoxic/potent substances, many foreign CDMOs and CMOs have begun to expand their service energy, especially for highly cytotoxic/potent active pharmaceutical ingredient (API) and final products. As of March 2024, the U.S. FDA has approved 14 ADCs for marketing, and global pharmaceutical companies are also competing to invest resources. This is also a battleground for the future cancer treatment market. With the cGMP plant, EirGenix has the capability of developing and manufacturing a monoclonal antibody drug process. At the same time, EirGenix forms a strategic alliance with Formosa Laboratories, which has the most experience in developing and manufacturing high-activity raw materials in Taiwan and has experienced antibody drug development and cGMP production talents and international cooperation networks, which is conducive to the development of ADC platform.

technology.

(iv) Market Competition Analysis of EG12112

Immune checkpoint inhibitors target specific signaling pathways in the immune system to further develop more precise cancer treatments. Compared with traditional chemotherapy, it has the advantages of lower toxicity and fewer side effects, making it better tolerated by patients. The current trend in cancer treatment also focuses on using new sequencing technologies to identify specific genetic mutations in cancer cells, thereby driving the global demand for immune checkpoint inhibitors and becoming the mainstream of current cancer treatment. In the near future, several after the patent of immune checkpoint inhibitors expires, the introduction of biosimilar drugs to provide more affordable treatments with the same efficacy will also be the focus of cancer treatment development.

(v) Market Competition Analysis of EG12164

J&J currently markets DARZALEX, a breakthrough CD38 monoclonal antibody therapy, in both IV and subcutaneous dosage forms globally, in addition to expanding the market and maintaining its competitive advantage through the patent protection strategy of subcutaneous dosage forms.

(B) New dosage forms and new drug delivery systems of biosimilars

(i) Market Competition Analysis of EG13084

Roche is currently marketing PHESGO replacement Pertuzumab in combination with trastuzumab and chemotherapy globally, emphasizing convenience and maintaining the clinical benefit of this combination therapy in reducing the risk of recurrence or death by 23% compared to the control group. It is foreseeable that the EG13084 that EirGenix focuses on R&D will work with EG1206A to expand the scope of treatment for patients and continue to expand the market of dual-target therapy in HER2 breast cancer treatment, which is also one of the important axes of EirGenix's EG13048 expanding its breast cancer treatment production line.

(ii) Market Competition Analysis of EG7412X

At present, "recombinant human hyaluronidase PH20 (rHuPH20)" is still monopolized by the American company Halozyme with ENHANZE's patented technology and has been licensed to a number of major international pharmaceutical companies for the application of new subcutaneous injection dosage forms of star drugs.

(C) Special biological drugs

(i) Market Competition Analysis of EG74032

At present, there are very few manufacturers with the production capacity of this product in the market. The main manufacturers are as follows:

Company	Location of Manufacturing Plant	Product
SynCon Bio Partner	Netherlands (Amsterdam)	Production of CRM197 with mutant Diphtheria Bacillus; Provision of Prevnar® and Meningites® manufactured by Pfizer, and Menveo® manufactured by Novartis
Pfenex, Inc.	India	Provision of various specifications of CRM197 raw materials, including raw materials conforming to cGMP specifications (CRM197 is expressed with pseudomonas fluorescent as host)

Except for SynCo Bio Partners, which "exclusively" supplies CRM197 to the original developers (Pfizer and Novartis), the only other manufacturer capable of providing this raw material is Pfenex in India. This indicates that there are currently very few competitors in the market with such production capabilities.

EirGenix uses a unique microbial expression system and process to produce high-purity EG74032. Compared with other CRM197 products currently on the market, EirGenix's EG74032 uses a microbial (E. Coli.) expression system and process to produce high-purity EG74032. With a high degree of competitive advantage, EirGenix has completed the development and mass production of the EG74032 process. The current mass production scale can reach 150 liters of fermentation tanks.

(3)An overview of the company's technologies and its research and development work

A. The company's technologies and its research and development work

EirGenix is a professional biopharmaceutical company with a high density of technology and experience, whose business strategy is mainly in two directions:

(A) Provide domestic and foreign biopharmaceutical development companies with high-quality and market-competitive entrusted process development and production services. EirGenix has cGMP-related facilities that comply with international regulatory standards for clinical/marketed production of biopharmaceuticals. It has two cGMP plants for mammalian cell and microbial fermentation and related technical manpower, which has greatly improved the integrity and quality of the production system for clinical trials and marketed biopharmaceuticals. complementarity.

(B) Simultaneously develop high-quality and market-competitive biopharmaceuticals/biosimilar drugs.

Through the above two business axes, EirGenix can provide customers with high-quality and cost-effective biotech drug manufacturing services, and jointly develop high-quality and cost-effective biotech drugs with partners to benefit the global medical system and their needs. All patients treated will be the biggest beneficiaries.

B. Successfully Developed Technique or Product

EirGenix and its subsidiary provide contracted process development and production service with high quality and market competitiveness for biopharmaceutical development companies at home and abroad. EirGenix has CGMP-related facilities that conform to international regulations and standards and can be used for biopharmaceuticals' clinical/market production. At the same time, EirGenix has two CGMP plants for mammalian cell and microbial fermentation and related technical manpower, greatly improving the integrity and complementarity of clinical trials and market biotech drug production systems. EirGenix has accumulated technology for many years, continuously introduced international talents and novel equipment to maintain international competitiveness and meet the requirements of international laws and regulations, and continuously carried out technology development.

C. Research and Development Implementation Progress

Item	Indications	Implementation Progress
EG12014	Early Breast Cancer (EBC) Metastatic Breast Cancer (MBC) Metastatic Gastric Cancer	EirGenix's "Trastuzumab" has obtained API license and API master file number from the Food and Drug Administration of Taiwan's Ministry of Health and Welfare. The biosimilar "EIRGASUN 150 mg" has obtained a marketing approval from Taiwan's Ministry of Health and Welfare and has been approved by the National Health Insurance Agency of the Ministry of Health and Welfare to be reimbursed by health insurance benefits. The latest health insurance drug price in 2025 is NT$11,323/tube. HERWENDA-Trastuzumab biosimilar EG12014 (150 mg, for intravenous use) has obtained marketing approval from EC.
EG1206A	Early Breast Cancer (EBC) Metastatic breast Cancer (MBC)	EirGenix's EG1206A achieved successful phase I clinical results in May 2023 and the current progress is entering phase III clinical trials.
TSY0110 (EG12043)	Breast Cancer Gastric Cancer	EG12043 (TSY0110) has received positive results from the Scientific Advice Meeting of the European Medicines Agency (EMA); and the Biosimilar Drug Development Type 2 Meeting (BPD Type 2) of the US Food and Drug Administration (FDA) and expect to apply for the phase I clinical trials in first half of 2025. The Company has received positive feedback from the European Medicines Agency (EMA) through a Scientific Advice Meeting and from the U.S. Food and Drug Administration (FDA) through a Biosimilar Product Development (BPD) Type 2 meeting. This product is being developed through a strategic alliance with Formosa Laboratories Inc and Formosa Pharmaceuticals Inc, both of which possess extensive experience in the research, development, and manufacturing of highly potent active pharmaceutical ingredients in Taiwan. By integrating their respective strengths, the alliance aims to enhance the antibody-drug conjugate (ADC) development platform. In addition, by expanding a comprehensive HER2 biosimilar product portfolio, the Company intends to collaborate with the most internationally competitive pharmaceutical partners for global marketing. The goal is to rapidly secure a leading position in the global HER2-positive breast cancer ADC market following the launch of EG12043 (TSY0110).
EG12112	Locally Advanced or Metastatic Urothelial Cancer Locally Advanced or Metastatic Non-Small Cell Lung Cancer Triple-Negative Breast Cancer Small Cell Lung Cancer Hepatocellular Carcinoma	Preclinical evaluation trials are currently underway.
EG12164	Multiple Myeloma	Preclinical evaluation trials are currently underway.
EG13084	Early Breast Cancer (EBC), Metastatic breast Cancer (MBC) /	At present, the development of subcutaneous injection is underway.
EG7412X	Early Breast Cancer (EBC), Metastatic breast Cancer (MBC) /	At present, the development of subcutaneous injection is underway.
EG74032	Conjugate Vaccine	At present, EirGenix has completed the development and pilot run of the EG74032 process, with the current production scale reaching a 150-liter fermentation tank, which has been sold at home and abroad.

D. R&D Expenses As of the date of issuance for the annual report in the latest 5 year

Unit: NT$ thousands; %

Item \ Year	2020	2021	2022	2023	2024
R&D Expenses(A)	1,561,722	893,510	800,144	952,290	785,882
Net Operation Revenue(B)	1,071,838	1,697,359	1,481,017	1,022,653	1,008,960
(A) / (B)	146	53	54	93	78

(4)Long-term and Short-term Development

A. The short-term development strategy is “Build up the foundation and move forward step by step.” The strategy plans for products in development and CDMO sales & marketing development are as follows:

(A) EG12014 approved by the FDA and other countries in Aisa.

(B) EG12014 (HERWENDA® - Sandoz | EIRGASUN® - EirGenix) market launch.

(C) EG1206A submits the application for Phase III trials.

(D) Application for EG12043 (TSY0110) clinical trials (IND).

(E) EG12112 pre-clinical preparation completed.

(F) EG12164 pre-clinical preparation completed.

(G) Expansion of Building B at Zhubei plant to increase the microbial capacity to 1,500 L in 2026.

B. The medium and long-term development strategy is “Products are developing and launching one after another to promote stable growth in revenue. The strategy plans for products in development and CDMO sales development are as follows:

(A) New dosage forms or new drug delivery systems of biosimilars: development of Trastuzumab high-concentration subcutaneous doses; planning for the development of EG12014+EG1206A dual-targeting high-concentration subcutaneous doses. The successful development of high-concentration subcutaneous doses will strengthen the product market share of these products and enable EirGenix as the primary supplier of biosimilar drugs for the treatment of HER2+ breast cancer.

(B) Developing the biosimilar for the treatment of blood cancer are currently ongoing. According to the development schedule, one new product will be introduced to the market each one to two years starting in 2030. Hence, a three-stage expansion of the mammalian capacity by 150,000L is under planning at Ciaotou Science Park, Kaohsiung. The new capacity can be used to manufacture in-house developed drugs and accept customers’ orders for commercial and scale production.

2. Market and Sales Overview

(1) Market Analysis

A. Sales (Service) Region

Unit: NT$ thousands; %

Year / Area	2023		2024		2025Q1	
	Amount	%	Amount	%	Amount	%
Taiwan	474,123	46.36	338,051	33.50	46,581	25.61
Japan	186,584	18.25	359,964	35.68	129,228	71.03
USA and Canada	119,293	11.67	165,939	16.45	6,029	3.31
Europe	242,186	23.68	143,869	14.26	-	-
Other Regions	467	0.04	1,137	0.11	85	0.05
Total	1,022,653	100.00	1,008,960	100.00	181,923	100.00

B. Market Share

At present, the CDMO business of EirGenix is extremely competitive in the market. In addition to a certain proportion of the market share in Taiwan, EirGenix has actively expanded to Asian markets such as Japan and the mainland; In the future, EirGenix will be committed to increasing the market share of Europe, America, and other regions. The self-developed products of EirGenix have not been sold on the market before, so there is no market share analysis at present.

C. Supply and Demand of the Market and Growth in the Future

(A) Biosimilar drugs

(i) EG12014

EG12014 is a biosimilar of Trastuzumab, and its R&D target HERCEPTIN has global annual sales of 1.38 billion CHF according to Roche's 2024 financial report, of which the European and US markets account for 41%. According to data from the Taiwan Health Insurance Administration, breast cancer ranked second among the top ten cancer health insurance medical expenses in Taiwan in 2023, with drug expenditures of 9.107 billion NTD (the average growth rate from 2019 to 2023 was 6.72%).

In 2025, the latest health insurance drug price of HERCEPTIN frozen crystal injection form (440 mg) was NT$29,895 per tube. Currently, the National Health Insurance reimbursed Trastuzumab for patients with early breast cancer (EBC), metastatic breast cancer (MBC) and metastatic gastric cancer (mGC). The number of breast cancer and gastric cancer patients in Taiwan increases every year, and medical expenses also increase accordingly. The latest health insurance price of EirGenix's EIRGASUN 150 mg in 2025 is NT$11,323/tube, which brings more benefits to more people with a more affordable price and wider treatment benefits. Patients who need to undergo breast cancer treatment can achieve expected clinical efficacy while reducing their medical expenses by using EG12014 (EIRGASUN 150 mg), which has no clinically significant difference in safety, quality and efficacy from HERCEPTIN, to achieve the purpose of truly benefiting the people.

(ii) EG1206A

EG1206A is a biosimilar of Pertuzumab. Since its R&D target PERJETA was launched in the United States in 2013, sales have grown rapidly every year. According to the results of the APHINITY trial of Pertuzumab combined with Trastuzumab and chemotherapy in the treatment of early breast cancer published by Roche in 2022, this combination therapy can reduce the risk of recurrence or death by 23% compared with the control group. From these excellent test results, it is foreseeable that the subsequent product development and therapeutic application of EG1206A will be more extensive. Roche is currently actively promoting the expansion of indications and is expected to continue to expand the treatment scope and market. Although Roche is currently marketing another subcutaneous injection drug PHESGO that combines Trastuzumab and Pertuzumab globally, which has affected the growth of PERJETA. According to Roche's 2024 annual financial report: the global annual sales of this product still reached 3.62 billion CHF, with an annual growth rate of 1%, and the European and US markets accounted for 55% of the revenue contribution.

(iii) TSY0110 (EG12043)

Roche's Trastuzumab emtansine (T-DM1) has been successfully marketed by using Linker to bind Trastuzumab antibody and cytotoxic chemical DM-1. The conjugate (Linker, Connector) of T-DM1 will not affect the antibody-dependent cytotoxic activity and will not interfere with the antibody neutralization activity dominated by HER2. Therefore, T-DM1 not only retains the anticancer effect of Trastuzumab but also enables the powerful cytotoxic drugs attached to it to exert a stronger effect. In Phase III clinical trials (EMILIA trial*) for patients with advanced breast cancer patients of HER2 overexpression and who have used Trastuzumab or Taxane, it was found that patients receiving T-DM1 treatment have a longer and better progression-free survival (T-DM1: 9.6 months; Lapatinib plus capecitabine: 6.4 months)(HR: 0.65; 95%CI: 0.55-0.77; P<0.001) and overall survival (T-DM1: 30.9 months; Lapatinib plus capecitabine: 25.1 months) (HR: 0.68; 95% CI: 0.55-0.85; P < 0.001) over patients treated with Lapatinib in combination with Capecitabine. It shows that this kind of treatment is progress that cannot be ignored in both clinical medicine and pharmacology.

As far as the global market is concerned, there are very few companies in the world that can provide ADC development services. EirGenix has formed a strategic alliance with Formosa Laboratories. According to the schedule plan, they will jointly become one of the world's leading manufacturers in the ADC field in the shortest possible time to expand their competitive advantage.

(iv) EG12112

EG12112 is a biosimilar of Atezolizumab. Its R&D target TECENTRIQ is an immune checkpoint inhibitor (Immune Checkpoint Inhibitor). According to Roche's 2024 annual financial report, global annual sales reached 3.64billion CHF, with the flat growth rateof which the European and US markets accounted for 72%. As the world's first approved PD-L1 immune checkpoint inhibitor, Roche has invested considerable resources in clinical trials for multiple cancer types, and has successively obtained results for locally advanced or metastatic urothelial cancer, locally advanced or metastatic non-Small cell lung cancer, triple negative breast cancer, small cell lung cancer, hepatocellular carcinoma and other cancer indications. According to a report by IMARC Group, the global immune checkpoint inhibitor market size will reach US$43.1 billion in 2023, and the market size is expected to reach US$157.2 billion by 2032. Immune checkpoint inhibitors are drugs that treat cancer by inhibiting specific proteins produced by immune system cells, such as T cells and cancer cells. It can be used alone or in combination with other cancer treatments, including chemotherapy and radiation therapy, to further enhance the effectiveness of the treatment.

(v) EG12164

Multiple myeloma is a disease caused by the malignant proliferation of plasma cells in the bone marrow. The normal function of plasma cells in the human body is to produce antibodies to resist invasion by foreign germs. Usually the number is not large. When specific germs enter the human body, the production of antibodies will be started. However, the plasma cells of multiple myeloma patients can only produce one type of antibody and cannot resist foreign germs. In addition, excessive production of plasma cells invades the bone marrow cavity, resulting in multiple myeloma patients with low immune function and very vulnerable to infection. Bacterial infection. Diagnosis is often delayed due to atypical symptoms. As the global population continues to age, the incidence rate of myeloma is also increasing year by year. According to 2022 The Lancet Haematology, there are approximately 176,000 newly diagnosed patients worldwide every year, accounting for 14% of blood tumors. Currently, there are more than 700 newly diagnosed cases of myeloma in Taiwan every year. DARZALEX has also driven a substantial growth in its revenue due to the excellent results of its clinical trials. According to J&J's 2024 annual financial report, global sales reached US$11.67 billion, an increase of 20% from 2023.

(B) New dosage forms and new drug delivery systems of biosimilars

(i) EG13084

EG13084 is a new subcutaneous injection drug that combines Trastuzumab and Pertuzumab. Its R&D target is PHESGO-approved indications for early breast cancer (EBC) and metastatic breast cancer (MBC). Since Roche obtained the marketing approval of PHESGO from the EMA and FDA in 2020, it has begun to strategically and actively convert PHESGO in Europe and the US for patients who use Trastuzumab and Pertuzumab in combination. According to Roche's 2024 annual financial report: the global annual sales of this product have to 1.74 billion CHF, with an annual growth rate of 62%. Among them, the European and US markets account for 75%. According to the excellent results of the APHINITY trial (Roche published in 2022, Pertuzumab combined with Trastuzumab and chemotherapy in the treatment of early breast cancer: this combination therapy can reduce the risk of recurrence or death by 23% compared with the control group and),

it is foreseeable that EG13084 and EG1206A will jointly expand the treatment scope of patients and continue to expand the market of dual-target therapy in the treatment of HER2 breast cancer.

(ii) EG7412X

According to the Hyaluronidase Market Size, Share & Trends Analysis Report 2023-2030 report, the global market value of hyaluronidase (hyaluronidase) in 2023 will be US$910 million, of which "recombinant human hyaluronidase PH20 (rHuPH20) "Accounting for 23%. Due to its stable purity, the market share is expected to grow more rapidly. It is estimated to grow at a compound growth rate of 9.4% by 2030 and is widely used in new dosage forms of pharmaceuticals.

(C) Special biological drugs

(i) EG74032

This product is a carrier protein made of diphtheria toxin through genetic improvement and amino acid replacement.

At present, it has been applied in commercially available vaccines of Pfizer and Novartis, with annual sales of billions of US dollars. In 2015, the global vaccine market value was nearly US$ 30 billion, while the market value of conjugate vaccines with carrier protein reached up to US$ 7 billion. These show that the future market for such products is quite amazing.

This protein has been widely used in commercially available products and clinical development products. There are more than 60 completed or ongoing clinical trials with relevant products on ClinicalTrials.gov of the National Institute of Health. Among them, only Novartis has carried out more than 20 clinical trials, which shows that the conjugate vaccine with this carrier protein has a great market.

In addition to the traditional vaccines for infectious disease, the research and development of cancer vaccines have attracted much attention in recent years. Both R&D organizations and biotech companies at home and abroad are actively investing in the development of cancer vaccines, hoping to bring a glimmer of light to all kinds of cancers that have no effective therapy yet.

In the early process, Corynebacterium diphtheria was used for production, followed by downstream recovery, purification, and other steps, and the yield and recovery rate were usually relatively low. In addition, for the acquisition of the strain, a license agreement needs to be signed with a specific organization, and the production organization needs to have a biological protection level that meets the standards before production. Compared with the above processes, the microbial expression platform is used for the EG74032 process developed by EirGenix, which will achieve the effects of a quite high yield and purity as well as immune enhancement. Compared with traditional processes or other products on the market, EirGenix's products will be competitive in quality and price and are expected to be widely used in research and development or marketing products.

EirGenix and its subsidiary CRM197 is expected to occupy a certain market share in the academic and pre-clinical markets.

D. Competitive niche

(A) The advanced technology platform of EirGenix helps customers shorten the time schedule of biopharmaceutical development.

(i) Cell line development

Customers only need to provide DNA expression sequences or amino acid sequences of proteins, and EirgGenix can complete the establishment of high-expression cell lines. EirgGenix possesses dual-platform cell lines, including the internationally renowned Life Technologies CHO-S cell line and our self-developed EG CHO K1 sv cell line platform. This platform includes cell lines, expression vectors, and culture media. Under normal culture conditions, it can achieve antibody protein yields of 3-10 grams per liter, reducing costs for customers in both drug development and commercial production stages.

(ii) Process development and Scale-up

In terms of cell culture process, with Ambr™ micro bioreactor, EirGenix can simulate the culture conditions of the large-volume bioreactor in a 15 ml test tube and can control and adjust a number of parameters on a small scale to achieve the comprehensive effect of saving time and cost.

In terms of process amplification, at present, many projects, including the customer's products and the EG12014 product within EirGenix, have successfully entered the cGMP plant for the product at 200/4,000 liters or more. EirGenix

has mastered the setting of various important parameters in bio-fermentation tanks of various scales in the process amplification of the cGMP plant. Once the culture condition parameters of small-scale fermentation tanks from 2 to 5 liters are available, they can be successfully amplified to a scale of 200, 500, 1,000, to 4,000 liters. This technology platform can save customers the time and various costs required in the process amplification.

(iii) Protein analysis and identification

Due to the characteristics of biopharmaceuticals, in the production process, each batch of products cannot be 100% the same. Various analytical methods are needed to identify the characteristics of the protein drugs produced. In addition, corresponding analytical methods are needed to detect the amino acid sequence of the protein, the purity of the product, impurity produced in the process, the activity of the protein, and the monitoring of microorganisms that may cause biosafety issue. The team of EirGenix has established the full identification, characterization and analytical methods of protein drugs internally to ensure the strictest control of product quality and safety at all stages and reduce the risks caused by unstable product quality in the drug development process.

(iv) Provide a full range of services to meet the needs of customers:

EirGenix also operates mammalian and microbial production facilities that adhere to PIC/S cGMP standards and can offer comprehensive services tailored to clients' requirements. The mammalian cell production line at the Xizhi Facility includes one cell bank production line, two upstream production suites, and one downstream purification production suite. The upstream production suites feature reactors with scales of 50-200-1000 liters and another suite with scales of 50-200 liters, all utilizing single-use bioreactors. In the Xizhi Facility's microbial cell production line, there is one upstream production suite and one downstream purification production suite, equipped with a 20L stainless-steel fermentor and a 100L stainless-steel fermentor in the upstream production line. At the Zhubei Facility, there are two mammalian cell production lines, each equipped with a 200-2000 (2x1000L)-12000 (6x2000L) liters single-use bioreactor upstream production suite and one downstream production suite. The use of single-use bioreactors offers advantages such as reduced cross-contamination and simplified equipment setup. Throughout the drug development phase, our company ensures maximum flexibility and a broad range of options in process development to accommodate the diverse needs of clients' drug development projects.

(B) EirGenix has formed the strategic industrial alliance with Formosa Laboratories in large molecule drugs and small molecular drugs.

At present, Formosa Laboratories, with a number of raw materials and anti-sunburn series active ingredient products marketed all over the world as well as ISO certificate, has successfully passed the GMP plant inspection certification of Taiwan Department of Health, FDA of the United States, BGV of Germany, EDQM of the European Union and PMDA of Japan, which is a major manufacturer of small molecule raw materials in the world. At present, Formosa Laboratories has built a high-activity raw material production plant for the production of small molecule drugs with high toxicity. In combination with EirGenix's ability to produce large molecule antibody drugs, EirGenix and Formosa Laboratories have jointly established a production platform for ADC, with EirGenix producing antibodies, Formosa Laboratories producing small molecule drugs and carrying out antibody-drug conjugation, and EirGenix carrying out various identification and analysis related to ADC products. The establishment plan of this production platform has been subsidized and supported by the Ministry of Economy's Industry Development Technology Plan. The alliance between EirGenix and Formosa Laboratories has made the establishment of the ADC production platform completed and will make EirGenix one of the few CMO companies in the world that can produce antibody-drug conjugates.

E. Favorable and Unfavorable Factors in the Long Term

(A) Favorable factors

(i) EirGenix has protein drug development platform technology and a cGMP pilot plant. In coordination with the toxicology laboratory and bio-safety testing laboratory previously established by the Biotechnology Center, EirGenix can integrate the upstream, midstream, and downstream protein drug R&D chains and provide a series of complete technical services.

(ii) At the same time, EirGenix has rich experience in cell line cloning and microbial process technology development and continues to introduce domestic and foreign experienced and technical talents. Good production and development quality, good manpower quality, low turnover rate, and high work efficiency can shorten the biopharmaceutical development time.

(iii) The relevant GMP production facilities comply with international regulations (including FDA GMP and PIC/S GMP), which is conducive to obtaining foreign sources of cases. Through business cooperation with strategic alliance partners, CDMO business has expanded rapidly.

(iv) The protein-drug market continues to grow, and there is still a wide range of therapeutic applications to be developed. Drugs have entered preclinical and Phase I/II clinical trials one after another. There is a high demand for CDMO at this scale at home and abroad. Upstream R&D organizations at home and abroad have invested heavily in the research and development of biopharmaceuticals. The number of pipelines for bio-pharmaceuticals continues to increase. There is an urgent need for mid-stream research and development institutions that can undertake research and development results in order to extend the results to pre-clinical and Phase I/II clinical trials. The demand for microbial fermentation systems is gradually increasing in biopharmaceutical companies at home and abroad. The establishment of a CGMP microbial fermentation system can be applied not only to mature microbial expression systems such as E. coli and Pichia but also to the mass production and development of DNA vaccines.

(v) The government actively constructs an environment conducive to the development of the bio-pharmaceutical industry, including tax exemption and tax relief, to further enhance the competitiveness of domestic manufacturers.

(vi) EirGenix's development of biosimilars follows the international guidance, and its quality has the competitive strength of major international factories. With the gradual development of products, active international cooperation will be conducive to the deep roots of the brand in the near future.

(B) Unfavorable factors and countermeasures

(i) There are relatively few CDMO projects in the late development stage and commercial production.

Countermeasures: EirGenix has completed the construction of the first cell line 12,000L (3 sets of 2x2,000 L) on the 3F for commercial scale production in the Hsinchu Biomedical Park. It was put into operation in January 2019 and mainly used for the production of our own products (EG12014 and EG1206A). The second production line 12,000L (3 sets of 2x2,000 L) on the 5F has been launched in November 2023. Currently, we have several projects in hand and are continuously communicating with domestic and foreign biopharmaceutical companies, including biosimilar drug developers, to seek opportunities for late development stage and commercial scale production cooperation. The commercial microbial production plant (350 L+1,000 L and 2x DSP suites) in Building B of the Hsinchu Park has started construction and is scheduled to be completed and put into operation in 2026. Some production capacity is currently reserved for the future needs of existing customers, and we will continue to communicate with domestic and foreign biopharmaceutical companies to seek projects for late development stage and production of CGT projects as well as DNA plasmids and enzymes related to mRNA.

(ii) Foreign bio-pharmaceutical manufacturers have been actively deployed, and their brand advantages will form pressure.

Countermeasures: EirGenix has established an experienced R&D team to continuously enter the market as early as possible with the development efficiency of new products (Biosimilar, Biobetter, etc.) through the improvement of R&D technology capabilities, passing US FDA, EMA, or Japan PMDA inspections will increase customer confidence, and to reduce the threat of price competition through the expansion of factories under the reduction of production costs. In addition, EirGenix has actively cooperated with local pharmaceutical companies to carry out clinical development, product production, and marketing.

(iii) For biosimilars products, the long R&D time is long and high fund investment make it unfavorable to the P&L.

Countermeasures: EirGenix has evaluated the R&D of a series of new indications related to HER2 with its professional development capability so as to expand the product market effectively and continuously carry out product life cycle management; has also sought strategic alliances and shared with domestic and foreign partners and combined with the capital market to ensure the smooth marketing of products.

(2) Production Procedures of Main Products

A. Major Products and Their Main Uses

(A) Biosimilar drugs

(i) EG12014

So far, there are three approved indications of Trastuzumab by the FDA of the United States, including the treatment of patients with early breast cancer (EBC), metastatic breast cancer (MBC), and metastatic gastric cancer (mGC) of HER2 overexpression or HER2 gene amplification. In early breast cancer (EBC), it includes (1) adjuvant therapy after surgery and chemotherapy (preoperative or postoperative). (2) Adjuvant therapy of Doxorubicin and Cyclophosphamide combined with Paclitaxel or Docetaxel. (3) Adjuvant therapy of Docetaxel combined with Carboplatin. (4) Preoperative chemotherapy and postoperative adjuvant therapy are used to treat locally advanced (including inflammatory) breast cancer or tumor (diameter > 2 cm); In metastatic breast cancer (MBC): (1) it is used alone for metastatic breast cancer that has been treated with chemotherapy once or more; Unless the patient is not suitable for using Anthracycline or Taxane, the previous chemotherapy should include at least Anthracycline or Taxane. It is used for patients positive in hormone receptors who have failed in hormone therapy unless the patient is not suitable for hormone therapy. (2) Combined with Paclitaxel or Docetaxel for patients with metastatic breast cancer that has not been treated with chemotherapy. (3) Combined with aromatic cyclase inhibitors for patients with hormone receptor-positive metastatic breast cancer; In metastatic gastric cancer (mGC), combined with capecitabine (or 5-fluorouracil) and cisplatin for the treatment for metastatic gastric adenocarcinoma (or gastroesophageal junction adenocarcinoma) of HER2 over-expression that has not been treated with chemotherapy.

(ii) EG1206A

EG1206A is a biosimilar of Pertuzumab. The reference drug of Pertuzumab, Perjeta, is very promising in clinical efficacy and sales prospect. As the incidence of breast cancer tends to be younger year by year and the 5-year recurrence rate of HER2+ early breast cancer is 17~40%, the utilization rate of EG1206A will continue to grow. It is estimated that the market demand for this drug will gradually increase in the future.

(iii) TSY0110 (EG12043)

Antibody-drug conjugates (ADC) are undoubtedly the most selective anti-cancer therapy for tumors, but their performance is not protruding in drug delivery. Therefore, antibody-drug conjugates (ADC) need to be combined with powerful drugs. At present, ADCs are commonly combined with maytansinoids (T-DM1) and dolastatin analogs (brentuximab vedotin), which act on microtubules and can inhibit microtubule kinetics. Once reaching picomolar concentration (pM), these drugs can show super activity to inhibit cell growth; Therefore, ADC is expected to kill the enemy more effectively by accurately "targeting" these cytotoxic drugs into the anti-cancer battlefield. After T-DM1 passes the examination at an extremely fast speed, the research on ADC becomes hot.

(iv) EG12112

The R&D target TECENTRIQ is an Fc-engineered, humanized monoclonal antibody that binds to PD-L1 and blocks its interaction with PD-1 and B7.1 receptors. Atezolizumab is an unglycosylated IgG1 kappa immunoglobulin with a calculated molecular weight of 145 kDa. Its pharmacological effect is that PD-L1 can be expressed on tumor cells and/or tumor-infiltrating immune cells, and can inhibit the anti-tumor immune response in the tumor microenvironment. PD-L1 binds to PD-1 and B7.1 receptors on T cells and antigen-presenting cells to inhibit the activity of cytotoxic T cells, T cell proliferation and cytokine production. Atezolizumab is a monoclonal antibody that binds to PD-L1 and blocks its interaction with PD-1 and B7.1 receptors. This releases PD-L1/PD-1-mediated suppression of immune responses, including activation of anti-tumor immune responses without inducing antibody-dependent cellular cytotoxicity. In syngeneic mouse tumor models, blocking PD-L1 activity resulted in reduced tumor growth. Indications span a variety of cancer types: 1. Locally advanced or metastatic urothelial cancer is suitable for the treatment of patients with locally advanced or metastatic urothelial cancer whose disease has worsened after receiving platinum-containing chemotherapy or who are not suitable for cisplatin-containing therapy. 2. Used alone for locally advanced or metastatic non-small cell lung cancer. It is suitable for the treatment of patients with locally advanced or metastatic non-small cell lung cancer whose disease has worsened after receiving platinum-containing chemotherapy. If patients have EGFR or ALK tumor gene abnormalities, they must first be treated with EGFR or ALK inhibitors. If the disease worsens after treatment, TECENTRIQ can be used. Used in combination with Avastin (bevacizumab), paclitaxel and carboplatin, as a first-line treatment for metastatic non-squamous non-small cell lung cancer without EGFR or ALK tumor gene abnormalities. 3. The combination of TECENTRIQ and nab-

paclitaxel for triple-negative breast cancer is suitable for the treatment of unresectable locally advanced or metastatic triple-negative breast cancer, and the tumor has PD-L1 manifestations (tumor-infiltrating immune cells (IC) ≥ 1%) and has not received Chemotherapy is used for patients with metastatic breast cancer. 4. Small cell lung cancer, combined with carboplatin and etoposide, is suitable for the first-line treatment of adults with extensive stage small cell lung cancer. 5. The combined use of hepatocellular carcinoma and bevacizumab is suitable for the treatment of patients with hepatocellular carcinoma who have not received systemic therapy and are unresectable or metastatic, and their liver function is Child-Pugh A.

(v) EG12164

The target of its R&D, DARZALEX, is a humanized IgG1κ monoclonal antibody that can bind to the CD38 antigen. This strain is produced in a mammalian cell line (Chinese Hamster Ovary [CHO]) through recombinant DNA technology. Its pharmacology Mechanism is an IgG1κ human monoclonal antibody (mAb) that binds to the CD38 protein that is highly expressed on the surface of multiple myeloma cells and to varying degrees on other cell types and tissues. CD38 protein has multiple functions, such as receptor-mediated adhesion, signaling and enzyme activity. DARZALEX is suitable for: 1. Patients who have received at least three previous therapies (including a protease inhibitor and an immunomodulator) as a single drug, or whose disease has worsened under treatment with both a protease inhibitor and an immunomodulator (double-refractory to a protease inhibitor and an immunomodulatory agent) in adults with multiple myeloma. 2. Use in combination with lenalidomide plus dexamethasone or with bortezomib plus dexamethasone to treat adult patients with multiple myeloma who have previously received at least one therapy.

(B) New dosage forms and new drug delivery systems of biosimilars

(i) EG13084

EG13084 is a new subcutaneous injection drug that combines Trastuzumab and Pertuzumab. Its R&D target is PHESGO-approved indications for early breast cancer (EBC) and metastatic breast cancer (MBC). In terms of early breast cancer (EBC), when EG13084 is used in combination with chemotherapy drugs for preoperative adjuvant therapy, it is suitable for patients with HER2-positive, locally advanced, inflammatory or early breast cancer (tumor diameter greater than 2cm or positive lymph nodes). Part of a complete treatment prescription. When used as adjuvant treatment after surgery, it is suitable for patients with early-stage breast cancer (EBC) who are HER2-positive and have a high risk of recurrence. (According to the results of the APHINITY clinical trial, in postoperative adjuvant therapy, patients with HER2-positive early breast cancer who have a high risk of recurrence are defined as having lymph node-positive breast cancer.) In terms of metastatic breast cancer (MBC), it is used together with docetaxel to treat metastasis patients with HER2-positive metastatic breast cancer who have not been treated with anti-HER2 or chemotherapy.

(ii) EG7412X

The R&D target of EG7412X is "recombinant human hyaluronidase PH20 (rHuPH20)", which is equivalent to the soluble fragment of human HYAL5. It is genetically engineered in hamster culture cells (CHO) culture containing a DNA plasmid encoding the enzyme. Produced as a type of hyaluronidase (hyaluronidase), its main function is to catalyze the degradation of hyaluronic acid (HA). According to the enzyme reaction products, they are divided into three different types: two eukaryotic endoglycosidase hydrolases and one prokaryotic lyase-type glycosidase. Hyaluronidase catalyzes the hydrolysis of HA, causing the viscosity of HA to decrease, thereby increasing tissue permeability. Therefore, it is often used in medicine together with other drugs, which can accelerate the dispersion and delivery of drugs through subcutaneous absorption.

(C) Special biological drugs

(i) EG74032

It is mainly used in vaccine products and used as a carrier to make conjugate vaccines. There are many commercially available conjugate vaccines, including Pfizer's Prevnar® and Prevnar® 13, Wyeth/Pfizer's Meningitec® and Novartis's Menveo®. At present, as a variety of products have been approved as infectious disease vaccines in Europe and the United States, representing that regulatory organizations have no doubts about the safety and effectiveness of CRM197 in improving immunity, and the subsequent technical and regulatory risks of acting as the raw material of conjugate vaccines are small, much academic research and clinical development projects are in progress.

B. Major Products and Their Production Processes

EirGenix's main core value in the product production process lies in the vertical integration of the upper, middle, and lower reaches of the industrial value chain. From cell line development and cell culture to process development and amplification to downstream product purification and drug stability analysis, EirGenix can master the industrial chain by itself, accurately master technology, and control costs.



Note: MCB/WCB (mother cell bank/working cell bank); WPBR (work production lot report); EPC (end production cell); VC (viral effectiveness)

C. The supply situation for the company's major raw materials

EirGenix's main service items are bio-pharmaceutical contract development & manufacturing organization (CDMO) and self-developed monoclonal antibody bio-similar drugs. The main raw materials are culture medium, buffer solution, chromatographic resin, single-use filter element, packaging materials, etc. The supply sources shall conform to international medical standards. In order to ensure the stable supply of raw materials, an inventory of qualified manufacturers is established to ensure that other supply sources meet the quality requirements.

D. A list of any suppliers and clients accounting for 10 percent or more of the company's total procurement (sales) amount in either of the two most recent fiscal years, the amounts bought from (sold to) each, the percentage of total procurement (sales) accounted for by each, and an explanation of the reason for increases or decreases in the above figures. Where the company is prohibited by contract from revealing the name of a client, or where a trading counterpart is an individual person who is not a related party, it may use a code in place of the actual name.

(A) Major Suppliers Information for the Last Two Calendar Years

As of the date of issuance for the annual report, the business of EirGenix is development of Biosimilars and new drugs, and the major revenue comes from CDMO.

Unit: NT$ thousands

Item	2023				2024				2025Q1			
	Company Name	Amount	Percent	Relation With Issuer	Company Name	Amount	Percent	Relation With Issuer	Company Name	Amount	%	Relation With Issuer
1	Cytiva	116,665	27.56	No	Cytiva	39,940	20.03	No	Mitek	31,160	37.51	No
2	Merck	116,351	27.49	No	Merck	28,327	14.21	No	Cytiva	16,558	19.93	No
3	Sartorius	49,139	11.61	No	Thermo Fisher	25,478	12.78	No	Thermo Fisher	16,263	19.58	No
4	Other	141,153	33.34	No	Sartorius	25,083	12.58	No	Merck	11,174	13.45	No
5					Cintrade	24,343	12.21	No	Others	7,919	9.53	No
6					Others	56,202	28.19	No				
	Net Purchases	423,308	100.00		Net Sales	199,373	100.00		Net Purchases	83,074	100.00	

Description of change:

EirGenix and its subsidiary mainly provide biopharmaceutical contract development & manufacturing organization (CDMO) business, and raw materials are mainly purchased according to the progress of each production process. Therefore, the main suppliers set different purchase prices according to the progress of their cases every year.

The industries of EirGenix and its subsidiary are bio-similar drug research and development and CDMO services. The main items purchased are protein ion exchange resin, culture medium, culture bag, filter element, reagent, and general consumables. In order to ensure stable supply quality and consistent comparison basis of experimental data, and some raw materials will be purchased from specific manufacturers according to project requirements. Raw materials cannot be arbitrarily changed in each process stage to avoid affecting test results, so it is a characteristic of the industry that a designated supplier supplies a single source of raw materials. Among the suppliers, Mitek and Thermo Fisher mainly supply Ion-Exchange Resin and Cytiva mainly supplies membrane and mixer bag. Merck mainly supplies reagents and culture bags. All three companies are internationally renowned biotechnology research and development factories or agent of Japanese renowned resin manufacturer. Apart from good quality and stable supply, they can also provide relevant data and technical support and supporting documents required for drug inspection and registration.

In the development of the Company's products, the applicability of the products is still used to test and screen the required raw materials. Except for some CDMO customers who demand specified materials, the raw materials selected by the Company will be put into production lines only after research and development tests and evaluations. The raw materials of the three major companies are on the candidate list and have no absolute dependence.

Major international biotech factories have a stable supply. If there is any commodity shutdown for the project to be shut down, they will announce in advance and propose alternative commodity schemes and provide sample tests to solve the risk of refueling or material cut-off connection. At present, the newly developed cases of EirGenix and its subsidiary, the medium protein ion exchange resin, colloid, filter, and bag, have been successfully replaced by other brands. The raw materials selected by the Company can be put into the production line only after research and development tests and evaluations. Consider providing customers with better quality and competitive advantages in price, and increasing alternative applicable materials of suppliers, research and development units will also consider using other alternative products or collecting relevant information on products in the market at the initial stage of research and development or testing, so as to cope with and reduce the risk of over-reliance on specific manufacturers.

If there are supply risks in the future, the Company has the ability to select suitable alternative materials from other supply brands through the research and development technology platform to reduce the risks and make the supply risks within the controllable range.

(B) Major Clients Information for the Last Two Calendar Years

Unit: NT$ thousands

Item	2023				2024				2025Q1			
	Company Name	Amount	Percent	Relation with Issuer	Company Name	Amount	Percent	Relation with Issuer	Company Name	Amount	Percent	Relation with Issuer
1	Company G	174,644	17.08	None	Company G	323,680	32.08	None	Company G	106,412	58.49	None
2	Company SA	144,479	14.13	None	Company IB	130,733	12.96	None	Company GN	48,597	26.71	None
3	Company MV	125,354	12.26	None	Others	554,547	54.96	None	Company IC	19,566	10.75	None
4	Company HB	113,042	11.05	None					Others	7,348	4.05	None
5	Company HC	109,281	10.68	None								
6	Others	355,853	34.80	None								
	Net Sales	1,022,653	100.00		Net Sales	1,008,960	100.00		Net Sales	181,923	100.00	

Description of change:

At present, the main source of income for EirGenix and its subsidiary is the bio-pharmaceutical contract development & manufacturing organization (CDMO). As service income and GMP production are recognized according to various contracts, services provided, or undergoing production progress, the sales number of major sales clients varies according to the progress of their cases each year. In addition, in April 2019, the Company signed a license agreement for the co-development of the breast cancer biosimilar EG12014 (Trastuzumab Biosimilar) with SA. The revenues of contract payment and milestone payment were recognized in stages in accordance with standard accounting procedures.

All revenues from the main clients of EirGenix and its subsidiary are presently recognized as the revenue from development and manufacturing services, except for the revenue from the license agreement for the co-development gradually recognized with SA over time. At present, for the development and manufacturing services commissioned by clients, the service contents include the preliminary development work and the back end GMP production, including process verification and verification work. Several clients are close to the listing stage and are also discussing the long-term production of future listing supply. Once the client's products are successfully listed, it is expected to have a long-term stable income from said product supply. As revenue is still growing in the past few years, in the future, with the launch of production plants year by year, the Company will look for potential clients of later products and products to be marketed closely and continue to maintain stable, productive creation and considerable revenue.

At the same time, the continuous expansion of foreign cases is also a medium-term plan to create value. It is obvious that European and American clients are increasing year by year. Due to its characteristics, if a good client relationship is well maintained and quality is ensured, then it is also the keyway to obtain stable considerable revenue. In addition to client maintenance, EirGenix and its subsidiary have also obtained the certification of foreign factories from Japan's Ministry of Health, Laboure, and Welfare. It is expected that in the future, they will gradually obtain internationally important legal certifications from the European Union, the United States, and other countries, which will be more conducive to accelerating the growth of revenue.

3. The number of employees employed for the two most recent fiscal years and during the current fiscal year up to the date of publication of the annual report, their average years of service, average age, and education levels.

Unit: Person; age; years; %

Year		2023	2024	2025 until the end of April
Employees	Management	19	20	20
	Supervisor	31	38	36
	Staff	338	341	342
	Total	388	399	398
Average Years of Age		37.50	38.13	38.06
Average Tears of Service		3.75	4.18	4.02
Education	Ph.D.	8.80	9.00	9.00
	Master's	68.00	68.90	67.80
	Bachelor's	23.20	22.10	23.20
	High School	-	-	-

4. Disbursements for Environmental Protection

(1) Any losses suffered by the company in the most recent fiscal year and up to the annual report publication date due to environmental pollution incidents (including any compensation paid and any violations of environmental protection laws or regulations found in environmental inspection, specifying the disposition dates, disposition reference numbers, the articles of law violated, and the content of the dispositions), and disclosing an estimate of possible expenses that could be incurred currently and in the future and measures being or to be taken. If a reasonable estimate cannot be made, an explanation of the facts of why it cannot be made shall be provided:

Since its establishment, EirGenix has been committed to environmental protection, which complies with relevant laws and policies of government on environmental protection. Therefore, the Company has not had any environmental pollution as of the date of issuance for the annual report in the last two years. In the future, the Company will continue to adhere to its consistent philosophy to maintain the best environmental protection results.

5. Labor Relations

(1) List any employee benefit plans, continuing education, training, retirement systems, and the status of their implementation, and the status of labor-management agreements and measures for preserving employees' rights and interests.

A. Employee Reward System

The Company rewards system relates to employee individual performance, his/her contribution to the company, and his/her personal work profession and job levels, as well as the Company's business performance. While the Company is profitable in the current year, 1-5% of the Company annual profit shall be issued to employees as a reward; within the amount, 10% should be reserved for fundamental levels of employees. Employee compensation consists of three parts: salary, bonus, and welfare. Employee salary is related to his/her work profession and position, while the bonus is connected to individual performance, department contribution, and annual company business performance results. As for welfare to employees, it must be not only in compliance with laws and regulations from the government and also designed to meet employee's needs from all aspects. The Company also issues stock-related rewards as welfare, such as Employee Stock Options, Restricted Stock Units, IPO/SPO reserved stock options for employees and in 2023 the Company issued Cash-equivalent stocks. All these non-cash rewards are provided to share the company accomplishments and to retain talents and to grow with the company.

B. Workplace diversity and equity

The Company respects the value of diversity and provides all the employees regardless of his/her race, ethnicity, gender, gender identity, sexual orientation, age and socioeconomical background with the equal opportunity on their job rights, compensation, and career development. The indigenous people and with disability are employed by the Company without any discrimination and inequality. In 2024, the new-hired female employee took 55%. In the entire company, the female employee is 45% and the female managers is 39%.

C. Employee Welfare

(A) In order to promote employee physical and mental health to reach the work-and-life balance, the Company holds an inhouse Employee Welfare Committee according to the Employee Welfare Fund Act. The Company appropriates funds for the Committee to handle welfare issues for employees to promote internal morale and a cozy work environment.

(B) Employee Leave Policy – Superior to the regulated standards of Labor Standards Act and the Regulations of Leave-Taking of Workers

(i) Employees are provided with annual personal leave available since his/her first day on board and the paid day leave are higher than the government regulation requirement.

(ii) Paid family care leave.

(C) Other benefits include flexibility of starting and finishing daily working time, wedding leave, funeral leave, hospitalization allowance, maternity allowance, pregnancy leave, employee lunch allowance, department teambuilding feasts, transportation allowance, welfare committee activities, employee outing allowance, and lottery draw-in the annual feast, group insurance, and occupational injury insurance. EirGenix care for the employees and their family members. The health insurance is covered to their family by their options. In the family day event by the Company, employees' family are invited.

D. Training and Development

Starting from the beliefs in lifelong learning, the Company provides learning for positive inter-promotion between work effectiveness, quality, and efficiency. The training program is annually planned to provide employee pre-service and on-the-job training. In addition to the 1st-day training for the newcomer to the Company, it covers three training topics, including professional, leadership and management, and core competency. Through these training courses, the profession of talents, the employee morale to the Company, and the competitiveness of the Company in the global industry are expected to develop in the meantime.

EIRGer's Learning Center is built to shape EirGenix into a learning organization. Also known as ELC, it provides employees with diversified training courses annually. Professional courses take the majority and follow with leadership program and core competency training:

(A) Experts Program. The training covers professional topics such as cGMP, CMC, biologics, and manufacturing.

(B) Leadership Program. This program is designed for the current managers and potential supervisors, in which management skills, team building, communication, coaching, strategical thinking, and leadership mindset are provided.

(C) Common Knowledge Program, as known as core competency training, in which ELC intends to build up morale and teamwork for employees, and also most common knowledge education and training courses are designed to develop employees.

In 2023, ELC program not only passed the Evaluation from Workforce Development Agency, Ministry of Labor; and also was awarded the Silver of the Talent Quality-management System, TTQS. In 2024, ELC offered 15 courses over 66 course hours, with a total of 1,953 participants and a total of 6,266 study hours.

E. Retirement Policy

Employees may apply for retirement under any of the following conditions:

(A) Where the employee attains the age of 55 and has worked for 15 years.

(B) Where the employee has worked for more than 25 years.

(C) Where the employee attains the age of 60 and has worked for 10 years.

The company's labor pension policy follows the Labor Pension Act for applicable employees. According to the "Monthly Contribution Wage Classification Table" stipulated by the Act, the company contributes no less than 6% of the employee's monthly wage to their individual labor pension account monthly. Since the company's establishment, three employees have retired, and the retirement procedures have been handled in accordance with the provisions of the Labor Pension Act.

Starting from July 1, 2005, our company has implemented a defined contribution retirement plan in accordance with the Labor Pension Act, applicable to employees of ROC (Taiwan) nationality. For employees who choose to adopt the labor pension system under the Labor Pension Act, the company contributes no less than 6% of the employee's monthly salary to their individual pension account managed by the Bureau of Labor Insurance. Upon retirement, employees may choose to receive their pension either as a monthly payment or a lump-sum payment, based on the amount accumulated in their personal pension account and investment returns.

In addition, the company has established a defined benefit retirement plan in accordance with the Labor Standards Act, applicable to years of service accrued by all regular employees and foreign employees before July 1, 2005, when the Labor Pension Act was implemented. Employees who meet the retirement eligibility criteria will receive pension payments calculated based on their years of service and the average salary of the six months prior to retirement. For years of service up to and including 15 years, two units are granted for each full year; for service exceeding 15 years, one unit is granted per year, with the total pension amount capped at a maximum of 45 units. The company contributes 2% of the total monthly payroll into a dedicated retirement fund account held under the name of the Labor Retirement Reserve Supervisory Committee with the Bank of Taiwan.

To support employees' retirement security, the company offers an employee stock trust. Employees can allocate a fixed amount from their monthly salary, and the company contributes an equivalent amount to a dedicated trust account. This initiative not only serves as an incentive for employee retention but also helps employees accumulate wealth and plan for their future retirement.

F. Labor-Management Dispute

The Company communicates with employees not only through Town Hall Meeting and Labor-Management Meetings but also through internal emails, bulletin boards display, and service feedback boxes for employees to provide their opinions at any time. The Company also meets the needs of employees in a timely manner through communication, education, and incentive mechanisms. The Company has not had any disputes between employers and employees requiring settlements in 2024.

G. Other Employee Rights Mechanism

The Company has established a comprehensive system and policies that clearly outline various management regulations, specifying employee rights, obligations, and benefits. We regularly review and revise the benefits to protect the rights and interests of all employees.

In 2023, our company received the Friendly Family Workplace Equality Measures Award from the New Taipei City Labor Bureau. In 2024, we were honored with the Outstanding Enterprise Award for Workplace Equality Promotion by the Hsinchu Science Park.

(2) List any losses suffered by the company in the most recent two fiscal years and up to the annual report publication date due to labor disputes (including any violations of the Labor Standards Act found in labor inspection, specifying the disposition dates, disposition reference numbers, the articles of law violated, the substance of the legal violations, and the content of the dispositions), and disclosing an estimate of possible expenses that could be incurred currently and in the future and measures being or to be taken. If a reasonable estimate cannot be made, an explanation of the facts of why it cannot be made shall be provided:

Since the establishment, EirGenix's labor relations have been harmonious without any loss caused by the labor-management dispute. In the future, both employees and EirGenix should complement each other and grow together to manage the relationships with the heart to avoid the risks of loss caused by the labor-management dispute.

6. Cyber security management

To protect EirGenix's assets and shareholder interests, we recognize the paramount importance of Information security. Therefore, our company has included Information security as an annual audit item to regularly review and assess security measures. We also periodically review and update various security settings and systems and collaborate with external professional vendors to ensure information and network security. In addition, to ensure the continuous and stable provision of information system services, we have established various backup mechanisms and backup systems and appropriately improve relevant processes and enhance computer hardware and software as contingency measures. The IT department regularly provides Information security information to company employees through various channels and is a member of the Taiwan Computer Emergency Response Team (TW-CERT) to receive real-time IT risk intelligence (TW-IAS intelligence). After assessing the risk level, applicability, and feasibility, Information security and information system personnel promptly update or adjust internal IT-related equipment, architecture, and operational guidelines to mitigate the potential for severe damage from various internal and external Information security risks. We regularly report on the implementation of Information security at board meetings.

(1) Describe the cyber security risk management framework, cyber security policies, concrete management programs, and investments in resources for cyber security management.

A. Information Security Risk Management Framework

By establishing an information security risk management framework, we mitigate unknown Information security threats and risks arising from changes in the internal and external information environment. To reduce unknown information security risks from the introduction of new information technology and external environmental changes, the IT department is responsible for overseeing information security and related matters, formulating relevant internal information security plans. After approval, Information security risk management is conducted in accordance with standard operating procedures, and internal information security inspections, personnel Information security awareness campaigns, and Information security drills are conducted regularly.

Our company's Information security framework is designed in a tiered manner, as shown below:



B. Information Security Policies

To achieve the goal of sustainable business operations and ensure the effective operation of our company's information systems to support the our operation of various businesses, ensure business continuity, and minimize operational losses, all our company employees shall adhere to this Information security management policy as the basis for management and compliance when using IT-related systems.

The information security policy is divided into the following sections:

(A) Systems and Standards: In response to changes in relevant laws and regulations, our company's business, and information technology, we update relevant Information security management standards, infrastructure, systems, and Information security protection technologies to maintain the confidentiality, integrity, and availability of critical information systems,

continuously protect information from various threats, and ensure that the access control and changes of critical information systems are recorded for audit purposes.

(B) Information Technology Management: Real-time updates and evaluations of information systems, and implementation of necessary control measures to ensure the security of data, systems, networks, and information infrastructure.

(C) Personnel and Organization: The IT department has one Certified Information Systems Security Professional (CISSP) who is responsible for Information security management-related operations and Information security technical training for colleagues in the IT department. The IT department then disseminates this information externally, conducting Information security training and campaigns for colleagues to enhance the Information security awareness and related professional skills of internal personnel, enabling them to understand how to prevent common cyberattacks.

C. IT Management Plans and Resources Invested in Information Security Management

We actively strengthen the security of the overall information system, from Information security standards to information infrastructure design, system maintenance and upgrades, professional personnel training, and employee Information security awareness campaigns, all of which are included in the overall scope of Information security considerations. We conduct annual self-assessments of whether relevant systems comply with environmental changes and make timely adjustments as needed. Since 2021, our company has introduced the Taiwan Intellectual Property Management System (TIPS) to strengthen the operational management of our company's confidential data.

Specific Information security management measures include the following:

Category	Description	Operating method
Permissions management	Personnel and group accounts and verification methods management, permissions management, and system management permissions management	▪ Personnel accounts management operations should proceed or be changed after an application is filed and approved by managers responsible in accordance with the operating procedures. Each user's use permissions should be immediately revoked after resignation or job change to prevent unauthorized access0 ▪ Regularly review system-related permissions. ▪ Life cycle management of system account and admin accounts. ▪ Adopt MFA and designated login to manage important systems.
Access management	Data flow control and auditing, physical equipment access management, audit records, and incident investigation	▪ Revise data flows into and out of important information systems and keep records of the access for auditing. ▪ Conduct physical security protection of the information system console. ▪ Analyze audit records and issue automatic warnings of abnormalities. ▪ Identify the information security level according to the importance and the degree of risk. ▪ Adopt digital rights management technology for important files to control the data flow to avoid unauthorized access.
Threat and risk management	Rate the information risks that may be caused by internal employees, external personnel, and potential vulnerabilities in the systems and take measures to reduce risks	▪ Standardize the user's computer preset. ▪ Launch operating regulations for external vendors to access the Company's information systems. ▪ Launch risk assessment procedures for adoption of new technologies. ▪ Deploy multiple brands' multi-layer firewalls and cloud email filtering to reduce the chance of external cyber-attacks and intrusion of phishing emails. ▪ Strengthen endpoint security, regularly update users' computers, and install antivirus software. ▪ Regularly offer information security education and training to improve personnel's awareness of information security.
System integrity and availability management	Maintain the availability and integrity of data and systems to resume normal operations in the event of a disaster or damage	▪ The host has been virtualized in a cluster to improve the availability of systems. ▪ Adopt large storage devices, regularly automate on-site and off-site backups, and perform recovery tests as planned to ensure the integrity and availability of systems. ▪ Adopt multiple redundancy mechanisms for infrastructure, multiple UPS systems with automatic generators, N+1 and 1+1 fan coil units, as well as multiple redundancy measures for internal and external network wires and equipment to reduce the chance of information service interruption.

Information Security Management Resource Allocation and Management:

(A) Conducted four (4) scheduled meetings on information security-related topics throughout 2024.

(B) Updated the "Information Security Learning Handbook 2024" to establish and reinforce information security awareness for all company employees.

(C) Maintained active membership in TWCERT/CC for ongoing cybersecurity threat intelligence sharing.

(D) In addition to monthly information security awareness sessions during regular meetings, the IT department promptly disseminates critical cybersecurity threat intelligence via internal messaging platforms and email whenever potential risks to the company's information security are identified.

(2) List any losses suffered by the company in the most recent fiscal year and up to the annual report publication date due to significant cyber security incidents, the possible impacts therefrom, and measures being or to be taken. If a reasonable estimate cannot be made, an explanation of the facts of why it cannot be made shall be provided: None.

(3) Effects of and Response to Changes in Technology and the Industry Relating to Corporate Finance and Sale

Given the rapid advancements in information technology and the evolving external landscape, we have engaged external professional cybersecurity consultants to develop and refine our company's information security policies. These policies, tailored to our specific needs, are based on the NIST Cybersecurity Framework (CSF) and relevant industry standards. This initiative aims to mitigate the impact of external changes on our financial operations. We are implementing these policies in phases, with regular reviews and adjustments, to establish a robust framework for evaluating and implementing all information systems and services.

Furthermore, given the increasing prevalence of sophisticated phishing emails, which have become a primary vector for cyberattacks within organizations, and the continuous evolution of attack techniques, we have taken additional security measures. Building upon existing cloud-based email protection, we have implemented email authentication protocols, including SPF (Sender Policy Framework), DKIM (DomainKeys Identified Mail), and DMARC (Domain-based Message Authentication, Reporting & Conformance), by the end of the first quarter of 2024. This initiative aligns with the industry-wide push by major email service providers such as Google and Yahoo to enforce email authentication. This proactive step aims to prevent the spoofing of internal personnel in phishing emails targeting both internal and external contacts. In addition, our company is intensifying its efforts to educate internal users on email security best practices, thereby enhancing their cybersecurity awareness and reducing the risk of successful phishing attacks.

Regarding network account authentication, we recognize the growing threat of unauthorized access attempts. To strengthen account security, we plan to implement Multi-Factor Authentication (MFA) in phases throughout the year. MFA will require multiple authentication methods for login verification, effectively preventing identity theft and mitigating the risk of sensitive information leakage or fraudulent activities conducted under a compromised identity.

7. Important Contracts

Type of Agreement	Counterparty	Period	Major Contents	Restrictions
Lease contract	Department Center for Biotechnology	2022/03～2026/12	Lease offices, laboratories, and plants	None
Lease contract	Hsinchu Science Park Bureau, Ministry of Science and Technology	2016/11~2036/11	Lease the land for plant construction in Zhubei Biomedical Science Park, Hsinchu	None
License agreement	Company SA	2019/04~	Grant the exclusive rights to commercialize the biosimilar EG12014 in license market	In accordance with that contract
CDMO	Company HB	2021/02 until project completion	Recombinant protein 1,000L GMP Production.	None
CDMO	Company G	2021/04 until project completion	Tech transfer, Recombinant protein GMP production	None
CDMO	Company AS	2021/09 until IND application	Process development and GMP production	None
CDMO	Company AP	2022/03 until IND application	Tech transfer, Process development & GMP production	None
CDMO	Company G	2022/09 until project completion	Perform stability study of recombinant protein	None
CDMO	Company HB	2023/02 until project completion	Recombinant protein 1,000L GMP Production	None
CDMO	Company OM	2023/02 until project completion	Antibody 2,000L GMP Production	None.
CDMO	Company AD	2023/06 until project completion	Tech transfer, Process development, GMP production and Raw material purchase	None
CDMO	Company B	2023/06 until project completion	Recombinant protein GMP production	None
CDMO	Company HC	2023/06 until project completion	Cell line development, Process development and Antibody GMP production	None
CDMO	Company IB	2023/09 until project completion	Cell line development, Process development and Antibody GMP production.	None
CDMO	Company U	2023/09 until project completion	Antibody 2,000L GMP Production.	None
CDMO	Company AM	2024/01 until project completion	Cell line development	None
CDMO	Company HB	2024/01 until project completion	Recombinant protein 200L GMP Production.	None
CDMO	Company C	2024/03 until project completion	Antibody 200L GMP production.	None
CDMO	Company UC	2024/04 until project completion	Cell line development	None
CDMO	Company MB	2024/04 until project completion	MCB Production and MCB Characterization	None
CDMO	Company AS	2024/04 until project completion	Antibody 200L GMP production.	None
CDMO	Company IC	2024/10 until project completion	Tech transfer and 50L R&D Production	None
CDMO	Company PS	2024/10 until project completion	Tech transfer and 200L GMP production	None
CDMO	Company GN	2024/12 until project completion	Tech transfer and 2000L GMP production	None
CDMO	Company G	2025/03 until project completion	Tech transfer from Xizhi to Zhubei and preparatory activities for commissioned recombinant protein GMP production	None

Co-development	Formosa Pharmaceuticals, Inc.	2022/03~	Co-developed the biosimilar drug TSY0110 (EG12043) of ADC for the treatment of breast cancer	In accordance with that contract
Material Supply	Clarity Pharmaceuticals, Ltd.	2025/02~	EG12014 Material Supply	In accordance with that contract
Loan	Hua Nan Commercial Bank, Ltd.	2022/02~2029/03	Credit of Zhubei plant expansion	The funds will be used for plant expansion and the purchase of machinery and equipment
Loan	Taiwan Business Bank Co., Ltd.	2024/06~2034/07	Credit of Zhubei plant expansion	
Construction	Exyte Taiwan Co., Ltd.	2024/06~2026/02	Mechanical and electrical engineering of Building B of Zhubei	None
Construction	Lee Ming	2024/07~2026/02	Civil engineering of Building B of Zhubei	None

V. Review of Financial Conditions, Financial Performance, and Risk Management

1. Financial Conditions

(1) Consolidated Financial Conditions

Unit: NT$ thousands; %

Item \ Year	2023	2024	Difference	
			Amount	%
Current Assets	6,915,506	5,952,002	(963,504)	(14)
Property, plant and equipment	3,337,685	3,906,086	568,401	17
Right-of-use Assets	329,236	319,084	(10,152)	(3)
Intangible Assets	28,269	21,115	(7,154)	(25)
Other Assets	551,863	678,129	126,266	23
Total Assets	11,162,559	10,876,416	(286,143)	(3)
Current Liabilities	707,165	947,370	240,205	34
Non-current Liabilities	437,931	670,789	232,858	53
Total Liabilities	1,145,096	1,618,159	473,063	41
Common Stock	3,060,516	3,062,492	1,976	-
Capital Surplus	7,830,216	6,954,889	(875,327)	(11)
Retained Earnings	(915,208)	(698,344)	216,864	(24)
Other Adjustments	41,939	230	(41,709)	(99)
Treasury stock	-	(61,010)	(61,010)	-
Total Shareholders' Equity	10,017,463	9,258,257	(759,206)	(8)
The major reason, impact and the response plan of the difference over 20% and the amount over 10 million: 1. Other Assets: Mainly because of the increase in equipment prepayments for the Zhubei plant Phase II facility. 2. Current Liabilities: The main reason is that the mammalian cell production line on the 5th floor of the Zhubei plant will be repaid next year, so the current portion of long-term debt has increased. 3. Non-Current Liabilities: Mainly because of the borrowed the long-term from the bank to expand the mammalian cell production line on the 5th floor of the Zhubei plant. 4. Other Adjustments: Mainly because of the decrease in unrealized gains and losses on financial assets invested in unlisted companies in 2024.				

(2) Individual Financial Condition

Unit: NT$ thousands; %

Item \ Year	2023	2024	Difference	
			Amount	%
Current Assets	6,909,802	5,947,166	(962,636)	(14)
Property, plant and equipment	3,337,069	3,905,678	568,609	17
Right-of-use Assets	329,236	319,084	(10,152)	(3)
Intangible Assets	28,269	21,115	(7,154)	(25)
Other Assets	559,412	687,462	128,050	23
Total Assets	11,163,788	1,0880,505	(283,283)	(3)
Current Liabilities	708,394	951,459	243,065	34
Non-current Liabilities	437,931	670,789	232,858	53
Total Liabilities	1,146,325	1,622,248	475,923	42
Common Stock	3,060,516	3,062,492	1,976	-
Capital Surplus	7,830,216	6,954,889	(875,327)	(11)
Retained Earnings	(915,208)	(698,344)	216,864	(24)
Treasury Stock	41,939	230	(41,709)	(99)
Other Adjustments	-	(61,010)	(61,010)	-
Total Shareholders' Equity	10,017,463	9,258,257	(759,206)	(8)
The major reason, impact and the response plan of the difference over 20% and the amount over 10 million: 1. Other Assets: Mainly because of the increase in equipment prepayments for the Zhubei plant Phase II facility. 2. Current Liabilities: The main reason is that the mammalian cell production line on the 5th floor of the Zhubei plant will be repaid next year, so the current portion of long-term debt has increased. 3. Non-Current Liabilities: Mainly because of the borrowed the long-term from the bank to expand the mammalian cell production line on the 5th floor of the Zhubei plant. 4. Other Adjustments: Mainly because of the decrease in unrealized gains and losses on financial assets invested in unlisted companies in 2024.				

(3) The main reasons for any material change in the company's financial situation during the past 2 fiscal years, and describe the effect thereof:

The Board of Directors resolution of the establishment of Phase II Facility and production equipment in Hsinchu Biomedical Science Park, the upper limit is NT$2.468 billion, and the Board of Directors resolution of the establishment of R&D laboratory、production line and production equipment, the upper limit is NT$1.1425 billion. The source of funds comes from cash capital increases, equity funds, and bank loans. After completion, it can accelerate to meet the demand for international CDMO orders to meet the demand for the marketing products of the self-owned product EG12014. It can also be sufficient to provide the drugs for Phase III clinical trials and marketing production demand for subsequent product development. The construction of this new plant will become an efficient engine for the company's rapid growth in the future and promotion of momentum internationally, which will be of positive help to the company's finance and business.

Through the injection of capital by private placement, the company can now accelerate the execution of its future strategic planning. For the product development unit, the product pipeline will be expanded to include more biosimilar drug products. For the CDMO unit, the current facility infrastructure will add additional production lines and facilities to handle even more diversified biological products, break into the field of cell and gene therapy, and extend services to further link upstream, midstream, and downstream development and manufacturing services. Lastly, EirGenix will seek to establish various forms of cooperation with international entities, including but not limited to collaborations, strategic alliances, or mergers and acquisitions. Soon, EirGenix will become an important hub for biopharmaceutical development and manufacturing on the global stage.

2. Financial Performance

(1) List of Analysis of Financial Performance- Consolidated

Unit: NT$ thousands; %

Item \ Year	2023	2024	Difference	%
Operating revenue	1,022,653	1,008,960	(13,693)	(1)
Operating costs	785,912	789,975	4,063	1
Gross profit (loss)	236,741	218,985	(17,756)	(8)
Operating expenses	1,268,718	1,172,786	(95,932)	(8)
Operating profit (loss)	(1,031,977)	(953,801)	78,176	(8)
Non-operating income	130,479	264,724	134,245	103
Non-operating expenses	(12,152)	(7,428)	4,724	(39)
Profit (loss) before tax	(913,650)	(696,505)	217,145	(24)
Income tax expense	(1,558)	(1,839)	(281)	18
Net Profit (Loss)	(915,208)	(698,344)	216,864	(24)
The main reason for the major change on Operating revenue, Net operating income (loss), and Income tax expense in currently 2 years: 1. Non-operating income: Mainly because of the favorable movements of the fluctuations in international exchange rate, and lead to the effects on foreign exchange net gain. 2. Loss before tax and Net loss: Mainly because the R&D of EG12014 nearly ended, and the completion of the EG1206A phase I clinical trial led to decreased R&D expenses and the favorable movements of the fluctuations in international exchange rate, and led to the effects on foreign exchange net gain.				

Note: All the finance data are audited by CPA.

(2) List of Analysis of Financial Performance- Individual

Unit: NT$ thousands; %

Item \ Year	2023	2024	Difference	%
Operating revenue	1,022,653	1,008,960	(13,693)	(1)
Operating costs	785,912	789,975	4,063	1
Gross profit (loss)	236,741	218,985	(17,756)	(8)
Operating expenses	1,272,135	1,176,674	(95,461)	(8)
Operating profit (loss)	(1,035,394)	(957,689)	77,705	(8)
Non-operating income	132,821	267,285	134,464	101
Non-operating expenses	(12,170)	(7,428)	4,742	(39)
Profit (loss) before tax	(914,743)	(697,832)	216,911	(24)
Income tax expense	(465)	(512)	(47)	10
Net Profit (Loss)	(915,208)	(698,344)	216,864	(24)
The main reason for the major change on Operating revenue, Net operating income (loss), and Income tax expense in currently 2 years: 1. Non-operating income: Mainly because of the favorable movements of the fluctuations in international exchange rate, and lead to the effects on foreign exchange net gain. 2. Loss before tax and Net loss: Mainly because the R&D of EG12014 nearly ended, and the completion of the EG1206A phase I clinical trial led to decreased R&D expenses and the favorable movements of the fluctuations in international exchange rate, and lead to the effects on foreign exchange net gain.				

Note: All the finance data are audited by CPA.

(3) Expected sales volume and its basis:

The self-owned biosimilars and new drugs of EirGenix and its subsidiary are still in development and not commercially available. At present, the main source of revenue is the CDMO business, and the Company will continue to provide customized CDMO services. The management team of EirGenix and its subsidiary puts forward the Company's overall objectives and strategies. Then, the research and development team will put forward various research and development project plans. After feasibility analysis, market sales scale, and financial evaluation, the implementation of the research and development plan and the timing of marketing sales are decided.

(4) The possible impact and the response plan for the company’s finance and business in the future.

EirGenix and its subsidiary continue to provide bio-drug development technical services and GMP production business and continue to research and develop bio-similar drugs. EirGenix and its subsidiary are financially sound and see no significant adverse impact on the ongoing R&D plan and financial business.

3. Analysis of Cash Flow

(1) Cash Flow Analysis for the Current Year

Unit: NT$ thousands; %

Item \ Year	2023	2024	Difference	%
Operating activities	(848,556)	(311,443)	537,113	(63%)
Investing activities	(219,018)	(1,015,048)	(796,030)	363%
Financing activities	(6,820)	370,890	377,710	(5,538%)

Analysis of change in cash flow:

1. Operating activities: Completing the EG1206A phase I clinical trial led to decreased R&D expenses and the favorable movements of the fluctuations in the international exchange rate, leading to the effects on foreign exchange net gain.
2. Investing activities: The decrease in time deposits over three months led to a reduction in financial assets measured at amortized cost and increased equipment prepayments for the Zhubei Plant Phase II facility.
3. Financing activities: Borrowed the long-term from the bank to expand the mammalian cell production line on the 5th floor of the Zhubei plant.

Improve plan for insufficient liquidity: None.

(2) Cash Flow Analysis for the Coming Year (2025)

Unit: NT$ thousands

Cash and Cash Equivalents, Beginning of Year (1)	Estimated Net Cash Flow from Operating Activities (2)	Estimated Cash Outflow (Inflow) (3)	Cash Surplus (Deficit) (1)+(2)-(3)	Leverage of Cash Deficit	
				Investment Plans	Financing Plans
4,097,584	(496,891)	(1,420,771)	2,179,922	-	-

Analysis of change in cash flow in the next year:

1. Operating activities: Mainly due to the continuous investment in R&D costs.
2. Investing activities: Mainly due to the payment of the plant expansion and the purchasing of machinery and equipment.
3. Financing activities: Mainly due to the bank loan for the Zhubei plant phase II facility expansion.

Improve plan for insufficient liquidity: None.

4. The effect of major capital expenditures during the most recent fiscal year on company's finance and business operations:

The Board of Directors resolution of the establishment of Phase II Facility and production equipment in Hsinchu Biomedical Science Park, the upper limit is NT$2.468 billion, and the Board of Directors resolution of the establishment of R&D laboratory、production line and production equipment, the upper limit is NT$1.1425 billion. After completion, it can accelerate to meet the demand for international CDMO orders to meet the demand for the marketing products of the self-owned product. It can also be sufficient to provide Phase III clinical drugs and meet the marketing production demand for subsequent product development. The construction of this new plant will become an efficient engine for the Company's rapid growth in the future and promotion of momentum internationally, which will be of positive help to the company's finance and business.

5. Investment Policy in the Last Year, Main Causes for Profits or Losses, Improvement Plans and Investment Plans for the Coming Year

(1) Investment Policy

The Company's reinvestment in other companies shall be implemented in accordance with the Investment Cycle and Regulations Governing the Acquisition and Disposal of Assets of the internal control system, which shall be discussed and approved by the Board of Directors or Shareholders' Meeting.

(2) Reasons of Investment Gain/Loss and its improving plan:

Year	Item	Recognized Investment Gain/(Loss)	Investment Policy	Reasons of Loss	Improving Plan
2024	EirGenix Europe GmbH	NTD 2,324 thousand	Development and Research on biotechnology drug and business development.	N/A	N/A
2024	EirGenix USA Inc.	NTD 194 thousand	Consultation of CDMO service	N/A	N/A

(3) The investment plans for the coming year: None.

(4) Investment plan in next year: None.

6. Analysis of Risk Management

(1) Effects of Changes in Interest Rates, Foreign Exchange Rates and Inflation on Corporate Finance, and Future Response Measures

A. The effect upon the company's profits (losses) of interest rates and response measures to be taken in the future:

(A) The effect upon the company’s profits (losses)

The Company's interest rate risk mainly comes from long and short-term borrowings from banks; the interest expenses of EirGenix and its subsidiaries amounted to NT$ 8,840 thousand and NT$ 2,300 thousand in 2024 and 2023; the increase mainly due to the interest rate increase by Central Bank. However, the company currently has enough operating funds to support it. Therefore, the impact of interest rate changes on the Company's profit or loss has gradually decreased.

(B) Response measures to be taken in the future.

EirGenix and its subsidiary will keep abreast of interest rate changes, maintain good interactive communication with banks to obtain preferential interest rates, and match up long and short-term capital planning to reduce the overall financing cost of the Company. At present, there is no effect of change in the interest rate on the company's operating results.

B. The effect upon the company's profits (losses) of exchange rate and response measures to be taken in the future

(A) The effect upon the company’s profits (losses)

EirGenix and its subsidiary mostly denominate receivables and payables in New Taiwan Dollars or important international currencies for current clients and suppliers. The net exchange (losses) gains of the Company for the years 2024 and 2023 amounted to NT$115,414 thousand and NT$ (9,431) thousand respectively, accounting for 11.44% and (0.92%) of the net operating revenues for the respective periods and have not had a significant impact on the Company's operation at present.

(B) Response measures to be taken in the future.

To reduce the impact of exchange rate changes on the Company's profit or loss in the future, EirGenix and its subsidiary will collect information on the exchange rate at any time, pay attention to the trends and changes in the exchange rate of major currencies in the international exchange market, grasp the exchange rate trends, and maintain a good interactive relationship with banks to obtain more extensive foreign exchange information and more preferential exchange rate quotations.

C. The effect upon the company's profits (losses) of changes in the inflation rate and response measures to be taken in the future.

(A) The effect upon the company’s profits (losses)

In April 2025, the Chief Accounting Office of the Executive Yuan noted an annual increase rate of 2.03% in the consumer price index. Inflation was slight, and there was no significant impact on the Company's profit or loss.

(B) Response measures to be taken in the future.

In the future, the Company will also continue to track the impact of inflation on various industry expenses and pay attention to market changes at any time as one of the bases for the Company's contingency decisions.

(2) Policies, Main Causes of Gain or Loss and Future Response Measures with Respect to High-risk, High-leveraged Investments, Lending or Endorsement Guarantees, and Derivatives Transactions

EirGenix has formulated the Procedures for Loaning Funds to Others, Procedures for Endorsements and Guarantees, Regulations Governing the Acquisition and Disposal of Assets, and other methods, and it has followed the specifications. EirGenix and its subsidiary focus on the development of the industry. As of the date of issuance for the annual report in the latest year, EirGenix and its subsidiary have not engaged in high-risk and highly leveraged investment or derivative merchandise transactions and have not lent funds or endorsement guarantees to others.

(3) Future Research & Development Projects and Corresponding Budget

A. Future Research & Development Projects:

Please refer to this Annual Report - V.Operational Highlights-D. The new products (services) are planning to development.

B. Expected to Spend on the Research and Development:

EirGenix and its subsidiary are expected to spend about NT$ 1,188,000,000 on the research and development of the above products, clinical trials, and the construction of cell line platforms in 2025. The research and development costs of the product development plans will be planned and adjusted according to the actual progress and plan objectives.

(4) Effects of and Response to Changes in Policies and Regulations Relating to Corporate Finance and Sales

The operation of EirGenix and its subsidiary follows the relevant current laws and regulations at home and abroad, and relevant personnel also pay attention to changes in laws and regulations at any time for the reference of the management echelon. Therefore, the Company can grasp and effectively respond to changes in important policies and laws at home and abroad in real time. As of the date of issuance of the annual report in the latest year, changes in policies and laws at home and abroad have had no significant adverse impact on the Company's finances and business.

(5) Effects of and Response to Changes in Technology and the Industry Relating to Corporate Finance and Sale

The government has actively promoted the biotechnology industries in recent years, and the biopharmaceutical industry has the characteristics of a high technical threshold, long R&D cycle, high professional technical demand, and added value. The threshold for the industry is relatively high, so it is not easy to produce drastic changes in a short period of time. Moreover, the Company, with a high degree of professional R&D capability, can closely grasp technological changes and industrial changes and take appropriate countermeasures as needed. As of the date of issuance of the annual report in the latest year, EirGenix and its subsidiary have not had a significant impact on the Company's financial business due to technological changes and industrial changes.

Considering the rapid changes in information technology and the external environment, to reduce the impact of external changes on our finances, the Company plans to revise relevant information security policies suitable for the operations together with external professional information security consultants with reference to the NIST Cybersecurity Framework (CSF) and relevant standards in the industry. We will implement the revised policies accordingly and review and adjust them regularly as the benchmark for evaluation and judgment when adopting various information systems and services.

(6) The Impact of Changes in Corporate Image on Corporate Risk Management, and the Company’s Response Measures

In recent years, the Company has established a strong presence in Taiwan and built solid relationships with clients in Japan. It is currently actively expanding into the European and U.S. markets, upholding a foundation of technological excellence and superior quality and adopting a customer-centric approach focused on client success. The Company is committed to becoming an internationally recognized biopharmaceutical enterprise rooted in Taiwan while targeting global markets, aiming to cultivate a positive international reputation. The Company adheres to its core corporate values of Empathy, Integrity, Responsibility, and Global Vision and integrates these principles into its daily operations and management. As of the date of issuance for the annual report in the latest year, EirGenix and its subsidiary have not had any negative impact on the Company due to changes in corporate image.

(7) Expected Benefits from, Risks Relating to and Response to Merger and Acquisition Plans

As of the date of issuance for the annual report in the latest year, EirGenix didn't have the acquisition plan.

(8) Expected Benefits from, Risks Relating to and Response to Factory Expansion Plans

A. Expected Benefits from Factory Expansion Plans

As the existing Xizhi plant reached full capacity at the end of 2016, a new PIC/S GMP biopharmaceutical plant with a commercial mass-production scale situated in the Zhubei Biomedical Park broke ground, and a disposable bioreactor (SUB) process was built. It can attract international and domestic clients' demand for large-scale production and contract production of products on the market in the future. Zhubei plant will be responsible for producing self-owned products and continue to undertake CDMO business.

The Zhubei plant phase I facility is completed, and the production capacity has reached 25,500 L. After the completion of the Zhubei plant phase II facility, the production capacity of the microbial cell production line will reach 1,500 L. The third production site in Southern Taiwan Science Park will expand the mammalian cell production line by 150,000 liters over the next 10 years. After the completion of the construction, revenue from the technical service of biopharmaceutical contract development is expected to increase.

B. Risks Relating to and Response to Factory Expansion Plans

The increased production capacity of the new plant will fluctuate with the biologics market, research and development status, and the receipt of orders for contract development cases. In addition to actively striving for domestic biopharmaceutical contract development orders, the Company will continue to expand and seek overseas orders. The expanded commercial plant is expected to be conducive to developing contract development cases and commission orders for biologics.

(9) Risks Relating to and Response to Excessive Concentration of Purchasing Sources and Excessive Customer Concentration

A. Risks Relating to and Response to Excessive Concentration of Purchasing Sources

Among the top ten suppliers of EirGenix and its subsidiaries in the last two years, Merck, Pall Singapore, and Cytiva make up over 15%. Because the raw materials for biotechnology research and development products have a high manufacturing technology threshold and strict quality requirements, their suppliers that can be internationally recognized are limited. The Company takes international pharmaceutical companies as its main customers. Therefore, the source of raw materials is internationally renowned international raw material suppliers with stable supply, which is the general trend of the raw material sources for the research and development of most biotechnology companies and pharmaceutical companies worldwide. However, the Company keeps an eye on the changing trend of raw material market supply and is committed to developing multiple suppliers to reduce the risk of centralized purchases.

B. Risks Relating to and Response to Excessive Customer Concentration

The proportion of the largest trade debtors of EirGenix and its subsidiary in the last two years was 32.08% and 17.08%, respectively. In terms of technical services for biopharmaceuticals, because of its high technical threshold and different characteristics of the developed products, EirGenix and its subsidiary establish long-term relationships with key clients, with the goal of cooperating in the development of multiple projects or large-scale projects, which is in line with the interests of both parties and the performance of development efficiency. EirGenix has successively developed several stable clients in the past few years and is continuing to cooperate and establish deep relationships with clients to balance the proportion of sales of individual clients. In the future, the Company will continue to develop clients to reduce the risk of sales concentration.

(10) Effects of, Risks Relating to and Response to Large Share Transfers or Changes in Shareholdings by Directors, Supervisors, or Shareholders with Shareholdings of over 10%: None.

(11) Effects of, Risks Relating to and Response to the Changes in Management Rights

As of the date of issuance of the annual report in the latest year, EirGenix and its subsidiary didn’t have the situation of changing management rights.

(12) Litigation or Non-litigation Matters, List major litigious, non-litigious or administrative disputes that: (1) involve the company and/or any company director, any company supervisor, the general manager, any person with actual responsibility for the firm, any major shareholder holding a stake of greater than 10 percent, and/or any company or companies controlled by the company; and (2) have been concluded by means of a final and unappealable judgment, or are still under litigation. Where such a dispute could materially affect shareholders' equity or the prices of the company's securities, the annual report shall disclose the facts of the dispute, amount of money at stake in the dispute, the date of litigation commencement, the main parties to the dispute, and the status of the dispute as of the date of publication of the annual report

A. The Company with significant litigation of final verdict or pendency, Non-contentious Cases, or administrative case that may materially influence stockholders’ equity or stock prices, has to disclose the relevant fact in contention, amount, beginning date of litigation, major parties involved, and the progress by print date of the annual financial report:

(A) Counterparty: BIOTOOLS Co., Ltd.

In October 2021, EirGenix, Inc. (“EirGenix”) procured certain enzymes from BIOTOOLS Co., Ltd. ("BIOTOOLS"). However, such enzymes supplied by BIOTOOLS failed to meet the standards set forth in the Certificate of Analysis (“COA”). Accordingly, EirGenix demanded a refund in the amount of NT$3.307 million from BIOTOOLS by filing a civil litigation before the Taiwan Shilin District Court, and the court granted judgment in favor of EirGenix on January 17, 2025.

Dissatisfied with the ruling, BIOTOOLS appealed before the Taiwan High Court on April 17, 2025, and the Taiwan High Court issued a notice requesting both parties to mediate on June 26, 2025.

B. Eirgenix’ Directors, Supervisors, president, business owner, critical shareholders with more than 10% overall equity, and affiliates with significant litigation of final verdict or pendency, Non-contentious Cases, or administrative case that may materially influence stockholders’ equity or stock prices, has to disclose the relevant fact in contention, amount, beginning date of litigation, major parties involved, and the progress by print date of the annual financial report:

(A) During the period from December 2022 to the end of 2023, Formosa Laboratories, Inc. (“Formosa”) was

involved in an employment dispute with its former employee, Mr. Chou. Mr. Chou contended that he was not incompetence, and he argued that the termination of his employment was in violation of the principle of ultima ratio. He therefore sought reinstatement of the employment relationship. The District Court dismissed Mr. Chou's claim, ruling only that Formosa was obligated to make additional contributions to Mr. Chou's labor pension account. Dissatisfied with the ruling, Mr. Chou appealed the decision, and the Appellate Court granted judgment on November 26, 2024 in disfavor of Mr. Chou, and Mr. Chou further appealed to the Highest Court, and as of April 30, 2024, this case is pending for Supreme Court for verdict.

(B) An employee of Formosa, Mr. Hsu, filed a lawsuit against Formosa, seeking for worker's compensation in the total amount of NT$4.162 million. This case is currently under trial before the District Court and has not reached a judgment yet.

(C) Yao-Hwa Glass Co., Ltd, Management Commission ("Committee") entered into an investment agreement with AsiaTone Communications Co., Ltd. (hereinafter "AsiaTone"), and subsequently disbursed investment funds. However, the company registration and capital increase procedures of AsiaTone were found to be criminally unlawful. The Taiwan High Court has rendered a criminal conviction against AsiaTone. Subsequently, the Ministry of Economic Affairs revoked AsiaTone's registration with final effect. The Committee initiated a civil proceeding, asserting that the investment agreement was void ab initio due to the unlawfulness of AsiaTone's incorporation, thereby rendering the subject matter of the investment agreement impossible to perform. In the first instance, the Taiwan Taipei District Court ruled against the Committee. Dissatisfied with the ruling, the Committee appealed. The case is currently under trial before the Taiwan High Court and has not yet been concluded.

(D) In 2024, Mr. Chang filed a lawsuit against Foxconn Technology Co., Ltd. ("FTC") seeking a declaratory judgment affirming the existence of an employment relationship between the parties. Mr. Chang also requested that FTC be ordered to pay relevant compensation from March 26, 2024, until the date of reinstatement. The case is currently under trial before the Taiwan Miaoli District Court in Taiwan.

(E) In 2024, Mr. Cheng filed a lawsuit against the FTC before the Taiwan Miaoli District Court. The FTC had issued a prior notice of termination based on alleged incompetence. Mr. Cheng contested the legality of the termination and filed suit seeking confirmation of the existence of the employment relationship. The Miaoli District Court rendered a judgment on December 2, 2024, dismissing Mr. Cheng's claims. As of the date of this assessment report, the statutory period for filing an appeal has not yet expired, and it remains unknown whether Mr. Cheng will appeal the first-instance judgment.

All these cases have been handled by our outside counsels, and for these cases involving our directors personally, their outcomes would not affect EirGenix's financial or business operations, nor have a material adverse effect on our shareholders' rights or the market price of EirGenix's securities.

(13) Other Major Risk and Response

A. Risk of Unsuccessful Product Development

The Company's biosimilar products must demonstrate high similarity in safety and efficacy to the approved reference biologics and obtain regulatory approvals from authorities such as the U.S. FDA, EMA, and Taiwan FDA before they can be marketed. Development failure risks may arise if preclinical or clinical studies do not achieve the required level of similarity, resulting in rejection by regulatory agencies. This could prevent product commercialization and lead to losses in R&D investment.

Mitigation Measures:

To mitigate the risk of development failure, the Company applies a robust product selection strategy based on clinical need, development feasibility, market size, competitive landscape, and intellectual property viability. This strategy enhances decision-making and reduces overall development risk.

B. Risk of Development Delays

The Company's R&D team possesses extensive experience in biologics development. Prior to initiating new biosimilar or reformulated product development, thorough assessments are conducted to ensure feasibility. A professional project management approach is applied to monitor and control progress at every development stage, thereby minimizing the risk of

delays.

C. Risk of Underperforming Sales or Inability to License Products

Sales performance of the Company's biosimilar products may be affected by rapid market changes or increased competition, resulting in unmet sales expectations.

Mitigation Measures:

(A)The Company actively engages in licensing and partnership discussions by leveraging its partners' distribution networks.

(B)It seeks high-quality international partners and builds global market access through localized sales networks.

(C)To secure early-market advantages, the Company accelerates biosimilar development and seeks to launch alongside first-wave competitors. It also establishes early-stage development partnerships to ensure licensing clarity in key regions.

(D)The Company focuses on oncology biosimilars, particularly HER2-positive breast cancer, a top global cancer by patient volume. It aligns product development with the latest international treatment guidelines and targets partnerships with companies experienced in biosimilar and oncology drug sales. Together, they will formulate compliant, agile marketing strategies and continuously optimize costs and brand value to reduce sales risks.

7. Other important matters: None.

VI. Special Disclosure

1. Information of Affiliated Companies

Please refer to the https://mopsov.twse.com.tw/mops/web/t57sb01_q10

2. Private Placement Securities in the Most Recent Years:

Please refer to the https://mops.twse.com.tw/mops/#/web/t116sb01

3. Other Matters that Require Additional Description: None.

4. If any of the situations listed in Article 36, paragraph 3, subparagraph 2 of the Securities and Exchange Act, which might materially affect shareholders' equity or the price of the company's securities, has occurred during the most recent fiscal year or during the current fiscal year up to the date of publication of the annual report:

Date	Material Information
2024/03/08	The Board of Directors resolved to sign the contract with clinical CRO and the relevant companies for Phase III clinical trial of the EG1206A
2024/06/14	Sandoz AG, licensing partner of EirGenix, Inc., has re-submitted the biosimilar drug EG12014 (Trastuzumab Biosimilar) 150 mg powder BLA to the US FDA
2024/07/15	FDA has officially accepted the BLA resubmission by Sandoz AG for Trastuzumab Biosimilar EG12014 150 mg powder for concentrate for solution for infusion
2024/12/10	Announcement of Sandoz (exclusive partner of EirGenix) receives complete response letter from US FDA, for EG12014 150 mg lyophilized powder

EirGenix, Inc.

President: Lee-Cheng Liu

Address: No.101, Lane 169, Kangning St., Xizhi Dist., New Taiepi City

Tel: +886-2-7708-0123 Fax: +886-2-7708-1666